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ABBREVIATIONS 
 
2D – two-dimensional  
[η] – intrinsic viscosity 
A* (ANS3S(6S)) – glucosamine-N,3-O-disulfate, mainly 6-O-sulfated 
1,6aANS – 1,6-anhydro-D-glucosamine-N-sulfate 
1,6aMNS – 1,6-anhydro-D-mannosamine-N-sulfate 
ANS(6S) – D-glucosamine-N-sulfate, mainly 6-O-sulfated in heparins 
ANAc(6S) – N-acetyl-D-glucosamine, optionally 6-O-sulfated 
aM.ol – 2,5-anhydro-D-mannitol 
AT – antithrombin III 
ATBR – antithrombin-binding region 
BMH – bovine mucosal heparin 
BLH – bovine lung heparin 
D – polydispersity 
DBA – dibutylamine 
dp – degree of polymerization 
ECM – extracellular matrix 
ESI-Q-TOF-MS – electrospray ionization – quadrupole – time-of-flight mass spectrometry 
G – D-glucuronic acid 
GAG – glycosaminoglycan 
Gal – galactose 
GalA – D-galacturonic acid 
GLR – D-glucuronic acid within the linkage region tetrasaccharide sequence 
gsG/gsI/gsU – glycol-split glucuronic/iduronic/uronic acid 
gs-heparin – glycol-split heparin 
1JC-H – one-bond proton-carbon coupling constant 
HA fraction – high affinity fraction (toward AT) 
HILIC – hydrophobic interaction liquid chromatography 
HMBC NMR – heteronuclear multiple bond correlation NMR 
HS – heparan sulfate 
HSQC – (two-dimentional) heteronuclear single quantum coherence NMR 
I(2S) – L-iduronic acid, mainly 2-O-sulfated in heparins 
IPRP-HPLC – ion-pair reversed phase high performance liquid chromatography 
LMWH – low molecular weight heparin 
LOD – limit of detection 
LOQ – limit of quantification 
LOL – limit of linearity 
LR – linkage region 
MNS – D-mannosamine-N-sulfate 
Mw – weight average molecular weight 
Mn – number average molecular weight 
NA fraction – no affinity fraction (toward AT) 
NMR – nuclear magnetic resonance 
NRE – non-reducing end 
OMH – ovine mucosal heparin 
R – remnant generated by the hydrolysis of glycol-split uronic acids 
R(Unr) – remnant generated by oxidation of non-sulfated uronic acid at the non-reducing end  
RALLS – right-angle laser light scattering  
RE – reducing end 
RI – refractive index 
PMH – porcine mucosal heparin 
RSD – relative standard deviation 
TDA – triple detector array 
TOCSY – total correlation spectroscopy 
TSD – trisulfated disaccharide 
S/N – signal-to-noise 
Ser – serine of the LR 
Serox – oxidized serine reside of the LR 
SEC – size-exclusion chromatography 
UFH – unfractionated heparin 
U – uronic acid 
U2S – 2-O-sulfated uronic acid 
ΔU2S – 4,5-unsaturated 2-O-sulfated uronic acid 
Xyl – xylose  
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INTRODUCTION 
Heparin is a sulfated polysaccharide extracted from animal organs, which is successfully 
used since more than fifty years in clinics as anticoagulant and antithrombotic drug (Casu and 
Lindahl, 2001) There is also a growing interest in exploiting new activities of heparin (Fuster 
et al., 2005; Lever et al., 2002). Among the heparin derivatives possessing additional, 
pharmaceutically exploitable activities, glycol-split (gs) heparins, obtained by periodate 
oxidation of non-sulfated uronic acids usually followed by borohydride reduction, are arousing 
interest in anticancer and anti-inflammatory therapies (Casu et al., 2010). While heparins are 
mainly composed of repeating disaccharide sequences of 2-O-sulfated L-iduronic acid (I2S) 
linked to D-glucosamine-N,6-O-disulfate (ANS6S) interrupted by some units containing non-
sulfated uronic acids (D-glucuronic acid (G) and L-iduronic acid (I)) and N-acetyl-D-
glucosamine (ANAc) residues (Casu and Lindahl, 2001), in glycol-split heparins the C(2)-C(3) 
bonds of G and I residues are “opened” (Naggi, 2005). 
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I and G – iduronic and glucuronic 
acids, I2S – 2-O-sulfated iduronic acid, 
A – glucosamine (N-sulfated or N-
acetylated), TSD – trisulfated 
disaccharide  
Given the increased local flexibility of gs residues, the interactions with proteins of the 
heparin sequences that remain substantially unaffected by the splitting reaction are expected to 
be facilitated (Casu et al., 2002). One important heparin-binding protein is heparanase. 
Overexpressed by tumors, this enzyme facilitates the release and activation of angiogenic 
growth factors stored by heparan sulfate proteoglycans (HSPGs) through partial cleavage of 
heparan sulfate (HS) chains. Nowadays, this enzyme represents an attractive target for 
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anticancer therapy and its inhibition is thought to be a very promising strategy in the 
development of new anti-cancer drugs (Pisano et al, 2014).  
The search of effective inhibitors of heparanase started from studying the inhibitory 
activity of heparin, the closest mimic of HS that is commercially available. Early studies 
demonstrated that heparin does inhibit heparanase (Lapierre et al, 1996) in experimental 
animal models. However, the high doses needed for an effective anticancer treatment may 
cause undesirable effects, such as bleeding complications, associated with heparin 
anticoagulant activity. Moreover, some of the G-ANS/NAc linkages of heparin are susceptible to 
heparanase cleavage, resulting in a partial depolymerisation and loss of inhibitory activity. In 
contrast, gs-heparins, structural analogs of heparin and HS, maintain affinity toward 
heparanase, but do not represent substrates for the enzyme due to the induced modification of 
glucuronic acid. The new medical uses of gs-heparins are favored by the loss of the 
anticoagulant activity, associated with the splitting of the essential glucuronic acid within the 
active site responsible for the anthrombin III (AT) binding (Islam et al., 2002). A number of 
non-anticoagulant gs-heparins, differing for the extent of glycol-splitting, and molecular 
weight, are being developed as potential antiangiogenic and antimetastatic drugs (Zhou et al., 
2011; Ritchie et al., 2011).   
In spite of the numerous studies on their biological activity, detailed structural analysis of 
gs heparins as well as structure–activity relationship have not been reported yet. Their 
structural characterization remains a very challenging task, firstly, due to the high 
microheterogeneity of the starting heparin (significantly depending on tissue and animal 
sources), and to the various side reactions that can occur under sometimes uncontrolled 
reaction conditions. In the case of more bioavailable and, consequently, more 
pharmacologically attractive, low molecular weight heparins (LMWHs) used as starting 
material, the end groups introduced by the depolymerisation processes induce additional 
 3
heterogeneity of the corresponding gs-derivatives. Evidently, an appropriate analytical 
approach is required for a pharmaceutical development of these potential drugs.  
The present study is focused on the development and application of an efficient 
analytical approach combining advanced techniques, such as NMR and LC-MS methods, for 
structural characterization of various gs-heparins and gs-LMWHs. The structural information 
obtained for gs-samples was expected to provide structural details about the sequences of the 
parent heparin/LMWH material. The long-term aim of this project includes the exploration of 
structural basis of heparin-related gs-oligosaccharide sequences for their optimal binding motif 
with heparanase and other target proteins. 
In Chapter I the state-of-art of the present topic is overviewed. Structural features, 
biosynthesis and interaction with proteins of heparin and HS as well as structure and 
bioactivity of LMWHs are discussed. The potential anticancer and anti-inflammation activity 
of gs-heparins/gs-LMWHs and the main problems in their preparation and structural analysis 
are also highlighted. In the last part of the Chapter I the main analytical techniques used for 
analysis of heparin-related samples (NMR, LC-MS, SEC-TDA) are reviewed.   
The overall goal of the study and the short-term objectives are described in Chapter II. 
Chapter III is focused on the development of the combined NMR/LC-MS approach 
using a gs-derivative of a porcine mucosal heparin (PMH) sample as a model. The potentiality 
of this method for both characterization and differentiation of gs-products originated from 
heparins of various tissue and animal sources are discussed in terms of average 
monosaccharide composition determined by NMR as well as LC-MS qualitative and 
quantitative analysis of the enzymatically digested samples. The advantages of the 
combination of glycol-splitting and enzymatic depolymerisation for the characterization of gs-
products and starting heparin samples are also discussed. A particular attention has been 
dedicated to the relevance of the diversity of antithrombin binding region (ATBR) in different 
heparins and to the length of undersulfated domains within their chains. Molecular weight 
 4
measurements as well as the dependence of the hydrodynamic properties on the introduced 
glycol-split units (determined by SEC-TDA) are also described. The possible control and 
monitoring of glycol-splitting reaction (including side-reactions) using the applied techniques 
is discussed. 
The applications of the developed approach for the characterization of the more 
biologically attractive but often more complex gs-LMWHs (gs-tinzaparin, gs-enoxaparin, gs-
dalteparin) are reported in Chapter IV. The developed LC-MS method for direct qualitative 
profiling of gs-LMWHs (possible because of the molecular weight lower than for 
unfractionated heparins) is discussed as a possible additional analytical tool for their 
compositional and structural analysis. The studied susceptibility to periodate 
oxidation/borohydride reduction of particular end-groups (at both reducing and non-reducing 
ends) of all the three LMWHs is highlighted. Among those, one of the most unexpected result 
was the oxidation of the enoxaparin 1,6-anhydro-D-mannosamine-N-sulfate, which was 
studied in detail. The potential application of the LC-MS method for the heparin sequencing is 
shown for sequences adjacent to the linkage region tetrasaccharide. 
General conclusions and future perspectives are discussed in Chapter V. 
The experimental details are reported in Chapter VI. 
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CHAPTER I: SCIENTIFIC BACKGROUND 
I.1. Heparin and heparan sulfate 
Heparin, clinically used as an anticoagulant in surgery and in both the treatment and 
prophylaxis of thrombosis, is one of the most widely used drugs. Given the large number of 
proteins of physiological and pathophysiological importance interacting with heparin and the 
structurally related HS, the range of their potential therapeutic applications (treatment of 
cancer, neurological disorders, inflammatory diseases, malaria treatment (Fuster et al., 2005; 
Lever et al., 2002)) is raising. Such an increasing interest in the exploiting of new activities of 
heparin requires development of analytical methods for their better structural characterization, 
even if, nowadays, heparin represents one of the most studied glycosaminoglycans (GAGs). 
This trend is reflected in the diagram (on the 
right), showing an almost constant high number 
of publications on heparin and a constant, but 
much lower publications number on HS 
(publication search with words “heparin” or 
“HS” in title/abstract/keywords found by 
sciencedirect searching system are shown).  
 
I.1.1. Glycosaminoglycan family 
GAGs are natural linear, polydisperse and heterogeneous polysaccharides that are present 
in every mammalian tissue and affect cell properties and functions, acting directly on cell 
receptors or via interactions with extracellular proteins. All GAGs are composed of repeating 
uronic acid and glycosamine disaccharide subunits that can be either O-/N-sulfated or not. 
Differences in the type of monosaccharide in the repeating unit as well as their sulfation 
pattern distinguish the major categories of GAGs: glucosaminoglycans (heparin, HS, 
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hyaluronic acid and keratan sulfate) characterized by D-glucosamine and 
galactosaminoglycans (chondroitin sulfate and dermatan sulfate), characterized by D-
galactosamine. Each GAG type, described in terms of its prevalent disaccharide unit, is shown 
in Table 1.1.  
Table 1.1. The most prevalent repeating disaccharide unit characteristic for each type of GAG 
GAG Uronic acid Galactose Glycosamine Main repeating disaccharide unit 
GLUCOSAMINOGLYCANS 
HEPARIN L-iduronic acid 2-O-sulfate (I2S) 
– D-glucosamine N-sulfate (ANS) 
O
OSO3
CO2OH OO
O
NHSO3
OH
CH2OSO3
-
-
-
-
 
I2S α(1→4) ANS α(1→4) 
HEPARAN 
SULFATE  
D-glucuronic 
acid (G) – 
N-acetyl-D-
glucosamine 
(ANAc) 
O
CH2OH
NHAc
OH
O
OH
-
OH O
CO2
O
 
G β(1→4) ANAc α(1→4) 
KERATAN 
SULFATE  – 
D-galactose 
(Gal) 
N-acetyl-D-
glucosamine 
(ANAc) 
O
OH
O
OH
O
O
OH
NHAc
CH2OH
CH2OH
O
 
Gal β(1→4) ANAc β(1→3) 
HYALURONIC 
ACID 
D-glucuronic 
acid (G) – 
N-acetyl-D-
glucosamine 
(ANAc) 
O
CH2OH
NHAc
O
HO
O
OH
CO2
OH
-
O
 
G β(1→3) ANAc β (1→4) 
GALACTOSAMINOGLYCANS 
N-acetyl-D-
galactosamine-
6-O-sulfate 
(GalNAc6S) 
O
CH2OSO3
NHAc
O
HO
O
OH
CO2
OH
-
O
-
 
G β(1→3) GalNAc6S β (1→4) CHONDROITIN 
SULFATE 
D-glucuronic 
acid (G) – 
N-acetyl-D-
galactosamine-
4-O-sulfate 
(GalNAc4S) 
O
CH2OH
NHAc
O
O3SO
O
OH
CO2
OH
-
O
-
 
G β(1→3) GalNAc4S β (1→4) 
DERMATAN 
SULFATE 
L-iduronic acid 
(I) – 
N-acetyl-D-
galactosamine-
4-O-sulfate 
(GalNAc) 
O
CH2OH
NHAc
O
O3SO
O
-
O
OH
CO2OH
-
 
I α(1→3) GalNAc4S β (1→4) 
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In each GAG type molecular size, structural sequence, composition and sulfation pattern 
may vary significantly, depending on the tissue origin, age and pathological conditions. Due to 
their biological functions in both physiological and pathological conditions, GAGs are being 
considered important biomarkers as well as potential pharmacological targets. Their 
involvement in the cell signalling and cancer progression and some structure–biological 
activity relationship has been recently reviewed (Afratis et al., 2012). 
 
I.1.2. Heparin/heparan sulfate: biosynthesis and structural microheterogeneity  
Heparin and HS are built up of repeating disaccharide units consisting of glucosamine 
(A) and uronic acid (U). Such a repeating structure is the result of a similar multistep 
biosynthesis pathway, occurring in the Golgi apparatus, which includes initiation, elongation 
and modification steps, described in detail below (Fig. 1.1). 
Initiation – the formation of a tetrasaccharide sequence GLR-Gal-Gal-Xyl (where, GLR – 
glucuronic acid of the linkage region (LR), Gal – galactose, Xyl – xylose) linking the 
heparin/HS chain to the core protein at the level of the serine (Ser) residues (Iacomini et al., 
1999). The LR can undergo the enzymatic modifications, as phosphorylation at C-2 of Xyl or 
sulfation at C-4 or C-6 of Gal residues. Remarkably, the 2-O-phosphorylation of the xylose 
residue, even if rare, was observed in both heparin/HS and chondroitin sulfate (CS), while 
sulfated galactose residues were found in the LR of CS and dermatan sulfate (DS), but not in 
heparin or HS (Tone et al., 2008). This finding suggests that the sulfate groups on the Gal 
residues may be involved in the selective chain assembly of CS/DS, while its absence leads to 
the synthesis of heparin and HS (Tone et al., 2008).   
Elongation – the first step of the generation of polysaccharide chain consisted in the 
subsequent addition of D-glucuronic acid (G) β1 → 4 linked to a N-acetyl-D-glucosamine 
(ANAc) building blocks catalyzed by glycosyltransferases.  
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Fig.1.1. Biosynthesis scheme of heparin/HS (taken from Capila et al.,  2002)  
Modification – the highly specific enzymatic modification of these chains, involving N-
deacetylation and N-sulfation of glucosamine residues, C5-epimerization of G to iduronic acid 
(I), and O-sulfation at either the C-2 of the U or the C-6 of the A residues (Fig.1.1). Since both 
C5-epimerization and O-sulfation depend on a prior N-sulfation of glucosamine units, the 
modified sequences tend to be clustered in the NS or NS/NA-domains (Capila et al.,  2002, 
Esko et al., 2001), as shown for heparin in Fig.1.2. As a final step, the O-sulfation at the C-3 of 
some A units can occur. This latter process plays a role in the synthesis of a specific 
pentasaccharide ANAc6S-G-ANS3S6S-I2S-ANS6S (AGA*IA) mainly within the N-sulfated domain 
(Fig.1.2) responsible for the interaction of heparin with antithrombin III (AT) (see I.1.4). The 
percentage of 3-O-sulfated glucosamine ranges from about 4 up to 8 % in commercial heparins 
(Guerrini et al., 2005, Zhang et al., 2011). As a minor modification, also G within heparin/HS 
chains may be 2-O-sulfated (Razi et al., 1995; Guerrini et al., 2007).  
Heparin is modified at the last “modification” step to a higher extent than HS. Their 
structural differences are discussed in the section I.1.3 
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Fig.1.2. Schematic representation of heparin domain structure  
G – glucuronic acid, I2S –iduronic acid 2-O-sulfate, ANS6S –  glucosamine N,6-O-disulfate, ANS –  glucosamine-N-
sulfate, ANAc – N-acetyl-glucosamine, Gal – galactose, Xyl – xylose, Ser – serine, ATBR – antithrombin binding 
region, Mw – weight average molecular weight 
 
Such a sequential enzymatic modification determines the formation of the specific 
saccharide sequences that mediate the interactions with plasma and tissue proteins and, 
consequently, the biological properties of heparin and HS (Casu et al, 1989; 2001). Each of 
these biosynthetic reactions usually does not proceed to completion, resulting in chains 
containing sequences modified to different extent. The structural microheterogeneity may 
further increase due to the cleavage of a macromolecular precursor of heparin/HS by 
heparanase, an endogeneous glucuronidase. The enzyme acts at the G-A glycosidic bond (see 
also I.1.4.3), leading to the formation of a glucosamine at the non-reducing end (NRE) (Gong 
et al, 2003; Sandbäck-Pikas et al., 1998). Because the extent of such a specific cleavage can 
vary under different pathological conditions, characterization of these disease-specific NRE 
sequences may amplify medical diagnosis possibilities (Lawrence et al., 2011). HS chains are 
generally longer than those of heparin, and have an average molecular weight of ~30 kDa as 
compared to 15-20 kDa for heparin (Shriver et al, 2012; Kjellén et al, 2000; Mulloy et al., 
2000). It is worth noting that heparin/HS structure (specific sulfation/N-acetylation pattern, 
polydispersity, molecular weight, etc.) varies for different tissues. Pharmaceutical heparin is 
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most often prepared from porcine intestinal mucosa (porcine mucosal heparin, PMH), even if 
historically it has also been obtained from bovine lung (bovine lung heparin, BLH) and can be 
also prepared from ovine intestine (ovine mucosal heparin, OMH) (Fu et al, 2013). Muslim 
countries use a substitute of PMH obtained from bovine organs (BLH and bovine mucosal 
heparin, BMH). The processes used during the heparin production can contribute to its 
structural complexity as well. The LR, present at the reducing end (RE) of some heparin 
chains, is the most sensitive sequence to such treatments, and its content and structure depends 
on the strength of oxidative “bleaching” treatment (Mourier et al, 2005, Fig.1.3). Usually a few 
percents (1.0-1.3%) of intact or partially modified LR remain in heparins (Zhang et al, 2011) 
and in some LMWHs. . 
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Fig. 1.3. Linkage region structures found in heparin after bleaching by permanganate treatment 
GLR – glucuronic acid of the LR sequence, Gal1/Gal2 – galactoses, Xyl – xylose, Ser – serine, ox-Xyl , ox-Ser, 
ox-GLR – corresponding oxidized forms 
Permanganate may oxidize vicinal hydroxyl-groups of GLR and Xyl as well as the serine amino-group, leading to 
shortening of LR sequence 
Because of the high microheterogeneity, the to-date partially undefined heparin structure 
needs further studies. Recently, several new details, better elucidating the heparin structure, 
have been discovered. For example, the results obtained by Xiao et al (2011) suggest that 
pharmaceutical heparin contains two undersulfated regions, an internal one, separating two 
highly sulfated domains, and the second one in the closest proximity to the LR, both 
susceptible to cleavage by the heparin lyase III (Fig. 1.4). 
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Fig. 1.4. Schematic representation of heparin chains containing two undersulfated domains 
(from Xiao et al, 2011)  
 
Interestingly, the oligosaccharides containing two and three adjacent AGA*IA sequences 
(Fig. 1.5) were isolated from a LMWH (Viskov et al., 2013; Mourier et al., 2014).  
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Fig. 1.5. Structure of a particular enoxaparin sequences containing two adjacent ATBR 
pentasaccharide sequences (Viskov et al., 2013) 
 
 
I.1.3. Structural differences between heparin and heparan sulfate  
Heparin attached to the serglycin core protein is synthesized exclusively in mast cells and 
cleaved from its core protein to be released into the extracellular matrix (ECM). On the 
contrary, HS, produced by virtually all the cells of human organism, can be covalently attached 
to a variety of core proteins, forming heparan sulfate proteoglycans (HSPGs), that are either 
secreted to the extracellular space, or associated with cell surface (Fig. 1.6). 
Heparin                             Heparan sulfate 
 
Fig. 1.6. Heparin and HS formation in the 
human organism   
 
Mast cells produce highly sulfated heparin 
attached to the serglycin core protein, stored in 
mast cell granules that can be released into the 
extracellular environment. Other cells synthesize 
less negatively charged HS, which is found at the 
cell surface as glypican and syndecan 
proteoglycans, and in the extracellular matrix. 
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Despite this difference, heparin and HS share the same precursor, N-acetyl-heparosan, 
consisting of ANAc and G residues. Heparin is often referred to as the more completely 
modified version of HS. Indeed, it is known to be more N- and O-sulfated than HS (Fig.1.7), 
and, consequently, to possess a higher negative charge density, the highest of any discovered 
biological macromolecules (Capila et al, 2002). Other than a higher N-sulfation degree, 
heparin is characterized by a higher content of iduronic acid due to a higher C5-epimerization 
extent. In fact, the prevalent heparin sequences are represented by a trisulfated disaccharide 
(TSD) L-iduronic acid 2-O-sulfate α1 → 4 D-glucosamine-N,6-O-disulfate (I2S-ANS6S) in 
heparin (Fig.1.7a) and D-glucuronic acid β1→ 4 N-acetyl-D-glucosamine (G-ANAc) in HS 
(Fig.1.7b), so that the heparin disaccharides contain an average of ~2.7 sulfate groups, whereas 
those of HS only ~1 sulfate group (Capila et al., 2002; Shriver et al., 2012). The structural 
heterogeneity of HS is much greater due to the lower sulfation (Fig.1.7c), thought to be a 
highly regulated process, producing very frequently alternated N-sulfated and N-acetylated 
domains (Fig.1.7c), and, thus, determining the HS role in various biological processes. 
 (a) (b) 
 
I2S – ANS6S G – ANAc 
(c)  
           
 
Heparin and HS contain 80-90% and 30-60% of ANS(6S), respectively 
(Carlsson et al, 2012). C5-epimerization degree of heparin is much higher than 
for HS. In fact, I is prevalent within heparin chains, while its epimer G 
represents the majority of the uronic acids in HS (Lindahl et al., 1998). 
 
Fig.1.7. The major 
repeating disaccharide unit 
in heparin (a) and HS (b)  
Panel (c) illustrates the 
difference in sulfation 
pattern and heterogeneity 
between heparin and HS 
(Carlsson et al, 2012) 
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I.1.4. Interactions with proteins 
The structural diversity of heparin/HS relies on the core of the wide range of biological 
processes that these molecules modulate by their interaction with numerous proteins, such as 
AT, fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), receptors, 
chemokines, etc. (Bernfield et al., 1999). The understanding of these interactions, which play 
important role in both normal physiological (blood coagulation, cell proliferation, etc.) as well 
as pathological (inflammation, tumor metastasis, angiogenesis etc.) processes, at the molecular 
level is of fundamental importance in the design of new highly specific therapeutic agents.  
Heparin/HS are known to exist as a helical structure that cannot fold into a tertiary 
structure due to their extremely high negative charge density (Capila et al., 2002). However, 
their interactions with some proteins are not aspecific and require defined sequences within 
their chains. The interaction specificity is thought to be associated with a particular orientation 
of sulfate and carboxyl groups within defined oligosaccharide sequences.  
An additional structural property, through which heparin/HS chains can alter the spatial 
orientation of their functional groups, is the conformational flexibility of I2S within linear 
sequences (Ferro et al., 1986 and 1990), which prevalently exist in chair 1C4 and skew-boat 
2S0 forms (Fig. 1.8). For example, I2S surrounded by two ANS6S residues, as frequently found in 
heparin-like sequences, showed the two forms 1C4 and 2S0 populated approximately at 60 and 
40%, respectively (Ferro et al., 1990). Importantly, the conformation of individual residues 
may be influenced by the adjacent sequences (Ferro et al., 1986, 1990; Yates et al., 2000). For 
I2S residue the higher the number of sulfate groups in the adjacent glucosamines, the higher the 
percentage of the 2S0 conformation. In contrast, both ANS/NAc and G are stable in 4C1 chair 
irrespective of substitution (Powell et al., 2004). From this point of view, the HS backbone 
with a lower content of I2S residues, possesses lower local flexibility. However, its lower 
sulfation degree and, consequently, the lower charge density, does not “block” its chain 
providing flexibility sufficient to interact with proteins (Khan et al., 2012).  
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Fig. 1.8. Equilibrium 
of 4C1, 2S0 and 1C4 
forms of I2S residues 
(Guerrini et al, 2006) 
The specificity of interactions between heparin/HS and proteins can be either a restrictive 
process, as for example, the highly specific heparin/HS–AT interaction (see I.1.4.1), or a more 
relaxed one, as in the case of their binding to FGFs (Kreuger et al., 1999).  
Among the proteins interacting with heparin/HS, there are also some enzymes that 
specifically cleave their chains leading to their depolymerization. Two types of such enzymes 
are known, the prokaryotic polysaccharide lyases (acting through an eliminative mechanism), 
also called heparin lyases (see I.1.4.2), and the eukaryotic glucuronyl hydrolases (acting 
through a hydrolytic mechanism), first of all, heparanase (see I.1.4.3) mentioned above as the 
enzyme degrading macroheparin.  
Hereafter, the interactions of heparin and HS with AT, heparin degrading heparinases 
and heparanase are discussed in detail. 
I.1.4.1. Heparin – antithrombin (III) interaction 
The first reported and the best studied example of the specific heparin–protein interaction 
of physiological significance is the “lock and key” interaction between heparin/HS and AT, 
leading to the inactivation of thrombin, factor Xa and other serine protease of the coagulation 
cascade. A specific pentasaccharide containing the disaccharide unit glucuronic acid – 
trisulfated glucosamine (G-A*) with the unusual but essential 3-O-sulfation (Fig. 1.2) is 
responsible for the interaction between heparin and AT, causing a conformational change in 
the serine protease inhibitor, thus allowing the loop with the reactive centre to interact with 
key coagulation enzymes, such as thrombin and factor Xa. Recent studies demonstrate that 
also the I residue preceding the antithrombin binding region (ATBR) pentasaccharide (Fig.1.9) 
may influence the AT-binding properties (Guerrini et al., 2006). It is worth noting that the 
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sulfation pattern of the ATBR sequence differs for heparins of different animal and tissue 
origin. For instance, its sulfated analogue (I2S)-ANS6S-G-ANS3S6S-I2S-ANS6S was reported to 
represent the prevalent ATBR sequence in bovine lung heparin (Loganathan et al., 1990). In 
Fig.1.9 the functional groups essential for AT-binding are shown. 
ATBR :     (I)      – ANAc6S – G      – ANS3S6S   – I2S – ANS6S
O O
CO2
O
OH
OHO O
O
OSO3
CO2OHO O
O
NHSO3
OH
CH2OSO3
-
-
-
-
O
OH
CO2OH
- O
NHAc
OH
CH2OSO3
-
O
O
NHSO3
OSO3
CH2OSO3
-
-
-
-
essential groups
contributing groups
Fig. 1.9. Structure of the major ATBR 
sequence found in PMH and the role of the 
individual charged groups in the AT 
activation  
(adapted from Petitou and van Boeckel, 2004) 
The first glucosamine can be also N-sulfated instead 
of N-acetylated. According to the heparin 
biosynthesis, in such a case, the iduronic acid 
preceeding the pentasaccharide sequence is almost 
always 2-O-sulfated (Loganathan et al., 1990) 
 
The pentasaccharide stimulates exclusively the AT-mediated inactivation of factor Xa 
(anti-Xa activity), whereas longer heparin fragments comprising both the ATBR sequence and 
a thrombin-binding domain are required for stimulating AT activity (Fig.1.10). 
 
Fig.1.10. Tertiary complex heparin – 
antithrombin (III) – coagulation factor  
(from Petitou and van Boeckel, 2004) 
 
ABD – antithrombin (III) binding domain responsible for 
exclusively the AT-III-mediated inactivation of factor Xa 
(anti-Xa activity),  
TBD – thrombin-binding domain 
 
I.1.4.2. Heparin-degrading lyases (or heparinases) I, II and III  
Flavobacterium heparinum produces three heparinases specific for different sequences of 
heparin (Gallagher et al., 1981). Heparinases I, II and III cleave A – U glycosidic bond leading 
to the formation of two oligosaccharides, one bearing a glucosamine at the RE and the second 
one bearing an unsaturated uronic acid at the NRE (Fig.1.11).  
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Fig.1.11. Mechanism of the eliminative depolymerization of 
heparin/HS chains by heparinases (Capila et al.,  2002) 
RE – reducing end, NRE – non-reducing end, B – enzyme basic centre  
 
The specificity of heparinases largely depends on the sulfation/acetylation pattern of the 
heparin/HS sequence (Annex 1). Heparinase I cleaves highly sulfated regions of heparin/HS at 
I2S, whereas heparinase II has a broader substrate specificity and cleaves glycosidic linkages 
containing both 2-O-sulfated and non-sulfated U residues. As a result of its broader specificity, 
heparinase II provides a most complete digestion of PMH (up to 95%), in comparison with 
~75% obtained by heparinase I (Xiao et al., 2011; Wang et al., 2012). Heparinase III acts 
prevalently at the glycosidic linkages ANAc-U within the undersulfated regions of heparin/HS, 
therefore, heparinase III results in the least digestion (~5%) of heparin samples. The present 
data indicate that 100% digestion cannot be performed, because some particular sequences are 
resistant to heparinases. It is generally accepted that the linkage at the non-reducing side of G-
ANS3S(6S) disaccharide unit is resistant toward heparinases I, II and III (Shriver et al., 2000; Yu 
et al., 2000). On the contrary, the linkage at the RE of this unit is extremely sensitive to 
heparinases I and II (Xiao, Zhao et al, 2011) as confirmed using the synthetic pentasaccharide 
ANS6S-G-ANS3S6S-I2S-AOMeNS6S as a model (Yu et al., 2000). As a result of this specificity, the 
exhaustive digestion of heparin/HS “truncates” the ATBR sequence generating 
oligosaccharides containing the important G-A* unit at the RE (Fig.1.12). Unlike heparinases I 
and II, heparinase III does  not recognized the linkage of the highly sulfated -ANS3S6S-I2S-  unit 
and, consequently, cannot cut the ATBR. Xiao et al (2011) suggested that the heparinase III 
specificity depends on the oligosaccharide sequence at the NRE of the linkage ANAc-U. It is 
likely that fully sulfated residues flanking the cleavage site from the NRE may prevent the 
action of heparinase III. 
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Fig.1.12. Synthetic heparin pentasaccharide 
(5) treated with by heparinase I affords a 
disaccharide (2) and a trisaccharide (3) 
(reported from Yu et al., 2000) 
 
Me – methyl group at the RE 
 
Results of many investigations on the heparinases substrate specificity have contributed 
to the structural elucidation of heparin/HS and understanding of the structure-function 
relationships. 
 
I.1.4.3. Heparanase   
Heparanase is a β-D-endoglucuronidase, which cleaves HS side chains of HSPGs, 
releasing fragments of 10-20 sugar units (3-6 kDa). The heparanase cDNA encodes for a 
polypeptide of 543 amino acids that appears as a heparanase inactive form of ~ 65 kDa. The 
protein undergoes a proteolytic cleavage that is likely to occur at two potential cleavage sites, 
Glu109 – Ser110 and Gln157 – Lys158, yielding an 8 kDa polypeptide at the N-terminus and a 50 
kDa polypeptide at the C-terminus that are non-covalently associated (Fig.1.13), forming the 
active heparanase form (Fairbanks et al., 1999; Levy-Adam et al., 2003). 
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Fig.1.13. Primary structure, critical amino 
acids and predicted three-dimensional 
structure of the heparanase heterodimer 
 
8 kDa (Gln36–Glu109) and 50 kDa (Lys158–Ile543) 
(gray) protein subunits (yellow and grey respectively)  
heterodimerize to yield an active enzyme. The heparin 
binding domains (HBD 1 and 2, blue and green) are in 
close proximity to the enzyme active site (red) 
 
(reported from Vlodavsky et al., 2007) 
The substrate specificity is not well-characterized, however, it is known that the linkage 
between G and ANS is susceptible to heparanase, while disaccharide units containing I/I2S are 
resistant. The heparanase cleavage is size dependent: the degradation rate is higher for longer 
sequences (dp 9 > dp 7 > dp 5), and the minimum size is thought to be trisaccharide sequence 
(Peterson and Liu, 2012). Moreover, the substrate specificity significantly depends on the 
sulfation/acetylation pattern of the HS sequences in proximity of the cleavage site (Annex 2, 
Okada et al., 2002; Peterson and Liu, 2013). This enzyme was shown to degrade substrates in 
two modes: both consecutive and gapped cleavage. In the first mode, heparanase cleaves each 
susceptible linkage starting from the NRE, while in the gapped mode the enzyme may skip few 
cleavage sites (Peterson and Liu, 2012). This latter mechanism may contribute to preserve the 
integrity of the sulfated domains of HS, necessary for its interaction with various biomolecules 
of the extracellular matrix (ECM). 
Both cell-surface and ECM HSPGs store various growth factors, cytokines, chemokines 
and other proteins (Fig.1.14). Heparanase-degradation of HSPGs releases these bioactive 
molecules, physiologically and pathologically important (Fig.1.14). While heparanase is 
confined inside specific cells under the normal conditions, it is overexpressed and found in the 
circulation of most human oncological and inflammation diseases (Pisano et al., 2014). In 
experimental tumors heparanase promotes tumor metastasis and angiogenesis. Moreover, also 
chronic inflammatory conditions, induced by heparanase and present in the most tumor 
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microenvironments, may contribute to cancer progression. Considering all its activities, 
heparanase has generated interest as target for anti-cancer and anti-inflammatory therapy. 
Current approaches for heparanase inhibition include development of chemically-modified 
heparins (such as glycol-split heparins, see I.3) and small molecule inhibitors, including small 
oligosaccharides such as PI-88 and PG545, Ferro et al, 2007 and 2012). Some of these 
compounds are currently in various stages of preclinical/clinical development. 
Heparanase
cleavage
Heparanase
cleavage
 
Fig.1.14. Heparanase-mediated 
release of bioactive molecules 
from the extracellular matrix 
(ECM) 
From (Vlodavsky and Friedman, 2001) 
HIGHLIGHTS 
The biosynthesis pathway determines structural microheterogeneity and polydispersity of 
heparin and heparan sulfate, which can be further increased during the manufacture 
processes. Detailed investigations are still required for the structural elucidation of heparin 
and the more complex HS, and their multifunctionality in terms of numerous biological 
activities they modulate.  
I.2. Low molecular weight heparins 
Despite of the increasing interest in the heparin therapeutic applications, its use is often 
limited by some undesirable side effects, such as bleeding complications or heparin-induced 
thrombocytopenia (HIT). This drawback stimulated detailed studies of the coagulation cascade 
and led to the development of low molecular weight heparins (LMWHs) at the end of the 20th 
century. The pharmaceutical differences between LMWH and unfractionated heparin (UFH), 
such as better bioavailability, more predictable anticoagulant activity and longer half-life, can 
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be explained by the decreased propensity of the former to bind to plasma proteins, entothelial 
cells, and macrophages due to their shorter chains (Weitz, 1997). For example, a shorter-chain 
heparin, containing an ATBR, but unable to accommodate thrombin binding, would retain AT-
mediated inactivation of factor Xa but prevent the formation of a ternary heparin-AT-thrombin 
complex (Fig.1.10). More selective anticoagulant/antithrombotic agents were synthesized by 
enzymatic and chemical depolymerisation. Various LMWHs (5–8 kDa) and ultra-LMWH (3 
kDa) were also generated (Shriver et al, 2000), and “at the beginning of the new millennium, 
LMW heparins have largely displaced heparin as the major clinical anticoagulant” (Capila et 
al., 2002). 
Four LMWHs, tinzaparin (“Innohep”, LEO Pharma), enoxaparin (“Clexane”, Sanofi-
Aventis), dalteparin (“Fragmin”, Pfizer) and nadroparin (“Fraxiparin”, GlaxoSmithKline) 
(Fig.1.15), are currently commercially available. 
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Fig.1.15. Simplified structures of tinzaparin, enoxaparin, dalteparin and nadroparin 
Internal sequences are substantially the same as in non-depolymerized heparin 
TSD – trisulfated disaccharide, ATBR – antithrombin binding region, ΔU – 4,5-unsaturated uronic acid, ΔU2S – 
4,5-unsaturated 2-O-sulfated uronic acid, U – saturated uronic acid,  ANS – glucosamine-N-sulfate, MNS – 
mannosamine-N-sulfate, 1,6aANS – 1,6-anhydro-glucosamine-N-sulfate, 1,6aMNS – 1,6-anhydro-mannosamine-N-
sulfate, aM.ol – 2,5-anhydro-mannitol. 
 
 21
Tinzaparin, obtained by the enzymatic beta-eliminative depolymerisation by heparinase I 
(Fig.1.11) of heparin at the level of the I2S, is characterized by unsaturated sulfated uronic acid 
(ΔU2S) at the NRE and N-sulfated glucosamine at the RE of its chains (Fig.1.15). Due to the 
highly selective and “soft” enzymatic depolymerization, tinzaparin is considered the LMWH 
most similar to UFH. LR present in the starting heparins are also preserved.  
Enoxaparin is obtained by chemical beta-elimination, a less selective process, that 
includes two critical steps: esterification of heparin to the corresponding heparin benzyl ester 
followed by alkaline β-eliminative cleavage of the intermediate benzyl ester (Lee et al., 2013). 
As a result of this treatment, the major enoxaparin oligosaccharides bear unsaturated uronic 
acids (ΔU2S or ΔU) at the NRE, while a partial epimerisation of the A residues leads to 
formation of its isomer D-mannosamine (M) residues at the RE. The mechanism of 
epimerization was studied by Toida and co-workers (1996) using heparan sulfate 
tetrasaccharides containing terminal N-acetylated glucosamine (Fig.1.16). It is worth noting 
that mannosamine residues found in enoxaparin are mainly N-sulfated (Guerrini et al., 2007), 
probably because of the high sulfation degree of heparin starting material, so that, the basic β-
eliminative depolymerisation, a statistically occurring process, cleaves with higher probability 
the glycosidic bond after N-sulfated glucosamine. 
Fig.1.16. Proposed mechanism of 
base-catalyzed epimerization of 
terminal glucosamine into 
mannosamine 
(reported from Toida et al., 1996) 
Basic treatment may also cause desulfation and dehydration of the RE amino sugars, so 
that several enoxaparin oligosaccharides bear unnatural epimeric 1,6-anhydro-glucosamine 
(1,6aA) and mannosamine (1,6aM) (Fig.1.15), which are prevalently N-sulfated (Guerrini et 
al., 2007). Other minor residues that can be generated during basic depolymerisation are an 
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C(2)-C(3) epoxy uronic acid, L-galacturonic acid GalA (as a result of the opening of  the 
epoxide ring) and G2S residues: ~2.5% of total uronic acid content for GalA and G2S, and        
< 0.5% for the epoxy uronic acid (Guerrini et al, 2007). 
Dalteparin and nadroparin are obtained by controlled deaminative treatment with nitrous 
acid followed by borohydride reduction leading to the formation of 2,5-anhydro-mannitol 
(aM.ol) ring at the RE and, unlike the other two LMWHs, saturated I or G at the NRE 
(Fig.1.17). As a minor modification, the deamination may lead to the formation of the internal 
ring contracted (Rc) 2-deoxy-2-C-hydroxymethyl pentofuranosidic residues (Baer et al., 1985; 
Horton et al., 1973; Shively et al, 1970).   
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Fig.1.17. Deaminative heparin depolymerization used for dalteparin preparation 
Unlike N-sulfated glucosamines, N-acetylated glucosamines are resistant to nitrous acid (Guo and 
Conrad et al., 1989; Turnbull et al., 1999). 
I/G – iduronic/glucuronic acid, ANS – glucosamine-N-sulfate, aM – 2,5-anhydro-mannose, aM.ol – 2,5-anhydro-
mannitol, Rc – ring contracted residue 
 
 
HIGHLIGHTS 
In general, even if it may slightly modify the internal sequences, depolymerisation 
processes preserves in the LMWHs the major biological functions of heparin. However, both 
chemical and enzymatic depolymerisation, modifying the heparin sequences at the site of chain 
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cleavage, make each LMWH structurally (Fig.1.15), and, to some extent biologically, different 
from each other (Linhardt et al., 1990). Consequently, the structural analysis of LMWHs is 
more complicated due to their higher heterogeneity induced by depolymerisation processes.  
 
I.3. Glycol-split heparins. Structure and biological activity 
In the last decade, several new therapeutic uses of heparins and LMWHs have been 
envisaged in various fields (Lever et al, 2002), especially in inflammation and cancer (Fuster et 
al., 2005). To reduce risks of bleeding in non-anticoagulant/non-antithrombotic uses of 
heparins and LMWHs, removal or inactivation of their ATBR is required. Although removal of 
the ATBR-containing chains could be achieved exploiting their interaction with AT (Höök et 
al., 1976) or by enzymatic digestion (Xiao et al, 2011), a more practical way of reducing 
anticoagulant properties, without impairing other biological activities, is periodate oxidation of 
heparins (Naggi, 2005; Mousa et al., 2006).  
Periodate oxidation is a classical reaction in carbohydrate chemistry that has been widely 
applied to determine vicinal carbons bearing unsubstituted hydroxyl and/or amino groups 
(Perlin et al., 2006). The mechanism includes formation of a monoester between periodate ion 
and hydroxyl group, the formation of a cyclic ester, and, finally, the ester decomposition into 
the oxidized products (Fig.1.18).  
 
Fig.1.18. Scheme of the mechanism of 1,2-diol oxidation by periodate (Babor et al., 1973) 
When applied to heparins, periodate oxidation mainly leads to the splitting of the C(2)-
C(3) bond of non-sulfated U, including the essential G within the ATBR (Islam et al., 2002) 
(Fig.1.19). Also GLR and Xyl residues of the LR sequence, containing vicinal hydroxyls, should 
be considered possible sites of oxidation (Fig.1.19c,d). The primary products of the glycol-
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splitting reaction (the polyaldehydic oxy-heparins) are usually stabilized by borohydride 
reduction, leading to reduced oxy-heparins (RO-heparins) (Naggi, 2005). Saturated NRE-
groups may be also affected by glycol-splitting due to the presence of 3,4-diol group (Fig.1.19). 
Under uncontrolled reaction conditions, first of all, pH, side hydrolytic reactions may take 
place, contributing in increased microheterogeneity and polydispersity of the gs-heparins. Both 
acidic and basic conditions can cause the cleavage of gs-heparin chains. Even if not studied in 
detail, acetal fragments of the gs-units are known to be labile and susceptible to hydrolysis 
(Conrad et al., 1992). Their hydrolytic cleavage should generate two shorter oligosaccharides, 
the first one, bearing a remnant of gsU (R) and the second one, bearing a glucosamine at its 
NRE (Fig.1.19e). These reactions rely on the principle of the so-called Smith degradation of 
carbohydrates that, historically, has been widely used for heparin depolymerisation. Extremely 
strong acid conditions may cleave also the glycosidic bonds (Jandik et al, 1996). It is worth 
noting that partial hydrolysis is used to reduce the molecular weight and, consequently, to 
improve the bioavailability of some gs-heparin under development (Leitgeb et al., 2011; Zhou et 
al., 2011). 
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Fig.1.19. Simplified formula of a representative ATBR-containing chain of PMH (a) and the 
corresponding gs derivative (b) obtained by periodate oxidation/borohydride reduction  
Structure (a) is adapted from (Xiao et al., 2011). The structure of the “full” linkage region LR is reported in (c) and 
(d) for heparin and gs-heparin, respectively, where GLR  is the G residue in the LR, Gal1 and Gal2 are two 
galactose residues, Xyl is xylose, Ser is serine (Iacomini et al., 1999).  The two glycol-split residues (gsGLR and 
gsXyl) in the LR of gs-heparin were not previously described (see text). Circled residues in the unmodified 
heparin structure (a) and (c) highlight unsubstituted diol groups susceptible of glycol-splitting 
 
 
Other properties that are not dependent on the intact structure of the AT-binding sequence 
are usually preserved in gs-heparins. Moreover, most of the literature data indicate that the 
glycol-splitting gives rise to a higher protein-binding activity of gs-heparins than their parent 
GAGs (Casu et al., 2002; Casu et al., 2010; Naggi, 2005). One of the factors is the increased 
local mobility of gs residues, which act as flexible joints along the polysaccharide chains, thus, 
facilitating interactions with the heparin/HS binding sites of proteins (Fig.1.20).  
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Fig.1.20. Molecular models of the most favored 
conformations of heparin octasaccharide
I2S-ANS6S-I2S-ANS6S-I2S-ANS6S-I2S-ANS6S (a)  and 
a “mono-glycol-split” octasaccharide  I2S-ANS6S-
I2S-ANS6S-gsI-ANS6S-I2S-ANS6S (b)  
 
(Casu and Naggi, 2003) 
 
The ability of gs-heparins to mimic heparin biological functions and their decreased 
anticoagulant activity led to the generation of a number of biologically active non-
anticoagulant gs-heparins, differing for molecular weight and extent of glycol-splitting      
(Table 1.2). Some of these potential drugs under development (such as M402, Zhou et al, 2011) 
were obtained from LMWHs. However, their structural features have not been reported yet.  
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Table 1.2. Glycol-split heparins and their biological activity 
Glycol-split derivative Biological activity Reference 
gs-heparin Retention of antilipemic activity Casu et al., 1986 
gs-heparin Antiangiogenic, antimetastatic activity (FGF2 and heparanase inhibitor) Lapierre et al, 1996 
gs-LMWH 
(“Vasoflux”) 
Anticoagulant activity Weitz, 1999 
undersulfated gs-LMWH Antiangiogenic activity                    (FGF2 antagonists) Casu et al, 2004 
undersulfated gs-LMWH Antiangiogenic activity                    (VEGF antagonists) Pisano et al, 2005 
gs-LMWH 
Antimalarial activity                      
(desegregating and                       
inhibiting parasite adhesion) 
Vogt et al, 2006 
gs-LMWH Antimetastatic activity Mousa et al, 2006 
gs-heparins Antimetastatic activity                     (P-selectin inhibitors) Hostetter et al, 2007 
gs-LMWH 
(“DF01”, obtained by 
hydrolysis of a gs-heparin) 
Labor pain reducing effect Ekman-Ordeberg et al, 2009 
N-acetyl-gs-heparin 
(“SST0001”) 
Antiangiogenic, antimetastatic  
(heparanase inhibitor) 
Naggi et al, 2005 
Ritchie et al,  2011 
Shafat et al, 2011 
gs-LMWH(s) 
Anticancer activity 
Increased tumor chemo responsiveness 
Phillips et al, 2011 
gs-LMWH(s) 
(“M402”) 
Anticancer activity through  
(multiple inhibition pathway) 
Zhou et al, 2011 
hydrolyzed gs-heparin 
(“DFX232” and “Sevapurin”) Antimalarial activity Leitgeb et al., 2011 
 
HIGHLIGHTS 
In spite of the current growing interest on gs-heparins as potential anticancer and anti-
inflammatory drugs, their structural characterization is still a challenging task, firstly, due to 
the high microheterogeneity of the starting material (determined predominantly by the 
biosynthesis pathway and structural complexity introduced during the manufacture processes). 
Moreover, uncontrolled reaction conditions may cause side reactions, such as hydrolysis at 
the level of gs residues (Fig.1.19e; Conrad et al., 1992) as well as hydrolytic cleavage of 
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glycosidic bonds (Jandik et al, 1996). In the case of LMWHs, the end-groups generated during 
the depolymerisation processes induce additional heterogeneity, making their analysis even 
more complex. Development of efficient and complementary analytical techniques has become 
increasingly important to structurally characterize these molecules and to identify motifs 
responsible for their interactions with proteins, in order to rationalize the seqrch of new 
potential drugs..  
 
I.4. Analytical methods for characterization of heparins and their derivatives 
Despite their medical and biological importance, heparin and HS are still incompletely 
characterized in terms of their molecular sequences (see section I.1). Most work concerning 
the structural characterization of heparin and HS has been performed on the former, largely as 
result of its abundance, commercial availability and lower heterogeneity than HS. While 
numerous studies have been published about the structural characterization of heparin in the 
last decades, detailed structural characterization of gs-heparins and gs-LMWHs have not been 
reported yet (see section I.3).  
Multistep and hybrid approaches are required for structurally characterizing heparin/HS 
and their derivatives. Due to the heparin/HS microheterogeneity (epimerization degree, 
sulfation and acetylation pattern) and polydispersity, their sequences are usually characterized 
in statistical terms, by nuclear magnetic resonance (NMR) spectroscopy and high-performance 
liquid chromatography coupled with mass spectrometry (HPLC-MS). Monodimensional (1H 
and 13C) and multidimensional NMR have been employed for the characterization of the intact 
chains (the so-called top-down approach) of both unfractionated and LMWHs. In the case of 
LC-MS analysis, the bottom-up approach, based on the identification/quantification of the 
fragments obtained by either partial or complete digestion, is usually applied. Together with 
NMR and LC-MS analysis, molecular weight distribution analysis and hydrodynamic 
properties determination may provide complementary structural information. 
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I.4.1. Nuclear magnetic resonance spectroscopy for heparin characterization 
NMR spectroscopy is recognized to be one of the most effective tools for the structural 
elucidation of oligosaccharides as well as heparins and LMWHs (Guerrini et al., 2005 and 
2007; Fu et al., 2013). For unmodified unfractionated heparins and LMWHs it was 
demonstrated that the monodimensional 1H NMR spectroscopy permits their structural 
characterization in terms of the monosaccharide composition, sulfation/acetylation pattern, 
position linkages, and relative I(2S) and G amounts (Guerrini et al., 2005, Guerrini et al., 2007) 
(Fig.1.21). The anomeric region (4.6 – 5.6 ppm) is the most informative and can be used for 
distinguishing the same residues with different environment (so-called sequence effect). 1H 
NMR was successfully used for the differentiation of PMH and BLH (Guerrini et al., 2001; Fu 
et al., 2013), for the control of heparin contaminations by over-sulfated CS (Keire et al., 2010). 
13C NMR analysis, utilized to determine the animal origin of heparin (Casu et al., 1996), was 
also successfully applied for the gs-heparin analysis (Casu et al., 2002).  Determination of total 
content of gs-uronic acids (gsU) was possible due to the difference in chemical shifts between 
anomeric carbons of unmodified non-sulfated uronic acids (~105 ppm) and those of the 
generated gs-units (~107 ppm). This approach can turn out useful for both quantifying total 
gsU content and monitoring the reaction completeness (Fig.1.22). However, the use of 
monodimensional NMR analysis of complex GAGs is often limited by strong signal 
overlapping, preventing quantitative analysis. The spectrum heterogeneity increases for 
LMWHs due to the presence of unnatural residues (such as end groups in LMWHs, Fig.1.15) 
causing additional signals (Guerrini et al., 2007). 
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Heparin
gs‐Heparin
A‐(gsU)
ANSI2S
U2OH
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I2S
gsU
ANSα
ppm  
Fig.1.21. 1H monodimensional NMR spectrum of 
unmodified pig mucosal heparin  
(from Guerrini et al., 2001) 
I/I2S – non-sulfated/2-O-sulfated iduronic acid, G – glucuronic acid, 
ANS/ANAc – N-sulfated/N-acetylated glucosamine, A3S – 
glucosamine-N,3-O-disulfate (mostly, 6-O-sulfated) 
 Fig.1.22. 13C monodimensional 
NMR spectrum of heparin and 50%-
2-O-desulfated gs-heparin  
(adapted form Casu et al., 2002) 
I2S – 2-O-sulfated iduronic acid, ANS –
glucosamine-N-sulfate, U2OH – non-sulfated 
uronic acid, ANSα – reducing glucosamine-
N-sulfate 
 
Two-dimentional (2D) NMR has wider applications. For example, heteronuclear 
single quantum coherence (HSQC) spectroscopy, based on the 1H – 13C correlation, permits to 
resolve signals that overlap in the monodimensional NMR spectra of heparins and LMWHs 
(Guerrini et al., 2005; Guerrini et al., 2007). Higher signal resolution, in turn, permits both 
identification of the constituent monosaccharide residues (Fig.1.23) and their quantitative 
evaluation.  
Fig.1.23. Partial HSQC spectrum of porcine 
mucosal heparin (from Guerrini et al., 2005) 
By 2D NMR analysis, sequence effect can be observed 
in the anomeric region: the same residues 1→4 linked 
to different units (shown in the parenthesis) have 
different and well-defined cross-peaks 
 
A – glucosamine, I – iduronic acid, G – glucuronic 
acid, LR – linkage region, nd – not determined 
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Quantitative analysis is based on the selection of analytical signals where the effect 
of 1JC-H coupling is minimal and differences in relaxation effects are sufficiently small to be 
neglected. The 1JC-H coupling constants of H1/C1 and H2/C2 were shown not to differ 
significantly for various internal and RE residues of heparin and LMWHs (Table 1.3). Hence, 
integration of well-resolved anomeric signals can be performed for quantifying the 
monosaccharide residues in heparins and LMWHs. Unlike the others moieties, for quantifying 
2-O-sulfated or non-sulfated 4,5-unsaturated uronic acid (ΔU(2S)) typical for tinzaparin and 
enoxaparin, the integration of the H4/C4 cross peaks that are well-separated from the others is 
recommended (Guerrini et al., 2007), even if its 1JC-H value slightly differs from the other 
signals of uronic acids (Table 1.3). In contrast, the corresponding anomeric signals (H1/C1 
ΔU(2S)) are in a complex region, so that their integration leads to higher errors of quantitative 
analysis (Guerrini et al., 2007). However, when high resolution NMR spectrometers are used, 
the integration of the anomeric signals may provide more accurate quantitative results. For 
quantifying aM.ol residues typical for dalteparin, the integration of H5/C5 signals was 
performed, because its 1JC-H value was found to be much closer to that of the other 
glucosamine residues (Table 1.3), permitting to compare sample differences with good 
precision.  
Table 1.3. 1JC-H coupling constants (Hz) of some internal residues and end groups of LMWHs 
(Guerrini et al, 2007)  
Tinzaparin, enoxaparin, 
dalteparin  Enoxaparin  Dalteparin 
Tinzaparin, 
enoxaparin, 
dalteparin 
Tinzaparin, 
enoxaparin  Enoxaparin 
Glucosamines    Uronic acids 
 
ANS‐(I2S)  ANS‐(‐I)  A*  1,6aANS  1,6aMNS  aM.ol  Ι2S  G  ΔU2S  G2S 
H1/C1  173  173  174  177  178    173  165  176  166 
H4/C4            148      168   
H2/C2  139    140  138  142  147        151 
H5/C5            151         
ANS – glucosamine-N-sulfate, A* – glucosamine-N,3-O,6-O-trisulfate, 1,6aANS – 1,6-anhydro-glucosamine-N-
sulfate, 1,6aMNS – 1,6-anhydro-mannosamine-N-sulfate, aM.ol – 2,5-anhydro-mannitol, I2S – iduronic acid 2-O-
sulfate, G – glucuronic acid, ΔU2S – 4,5-unsaturated uronic acid 2-O-sulfate, G2S – glucuronic acid 2-O-sulfate 
 
Among the other 2D NMR methods that are being used for heparin analysis, there are 
correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY), heteronuclear 
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multiple-bond correlation spectroscopy (HMBC), and nuclear Overhauser effect spectroscopy 
(NOESY) (Guglieri et al., 2008). Modern methods for the mathematical analysis of multiple 
complex datasets can provide objective, systematic interpretations of the spectra, and have the 
advantage that more than two types of spectra can be combined. Principal component analysis 
(PCA) has been applied to NMR and CD of heparin and other glycosaminoglycans (Rudd et al. 
2012). 
Apart from its use for qualitative and quantitative analysis, NMR can be a powerful tool 
for studying interactions between heparin and heparin/HS-binding proteins. The main 
drawback is that isolation or synthesis of structurally homogeneous oligosaccharides is 
required. NMR studies were performed on the interaction of heparin oligosaccharides with AT 
(Guerrini et al, 2006; Viskov et al, 2013) and growth factors (Guglieri et al., 2008), etc.  
HIGHLIGHTS 
The 2D NMR method can disclose structural differences and reveal particular sequences 
of heparin/HS and their derivatives, in terms of the relative distribution of the major 
monosaccharide residues and certain functional groups (N-, 6-O- and 3-O-substitutions). 
However, it provides information only about the average composition. Moreover, due to its 
relatively low sensitivity, this method could have challenges for analyzing intact heparin 
samples, containing unusual sequences. In favourable cases, when standard oligosaccharides 
are available, NMR can be a powerful technique for heparin     oligosaccharide–protein 
interaction studies. 
 
I.4.2. Hybrid LC/ESI-MS analysis for heparin structural characterization 
Direct ESI-MS analysis can be performed for simple mixtures of oligosaccharides (Behr 
et al., 2005; Camara et al, 2007). However, hybrid methods, combining LC separation and MS 
identification, are most often used to overcome the problem of the high heterogeneity and 
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polydispersity. The main problem in the MS of heparins is that desulfation may occur during 
the spectrum acquisition, because of high acidity of the sulfate-groups and their lability. 
However, with the development of soft electrospray ionization (ESI) methods, it was shown 
that desulfation can be minimized by optimizing the ionization parameters and solvent 
composition (Huber and Krajete, 2000). Careful control of the sample solution and mobile 
phase pH is still necessary to avoid the desulfation during the chromatographic separation and 
MS detection. Nowadays, negative-mode ESI/MS is being increasingly applied to heparin 
oligosaccharides structural characterization (Thanawiroon et al, 2004; Doneau et al., 2009; 
Langeslay et al, 2013; Wang et al., 2012). Due to the development of high resolution mass 
analyzers, such as quadrupole – time-of-flight (Q-TOF) and Fourier transform ion cyclotron 
resonance (FT-ICR) MS, accurate molecular weight measurements can be made. In favourable 
cases, also matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometric analysis, characterized by very soft ionization mechanism, can be performed 
without previous chromatographic separation (Sturiale et al., 2001). However, it works only 
for simple oligosaccharide fractions and cannot resolve complex mixtures due to signal 
overlapping.  
In comparison with other analytical techniques, the MS method has several advantages: 
high sensitivity, detection specificity, low sample consumption, etc. Detection specificity is 
very important because oligosaccharide standards are generally not available, except for 
disaccharides. The tandem mass spectrometry (MS/MS) has provided new possibilities to 
determine oligosaccharide sequences. Several successful studies were performed (Zaia et al., 
2003; Wolff et al., 2007), however, labile sulfate groups still limit MS/MS analysis.  
Despite of the progress in heparin structural characterization, analysis of intact heparin is 
still complicated due to the sample complexity and high molecular weight as well as absence 
of databases for heparin oligosaccharides identification. Most often, in order to simplify the 
analytical assay, chemical- or/and enzymatic depolymerisation is employed for its sequencing. 
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In fact, most of the work was done on the disaccharides generated by heparin depolymerisation 
(Wang et al., 2012; Zhang et al., 2011; Kuberan et al., 2002). 
Among chemical depolymerisation processes, nitrous acid treatment (Turnbull et al., 
1999; Stringer et al., 2003) is the most widely used. The degradation process relies on the 
reaction of deamination of N-sulfated glucosamine, often followed by borohydride reduction, 
leading to the formation of the 2,5-anhydromannitol (aM.ol) RE residues typical for dalteparin 
(see I.2). The 2,5-anhydromannose (aM) residues are easily distinguishable from natural 
glucosamine residues by MS analysis due to the mass difference of 17 Da (or 15 Da for the 
reduced aM.ol form). However, the absence of a chromophore may limit the adoption of this 
technique for UV detection. It is important to note that N-acetylated glucosamines are resistant 
to oxidation by nitrous acid, providing a certain selectivity of such a treatment (Guo and 
Conrad et al., 1989; Turnbull et al., 1999). In order to obtain more structural information, 
chemical degradation is often combined with enzymatic cleavage (Turnbull et al., 1999; 
Stringer et al., 2003). 
For the enzymatic depolymerisation heparin lyases I, II and III are usually used (see 
I.1.4). Enzymatic reactions afford more specific cleavage than the chemical ones, and as a 
result of this specificity, exhaustive depolymerisation of heparins is also possible. Disaccharide 
building blocks analysis of completely depolymerised heparin is widely used for characterizing 
individual heparin samples and comparing heparins of different animal and tissue origins 
(Zhang et al., 2011; Fu et al., 2013) as well as for controlling the LMWHs preparation (Lee et 
al., 2013). Identification is favored and quantitative analysis is possible because standards of 
disaccharides with different sulfation/N-acetylation patterns are commercially available. This 
methodology provides average disaccharide composition, but does not give information about 
heparin sequences. Because the functional sequences of heparin/HS are usually longer, partial 
depolymerisation (by each of the three heparinases) and analysis of larger oligosaccharides 
may be also useful for heparin/LMWH mapping (Mourier et al., 2004; Zhang et al., 2011; Fu 
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et al, 2013; Lee et al., 2013) mapping. A preliminary reduction of generated oligosaccharides 
is often used to mark the disaccharide unit located at the RE (Mourier et al., 2004).  
However, it is still complicated to determine, for example, the sulfate group distribution.  
Strong anion exchange (SAX) chromatography has been traditionally used for the highly 
charged heparin oligosaccharide separation as sample preparation step (Pervin et al., 1995, 
Xiao et al., 2011). It was also applied for the quantification of oversulfated CS contaminating 
heparin samples (Keire et al, 2010). The main drawback of this method is that it cannot be 
directly coupled with MS due to the use of strong electrolytes as eluents. However, it can be 
used with a UV detector for analytes bearing chromophores when their standards are available, 
for example, for analysis  of unsaturated disaccharides (Zhang et al., 2011).  
Among the other chromatographic approaches amenable to online ESI-MS analysis there 
are size exclusion chromatography (SEC), hydrophilic interaction liquid chromatography 
(HILIC), and ion-pair reversed phase liquid chromatography (IPRP-LC). 
An online SEC/ESI-MS method was developed for determining the molecular weights of 
tinzaparin oligosaccharides (Henriksen et al., 2004). One of the drawbacks of SEC is that the 
very high salt concentration in mobile phases leads to more complex mass spectra due to the 
formation of numerous adducts with cations. For solving this problem and minimizing salts 
influence on mass spectra an online cation exchange column has to be coupled with the SEC 
one (Henriksen et al., 2004). Another limitation of SEC is its low resolution that does not 
provide complete separation of oligosaccharides with similar chain length. In spite of low 
resolution power and technical problems in coupling SEC with MS, nowadays, SEC is widely 
used in either high or low pressure mode, first of all, for sample preparation (fractionation and 
desalting) as well as for molecular weight determination (see I.4.3). It can be used also for 
studying heparin–protein interactions when structurally homogeneous oligosaccharides are 
available. For example, SEC-MS, along with NMR, was successfully applied for studying the 
interactions between ATBR-containing octasaccharides and AT (Viskov et al., 2013).  
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Recently, the HILIC/ESI-MS method was developed for screening and quantitative 
analysis of a library of AT-binding heparin/HS oligosaccharides (Naimy et al, 2008) and for 
sequencing and profiling heparins of different origin (Fu et al, 2013). Generally, typical HILIC 
stationary phases consist of classical silica gels modified with polar functional groups 
(Buszewski et al., 2012). The separation is based on different overall polarity determined by 
size, sulfation pattern and N-acetylation content. However, this technique is characterized by a 
rather low resolution, insufficient for isomer separation. 
Nowadays, one of the most widely used chromatographic approaches for the heparin 
oligosaccharides analysis is an ion pair reversed phase high performance liquid 
chromatography (IPRP-HPLC) that can be easily coupled with ESI-MS. For separating 
strong anions, like sulfated oligosaccharides, octadecyl (C18) columns, dynamically modified 
by lipophilic alkyl ammonium salt present in eluent, are often used. Briefly, the separation is 
based on the different analyte distribution between eluent and stationary reversed (e.g., C18) 
phase dynamically modified by an aliphatic amine (Fig.1.24). Given the dynamical mechanism 
of the column modification, the equilibria occurring in the eluent should be considered. So, the 
separation mechanism may be also explained as the distribution of oligosaccharide-amine ion 
pair (having total neutral charge) between reversed phase and eluent (Fig.1.24). Given the 
separation mechanism, oligosaccharides are eluted from the column in dependence, first of all, 
on their charge. It is also sensitive to the sulfate distribution and steric hindrance, providing 
positional isomers separation (Kuberan et al, 2002; Thanawiroon et al., 2004; Lawrence et al, 
2004; Doneanu et al., 2009; Jones et al., 2010).The method allows the direct analysis of 
aqueous solutions of oligosaccharides without derivatization.  
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RPIP separation is believed to 
occur through a combination of 
two mechanisms.  
In the classical model, the 
hydrophobic ion pair agent (an 
amine) and the analyte 
(sulfated oligosaccharide) form 
in the eluent a neutral species 
which then interacts with the 
hydrophobic stationary phase. 
The dynamic ion-exchange 
model suggests that the ion pair 
amine is first adsorbed onto the 
stationary phase, dynamically 
modifying its surface, which 
then acts as ion exchange sites 
for the oppositely charged 
oligosaccharides.  
 
This method has the advantage of simplifying the mass spectra by preventing the 
formation of adducts of oligosaccharides with alkali and earth alkali cations, almost always 
present in the heparin samples. Minimizing cation adduction provides higher sensitivity of MS 
detection. Like the other methods, this technique limits the detection of larger oligosaccharides 
due to the very low ionization. For instance, several studies reported that it was possible to 
obtain mass spectra only up to tetradecasaccharides (Thanawiroon et al, 2004). The use of n-
hexylamine with 1,1,1,3,3,3-hexafluoro-2-propanol as a counter-ion (Doneau et al., 2009) and 
dibutylamine (Langeslay et al, 2013) allowed to detect oligosaccharides up to dp 22. 
The high specificity of both separation mechanism and negative-mode ESI-MS permits 
to avoid matrix effects and facilitates the identification of oligosaccharides. Moreover, sulfated 
oligosaccharides are characterized by specific isotope pattern and monoisotopic exact mass 
due to the presence of sulfur atoms allowing their indentification.  
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HIGHLIGHTS 
Nowadays, ESI-MS coupled with HPLC is a powerful technique that, in part, permits to 
overcome the problems of heparin structural analysis associated with its compositional 
microheterogeneity. Generally, it is performed on the fragments generated by specific 
enzymatic or/and chemical treatment. However, often pre-digestion is not sufficient for 
heparin analysis, and coupling of different chromatographic techniques, such as SEC-
fractionation and further LC/ESI-MS analysis, is required to improve the resolving power. It is 
worth noting that LC-MS analysis cannot solve several tasks that can be tackled by NMR 
spectroscopy, and vice-versa. For example, NMR permits to distinguish iduronic and 
glucuronic acids as well as enoxaparin typical terminal groups 1,6-anhydro-glucosamine and 
1,6-anhydro-mannosamine, whereas LC-MS analysis, even if can separate such isomers, 
cannot distinguish them because of the same mass. On the contrary, LC-MS allows to 
determine individual heparin oligosaccharides and to fingerprint oligosaccharide mixtures, 
whereas NMR provides information on average monosaccharide composition. Evidently, these 
two powerful analytical methods may provide more structural information, when used in 
combination. 
 
I.4.3. Molecular weight distribution and hydrodynamic properties of heparin in solution 
by SEC-TDA 
Molecular weight distribution is one of the parameters used for describing the 
polydispersity of heparin, contributing to its structural heterogeneity. A convenient way to 
describe molecular weight distribution is a combination of number-average mean molecular 
weight (Mn) and weight average mean molecular weight (Mw), while ratio Mw/Mn expresses 
the polydispersity of polymers. 
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SEC represents the most widely used method for measuring molecular weight and size 
distribution (Mulloy et al., 1997; Bertini et al., 2005; Gray et al., 2008; Sommers et al., 2011). 
However, a set of heparin reference standards with well-defined molecular weight, which are 
not commercially available, is required for column calibration. In order to overcome this 
problem, SEC can be coupled with triple detector array (TDA), including three online 
detectors, right-angle laser light scattering (RALLS), refractometer (measuring refractive index 
(RI)) and viscosimeter. Combination of these detectors permits to characterize the molecular 
weight distribution without calibrating the chromatographic column (Fig. 1.25, Bertini et al., 
2005). The elaboration of LS and concentration RI detector responses gives molecular weight 
values: 
CdcdnKRI  /    and   CdcdnMwKLS  2)/(' ,                                                
 where RI and LS – refractometer and light-scattering response, K/K’ – curve constants, dn/dc – differential 
index of refraction equal to 0.12 ml/g (Bertini et al., 2005), C – concentration, Mw - weight average mean 
molecular weight. The dn/dc parameter is used to convert RI response to the concentration value, that, then, 
is used to calculate Mw using LS data. 
 
 
 
Fig.1.25. Molecular weight distribution 
of an unfractionated heparin and Mark-
Houwink plot (from Bertini et al., 2005) 
Fig.1.26. SEC-TDA profile of three LMWHs 
(tinzaparin. enoxaparin, dalteparin) compared 
with an unfractionated heparin (UFH) 
(from Bisio et al., 2009) 
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The method was successfully applied for the molecular weight determination of 
unfractionated heparins and dermatan sulfates (Bertini et al., 2005) as well as commercially 
available LMWHs and their fractions with and without affinity towards AT (Bisio et al, 2009). 
The SEC-TDA approach can also provide parameters describing the hydrodynamic 
properties of GAGs. Mw value together with the viscosity data permits to calculate the value of 
the intrinsic viscosity ([η]): CK  ][ , where η, K, and C refer to the measured viscosity, 
curve constant, analyte concentration, respectively. The obtained results, in turn, may be used 
to calculate the parameters a and K for the Mark-Houwink relationship: aMK ][  through 
the double logarithmic plot of intrinsic viscosity versus molecular weight (Fig.1.25, Bertini et 
al., 2005). 
SEC coupled with multiple detector was applied to monitor the Mark-Houwink 
parameters of neutral polysaccharides upon glycol-splitting (Vold et al., 2006). The reported 
results show that the persistence length, generally used for describing the stiffness of the 
macromolecule, decreases with increasing degree of glycol-splitting. This is in agreement with 
the molecular modelling data obtained for gs-oligosaccharides (Fig.1.20, Casu et., 2004). 
 
HIGHLIGHTS 
Molecular weight of polydisperse heparin-related samples has to be described using 
number average Mn and weight average Mw molecular weight as well as their ratio. The use of 
TDA as detector after SEC separation permits to overcome the problem of the absence of 
standards for microheterogeneous and polydisperse polymers such as heparin. Combination of 
LS detector and viscosimeter may provide information also about hydrodynamic properties 
that may be extremely important for studying biological functions of heparins and their related 
compounds (for example, gs-heparins). 
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CHAPTER II: OBJECTIVES OF THE WORK 
In spite of the increasing interest on the biological activity of gs heparins, their structural 
characterization has not been reported yet. As mentioned in the Introduction, difficulties in 
their analysis are due to, first of all, high chemical heterogeneity and polydispersity of starting 
material, increasing for LMWH during depolymerisation processes. Glycol-splitting reactions, 
along with possible side reactions, are expected to introduce further local modifications and  
further contribute to the microheteregeneity and polydispersity of the final gs-product. 
Evidently, pharmaceutical development of gs-heparins requires setting up appropriate 
analytical methods to control and guarantee preparation reproducibility and to establish 
correlations between structure and biological activity. The main analytical techniques used for 
the heparin characterization (NMR and LC-MS) should be considered the best candidates for 
solving this challenging task.  
The overall goal of the Ph.D project is to develop an efficient analytical approach, 
combining NMR and LC-MS, to structurally characterize gs-derivatives generated from 
various heparin/LMWH sources. The future prospective of this study includes the exploration 
of structural basis of gs-oligosaccharides for their optimal binding with heparanase.  
To achieve the main goal of the study the following objectives have been defined: 
1. To assign all the signals in the 2D HSQC NMR spectra characteristic for gs-
heparins and to compare gs-samples obtained from heparins of different sources 
For this purpose, gs-derivatives of the UFHs of different origin (differing by sulfation 
pattern, N-acetylation degree, relative content of G and I residues) have been prepared by 
periodate oxidation followed by borohydride reduction. 
2. To develop a selective and reproducible LC-MS method for gs-heparin analysis 
Among the other separation techniques used for heparin sequencing, such as strong anion 
exchange chromatography and capillary electrophoresis, ion-pair mode of the reversed phase 
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liquid chromatography has an important advantage because it can be easily coupled with mass 
spectrometry, that is extremely important considering the high heterogeneity of heparin 
samples and the absence of the oligosaccharide standards. The HPLC system was coupled with 
an ESI-Q-TOF mass spectrometer providing high resolution and mass accuracy.  
The combination of enzymatic digestion and glycol-splitting before LC-MS analysis is 
expected to provide more structural information also for differentiating unmodified heparins of 
different sources. Possibility of the quantitative analysis should be also evaluated. 
3. To apply the developed LC-MS method and NMR analysis to the structural 
characterization of gs-LMWHs, considered more pharmaceutically attractive than gs-heparins 
Three commercially available LMWHs (tinzaparin, enoxaparin and dalteparin), differing 
mainly in molecular weight and chemical nature of the end-groups, were chosen for 
characterization by the developed method. The susceptibility of the particular terminal groups 
should be also verified for each LMWH. 
4. To determine molecular weight distribution and hydrodynamic parameters by 
SEC-TDA of gs-derivatives and compare them with the values obtained for unmodified 
samples 
Biological functions of heparin-related samples may depend on the length and 
conformation in solution. Given the higher local flexibility of glycol-split uronic acids, 
hydrodynamic properties may be affected by glycol-splitting reaction. In this context, SEC-
TDA represents a promising tool for characterization of gs-heparins. 
5. To apply the developed approach for preparing and screening potential 
heparanase inhibitors. 
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CHAPTER III: DEVELOPMENT OF THE ANALYTICAL APPROACH FOR 
CHARACTERIZING GLYCOL-SPLIT HEPARINS AND  
THEIR STARTING MATERIALS 
Part of the present results has been published in: Alekseeva A., Casu B., Torri G., Pierro S., Naggi A. 
Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis 
of their heparinase-generated oligosaccharides. Analytical Biochemistry. 434 (2013) 112-122. 
 
A gs-derivative of PMH (gs-PMH), prepared by periodate oxidation followed by 
borohydride reduction of porcine mucosal heparin as described in the Experimental section, 
was chosen as a model for the IPRP-HPLC/ESI-MS method optimization and for signal 
assignment in the NMR spectra. Additionally, gs-derivatives of heparins of different animal 
and tissue origin (OMH, BMH, BLH) as well as those of the PMH fraction with high affinity 
towards AT, N-acetyl-heparosan (K5), N-acetylated bovine lung heparin (NAc-BLH), and 
partially 2-O-desulfated PMH were studied to verify the specificity of both the LC-MS and 
NMR methods. The latter gs-derivative, called also “heparanase-inhibitor-III” (HI-3), was 
chosen for its high inhibitory activity towards heparanase (Casu et al., 2004).  
The wide range of the model compounds, obtained from natural and semi-synthetic 
heparin samples was expected to be sufficient to evaluate the potential of NMR, SEC-TDA 
and LC-MS techniques for both the structural characterization of individual gs-heparins and 
the differentiation of samples of different animal and tissue origin. Combination of glycol-
splitting and specific enzymatic digestion before LC-MS analysis was expected to provide 
further important information about sequences in the original heparins. 
 
III.1. Molecular weight determination by SEC-TDA 
Molecular weight determinations were performed by HP-SEC-TDA using two TSKgel 
G2500 and G3000 columns in order to achieve a sufficient chromatographic resolution, and 0.1 
M NaNO3 as eluent. All molecular weight parameters (number-average mean molecular mass 
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(Mn), weight-average mean molecular mass (Mw), and polydispersity (Mw/Mn, D)) were 
determined for each sample (Table 3.1). In Table 3.1 also the cumulative fraction weights for 
chains with Mw below 8 kDa and above 20 kDa are reported. 
Table 3.1. Average molecular weight (Mw), polydispersity (D), hydrodynamic radius (Rh) and 
fractions weights for fractions with molecular weight < 8 kDa and >20 kDa, obtained for 
parent heparins and their glycol-split derivatives by SEC-TDA 
Fraction weight, % mass 
Sample  Mw, kDa  D  Rh, nm 
< 8 kDa  > 20 kDa 
PMH  19.1  1.3  4.2  3  27 
BLH  15.8  1.4  3.6  16  18 
OMH  14.8  1.6  3.5  24  18 Pa
re
nt
 
he
pa
rin
s 
BMH  17.8  1.5  4.0  4  26 
 
gs‐PMH  10.8  1.5  2.7  54  7 
gs‐BLH  11.4  1.4  2.8  50  8 
gs‐OMH  9.9  1.6  2.1  78  3 
Gl
yc
ol
‐sp
lit
 
he
pa
rin
s 
gs‐BMH  10.5  1.6  2.5  62  5 
 Rh and fraction weight (% mass) were determined using 0.01M NaNO3 as eluent  
 Mw and D were measured using 0.1M NaNO3 as eluent in order to avoid aggregation 
 
 
Upon glycol-splitting the molecular weight of heparins decreased of about 30-40%, 
while polydispersity (D) slightly increased for the analyzed samples (Table 3.1), along with 
increase of the content of shorter-chain oligosaccharides (Table 3.1), indicating that hydrolytic 
side reactions occurred during gs-derivative preparation. Based on the heparin structure 
proposed by Xiao and co-workers (Fig. 1.4), the internal undersulfated domain should be 
enriched in gs-units separating two long sulfated regions. In their study 7 kDa and 12 kDa 
fragments were observed after enzymatic hydrolysis of a heparin with heparinase III. 
Consequently, even slight hydrolysis of gs-units, which may statistically occur within that 
region, should lead to the significant decrease of Mw.  
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III.2. Nuclear magnetic resonance for structural characterization of gs-heparins 
As reported in the Introduction, structural characterization of heparins has relied largely 
on 1H and 13C NMR analysis. Monodimensional NMR spectroscopy was shown to be a useful 
tool for determining the extent of glycol splitting (Casu et al, 2002; Casu et al, 2004). 
However, due to the significant signal overlapping, monodimensional spectra cannot be used 
for distinguishing gsG from gsI residues, nor for quantitative analysis. In contrast, 2D NMR 
spectra, especially in the 1H/13C HSQC approach previously applied to quantify typical 
residues and substituent groups of heparins (Guerrini et al, 2005) and LMWHs (Guerrini et 
al., 2007), was expected to provide a more complete characterization of gs-heparins. Its 
possibilities were studied in both qualitative and quantitative aspects. 
 
III.2.1. Qualitative HSQC NMR analysis. Signal assignment 
Initially, the gs-derivative of a PMH sample was chosen as model for the signal 
assignment in the HSQC spectrum. In the 2D NMR spectra cross peaks of typical residues of 
both unmodified PMH and its gs-derivative are located in characteristic subregions (Fig. 3.1). 
The cross-peaks of the unmodified PMH and those not affected by glycol-splitting in gs-PMH 
are at the positions previously assigned by Guerrini et al. (2005 and 2007). For both gs-PMH 
and PMH, the strongest cross peaks in the anomeric region (4.4-5.5/98-107 ppm (Guerrini et 
al., 2005)) are those of the internal “regular” sequences I2S-ANS(6S), not affected by glycol-
splitting (Fig.3.1). The same can be observed for the “ring” region signals of I2S and ANS/NAc  
(Fig.3.1).  
Anomeric cross-peaks of non-sulfated G (4.5-4.7/104-107 ppm) and I (4.9-5.0/105 ppm) 
and those associated with these residues (ANS-(I), ANS-(G)) were shown to disappear upon 
glycol-splitting (Fig.3.1a,c). Also the H2/C2 cross-peak of G (3.4/76 ppm) may be used as a 
marker of the reaction completeness (Fig.3.1b,d). New anomeric signals at 4.98/106.9 ppm and 
at 4.87/106.6 ppm, appeared in the spectrum region typical for heparin uronic acids, were 
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supposed to be those of gs-residues. The first one is compatible with previous assignments for 
gsI residues of a gs heparin (Casu et al, 2002). Both cross-peaks were shown to correlate with 
a primary alcohol group at ~ 3.7/65 ppm in the HSQC-TOCSY-DEPT spectrum (Fig. 3.2), 
confirming their nature. 
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Fig.3.1. Two-dimensional HSQC NMR spectra of porcine mucosal heparin (a, c) and the 
corresponding gs-derivative (b, d) 
Together with the monosaccharide residue, the unit following it is indicated in parenthesis, in order to show the 
sequence effect.  A – glucosamine, I – iduronic acid, G – glucuronic acid, gsU – glycol-split uronic acid, 
Gal1,Gal2, Xyl and Ser – linkage region residues (see Fig.1.19), R – remnant of the hydrolyzed gsU (Fig.1.19) 
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Fig.3.2. HSQC-TOCSY-DEPT 
and HSQC spectra of glycol-
split porcine mucosal heparin 
The HSQC-TOCSY-DEPT spectrum 
is shown in black (positive signals) 
and green (negative signals of CH2 
moiety), while the HSQC spectrum is 
shown in red  
 
Correlation between anomeric signal 
of gsI and a primary alcohol is not 
shown in the figure because of its low 
amount (low signal-to-noise ratio) 
 
HI-3 and gs-derivatives of N-acetyl-heparosan (K5) and N-Ac-BLH (this latter 
previously obtained in our laboratory) were used to distinguish between gsI and gsG. In the 
case of HI-3, a gs heparin derived from partially 2-O-desulfated PMH, the expected intensity 
increase of the signal at 4.98/106.9 ppm (Fig. 3.3a) with respect to the gs-derivative of 
unmodified PMH (Fig. 3.1c) was observed. Consequently, it has been attributed to gsI residues 
linked to ANS (this latter being mainly 6-O-sulfated).  
 
Fig.3.3. Two-dimensional HSQC NMR spectra of HI-3 (a), gs-NAc-BLH (b) and gs-K5 (c) 
Together with the monosaccharide residue, the residue following it is indicated in parenthesis, in order to show 
the sequence effect. A – glucosamine, I – iduronic acid, G – glucuronic acid, gsU – glycol-split uronic acid, Gal1, 
Gal2, Xyl and Ser – linkage region residues (see Fig.1.19). 
6-O-Sulfation of glucosamine residues is indicated only for gs-NAc-BLH (b) where its presence is known to be 
very high (>90 %, Guerrini et al., 2001) 
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The spectrum of the gs-derivative of the totally N-acetylated BLH (Fig. 3.3b), known to 
be highly 6-O-sulfated and to contain an extremely low quantity of glucuronic acid (Guerrini 
et al., 2001), was also obtained. Accordingly, the cross peak with chemical shift 4.92/106.9 
ppm was attributed to gsI residues followed by N-acetylated and 6-O-sulfated glucosamine 
(ANAc6S). The second minor signal at 4.81/106.2 ppm was assigned to gsG linked to ANAc6S. 
The chemical shifts gsI-(ANS6S) and gsI-(ANAc6S) are slightly different from each other due to 
the so-called sequence effect. It is worth noting that the sequences (I-ANAc) are rare in natural 
heparins (Yates et al, 1996) due to the specific biosynthesis pathway, during which 
epimerization of G to I mainly occurs within the NS-domain (see I.1.2). However, their 
characterization may be important for the development of the semi-synthetic N-acetylated gs-
heparins, such as the potential drug SST0001 possessing high anticancer activity (Naggi et al, 
2005; Ritchie et al, 2011; Shafat et al, 2011).  
As for the gsI residue, also ANS followed by gsI (~5.34/99.0 ppm, Fig.3.3a) is almost at 
the same position published by Casu (2002), and its intensity increased in the HI-3 spectrum 
due to the high content of gsI units within NS-domains.  
The HSQC spectrum of the gs-derivative of polysaccharide K5, constituted only by the 
repeating disaccharide units ANAc-G, was also informative (Fig. 3.3c). The cross-peak 
observed at 4.71/106.7 ppm should correspond to the gsG of the repeated gsG-ANAc units. 
Interestingly, it differs from the corresponding signal found in the spectrum of the gs-NAc-
BLH (4.81/106.2 ppm). This may be caused by a sequence effect – due to the presence of 6-O-
sulfated ANAc residues within gs-NAc-BLH chains, which are not present in the gs-K5.  
The second signal observed in the gs-K5 spectrum (5.09/99.5 ppm, Fig.3.3c) corresponds 
to ANAc of the repeating gsG-ANAc units. Its chemical shift is slightly different in the gs-PMH 
and HI-3 spectra (5.12/99.0 ppm) due to the sequence effect. In the case of gs-NAc-BLH this 
cross peak is at 5.12/98.2 ppm probably because of the 6-O-sulfation of ANAc (>90% for BLH, 
Guerrini et al., 2001). 
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Hexa- and octasaccharide fractions of gs-tinzaparin (i.e., the gs derivative of a LMWH 
rich in N-sulfated regions) were used to determine the chemical shift of gsG followed by ANS. 
Among commercially available LMWHs, tinzaparin is considered one of the most similar to 
the unfractionated heparin (see I.2). Additionally, it is known that ANAc residues are rarely 
present within its shorter oligosaccharides (Henriksen et al., 2004). The absence of the H2/C2 
signal at ~3.9/56.0 ppm in the HSQC spectrum (Guerrini et al., 2005) confirmed that dp 6 and 
dp 8 gs-tinzaparin fractions contained only trace amounts of ANAc. The chemical shift of the 
gsG-(ANS) cross peak varies from 4.90/106.4 ppm (dp 8) to 4.88/106.6 ppm (dp 6), 
corresponding to the value obtained for the gs-PMH (4.87/106.6 ppm). From the spectrum the 
value of H1/C1 chemical shift for ANS-(gsG) is 5.37/98.9 ppm, similar to the value 5.32/98.9 
ppm previously found for ANS-(gsI) (Casu et al., 2002). 
 
Fig.3.4. Two-dimensional HSQC NMR 
spectrum of the hexasaccharide fraction of 
gs-tinzaparin 
 
Together with the monosaccharide residue, the 
residue following it is indicated in parenthesis, to 
highlight the sequence effect, when observed.  
A – glucosamine, I – iduronic acid, G – glucuronic 
acid, gsU – glycol-split uronic acid, ΔU2S – 2-O-
sulfated 4,5-unsaturated uronic acid (see Fig.1.15). 
A-ol indicates a reduced glucosamine (alditol form) 
at the RE of oligosaccharide chains (see chapter IV) 
 
Also the chemical shift for the anomeric signal of gsG-(A*), 4.93/103.5 ppm, was 
previously determined using a gs-derivative of the synthetic pentasaccharide AGA*IAOMe 
(Master degree thesis of Monica Ferro). A signal with similar chemical shift (4.94/103.1 ppm) 
is detectable in the HI-3 spectrum (Fig. 3.3a). Based on the chemical nature of HI-3, with a 
high content of gsI residues, the observed cross peak may correspond to gsI-(A*) that is likely 
to be generated by 2-O-desulfation, and further splitting, of sequences initially containing I2S 
that precedes trisulfated glucosamine A*. 
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The chemical shifts of the anomeric H1/C1 signals of both gs-uronic acids and 
glucosamines linked to the gs-units are summarized in Table 3.2. 
Table 3.2.  1H and 13C chemical shifts in the anomeric region (H1/C1) 
characteristic for gs-heparins 
RESIDUE  1H, ppm  13C, ppm 
Glycol‐split uronic acids 
‐(gsG‐(ANAc))n‐ a  4.71  106.7 
gsG‐(ANAc6S) b  4.81  106.2 
gsG‐(ANS) c  4.88 (dp 6) 4.90 (dp 8) 
106.6 (dp 6) 
106.4 (dp 8) 
gsG d  4.87  106.6 
gsI‐(ANAc6S) b  4.92  106.9 
gsI‐(ANS) d,e  4.98  106.9 
gsG‐(A*) f  4.93  103.5 
gsGLR g  4.92  107.7 
gsXyl g  4.75  105.9 
Amino sugars 
‐(ANAc‐(gsG))n‐ a  5.09  99.5 
ANAc6S‐(gsI) b  5.12  98.2 
ANAc‐(gsU) d  5.12  99.0 
ANS‐(gsG) c  5.37 (dp 6) 5.38 (dp 8) 
98.9 (dp 6) 
98.8 (dp 8) 
ANS‐(gsI) e  5.32  98.9 
a assignment consistent with the 2D NMR spectrum of gs-K5 (gs-derivative of N-acetyl-heparosan) 
b assignment consistent with the 2D NMR spectrum of gs-derivative of N-acetylated BLH  
c determined using hexa- and octasaccharide fractions of gs-tinzaparin 
d value observed for gs-heparins in the present study 
e published by Casu and co-workers (2002) 
f obtained for using gs-derivative of AGA*IAOMe; A* = ANS3S(6S) 
g observed in gs-heparins and some gs-LMWHs (see also Chapter IV, Fig.4.6) 
 
Together with internal non-sulfated uronic acid residues, also GLR and Xyl of the LR can 
be split because of the vicinal OH-groups in their structures. A cross-peak at 4.92/107.7 ppm 
was attributed to the gsGLR because: i) it correlates with the primary alcohol group in the 
HSCQ-TOCSY spectrum (Fig. 3.2); ii) the ratio of peak volumes gsGLR : Gal1 : Gal2 is about 
1:1:1 in each sample where these signals are present; iii) it is absent in gs-heparins with no or 
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low LR content (K5, BLH); iv) its quantity increases substantially in gs-tinzaparin, known to 
have a high content of LR sequence preserved during soft depolymerisation process (Bisio et 
al, 2009), and a fraction of the gs-enoxaparin digest enriched in gsLR-bearing oligosaccharides 
(see Chapter IV). This latter sample was used for determining the chemical shift of gs-Xyl 
(Table 3.2, see also Chapter IV, Fig.4.6).  The other two cross-peaks clearly seen in the 
anomeric region of gs-PMH were assigned to the two Gal residues. The long-range correlation 
of H1/C1 cross-peaks with H3/C3 signals typical for galactose of the heparin LR (Xiao et al., 
2011) was shown by HMBC spectroscopy (Fig.3.5). Gal residue with the chemical shift 
(4.67/106.9 ppm) unaffected by glycol-splitting was attributed to Gal1 followed by Gal2 (Fig. 
1.19). In contrast, the Gal2 residue shifted after glycol-splitting (4.62/104.9 ppm), probably 
because it is affected by the adjacent gs-Xyl.  
Gal1 H1/C1
Gal2 H1/C1
Gal H3/C3
Gal H3/C3
 
Fig.3.5. HSQC (red) and HMBC 
(black) NMR spectra of glycol-split 
porcine mucosal heparin (gs-PMH) 
 
Correlation between anomeric cross peaks 
of two galactose residues of the LR 
sequence with the corresponding H3/C3 
signals is shown 
Notably, a cross-peak not related to the TSD regular sequences (H1/C1 5.53/99.1 ppm), 
attributable to the 3-O-sulfated aminosugar ANS3S(6S) (A*) is common to both gs and 
unmodified PMH. However, in the spectrum of gs-PMH, two H2/C2 cross-peaks, one of 
which corresponding to internal A* and the other to NRE-terminal A* (A*NRE) residues (Rudd 
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et al, 2013), are observed. The notable increase of A*NRE may be explained by partial 
hydrolysis of gs-PMH at the level of gsG/gsI followed by A* (Fig. 1.19e). Indeed, the decrease 
of the molecular weight after glycol-splitting as determined by SEC-TDA (see III.1) suggested 
that a hydrolytic side-reaction occured. Interestingly, the Linhard’s group reported that the 
ATBR is the first sequence to be hydrolyzed in a gs-heparin under basic conditions (Islam et 
al., 2002).  
Unexpectedly, signals in the “reducing end region” (4.7-5.2/91-98 ppm) are present in 
the gs-PMH (Fig.3.1). By comparison with the spectra of heparin oligosaccharides (Guerrini et 
al, 2008), they are attributable to anomers α (5.16/92.7 ppm) and β (4.77/97.5) of ANAc 
residues. Also less intense spots are observable at fields typical for RE residues of ANS, i.e., at 
5.44/93.9 (α) and 4.72/98.7 (β) ppm. The appearance of RE cross-peaks, which are usually 
absent in the spectra of UFHs, may indicate that also hydrolysis of some glycosidic bonds 
occurred (especially, at the level of N-acetylated regions).  
During gs-heparins preparation the pH was adjusted by adding 0,1 M HCl solution to 4 
to destroy NaBH4 in excess, and then increased up to 7 with NaOH to neutralize the acid 
excess in order to avoid desulfation. The pH adjustment, during which an acidic environment 
may be locally created, should be one of the most critical steps. To identify marker signals 
related to these side reactions, we completely hydrolyzed a gs-PMH sample by Smith 
degradation. SEC-TDA analysis of its hydrolysis products showed a Mw decrease from 10.8 to 
5.4 kDa, indicating that the sample was partially depolymerized. As expected, the gsG and gsI 
cross-peaks and the associated signals (ANS-(gsI), ANAc-(gsU)) totally disappeared upon 
hydrolysis (Fig.3.6). The cross-peak at 5.11/100.8 ppm resistant to the hydrolysis was shown 
to correspond to ANAc followed by R. It correlates with H2/C2 of the ANAc unit in the TOCSY 
spectrum (Fig. 3.6c). Also long-range correlation between this signal and C(3) of the remnant 
was shown in the HMBC spectrum (Fig. 3.6b). The same experiments were performed for 
determining the position of ANS-(R) in the HSQC spectrum (5.37/101 ppm, Fig. 3.6).  
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Fig. 3.6. NMR study of the hydrolyzed glycol-split porcine mucosal heparin  
(a) Superimposed 2D HSQC NMR spectra of gs-PMH before (blue spots) and after Smith degradation (orange 
spots), (b) HSQC (black spots) and HMBC (red spots) of the hydrolyzed gs-PMH, (c) TOCSY NMR spectrum of 
the hydrolyzed gs-PMH 
A – glucosamine, I – iduronic acid, G – glucuronic acid, gsI/gsG/gsU – glycol-split iduronic/glucuronic/uronic 
acid, Gal1/Gal2– galactose residues of the linkage region, gsXyl – glycol-split xylose, R – remnant of gsU. 
Together with the monosaccharide residue, the residue following it is indicated in parenthesis, in order to show 
the sequence effect.  
 
 
Together with the glucosamines bearing remnant, also strong RE-signals (ANSα, ANAcα, 
ANAcβ) appeared in the anomeric region of the HSQC spectrum (Fig.3.6a), indicating chain 
shortening. As mentioned in the Introduction (I.3), the hydrolysis of the glycosidic bonds may 
occur under aggressive acidic conditions (Jandik et al., 1996).  
 
 
H2 
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III.2.2. Quantitative HSQC NMR analysis. Comparison of different gs-heparins 
Though with different relative intensities, the HSQC spectra of gs-BLH, gs-OMH, gs-
BMH (Fig.3.7) display cross peaks similar to those of gs-PMH.  Except for the highly sulfated 
and very low acetylated BLH, the gs-heparins are difficult to be distinguished at first glance. 
The major differences include intensities of cross peaks typical for gsG and gsI as well as their 
ratio. To better characterize these samples, quantitative 1H/13C HSQC NMR was applied as 
described for unmodified heparins and other GAGs (Guerrini et al, 2005 and 2007).  
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Fig. 3.7. Anomeric region of 2D HSQC NMR spectra of gs-heparins of different origin 
(a) – gs-PMH, (b) – gs-BMH, (c) – gs-OMH, (d) – gs-BLH 
A – glucosamine, I – iduronic acid, G – glucuronic acid, gsI/gsG/gsU – glycol-split iduronic/glucuronic/uronic 
acid, Gal1/Gal2– galactose residues of the linkage region, gsXyl – glycol-split xylose, R – remnant of gsU. 
Together with the monosaccharide residue, the residue following it is indicated in parenthesis, in order to show 
the sequence effect.  
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Even if the HSQC spectra are currently exploited for quantitative evaluation of 
individual monosaccharide and disaccharide units in heparins (Guerrini et al., 2005)  and 
LMWHs (Guerrini et al., 2007), it was necessary to consider that the local flexibility of gs 
residues may affect their relaxation times and scalar coupling values. Relaxation time T2 
values, previously measured for a heparin and a gs-heparin samples (Casu et al., 2002), were 
found to be higher for both unmodified and gs residues in the gs-heparin with respect to the 
unmodified sample. However, no significant differences were observed for various residues 
(for example, I2S and gsU) within the same sample. The one bond coupling constants (1JC-H) 
for gs-residues gsI and gsG were measured in the present study using a gs-PMH sample and 
were found equal to 162 Hz, value very close to the values obtained for anomeric signals of 
unmodified uronic acids (Table 1.3, Guerrini et al, 2005). From this point of view, the gs-
residue response in HSQC spectra should be the same that for unmodified residues present 
within heparin chains, indicating that quantitative compositional analysis can be performed by 
peak volume integration, as currently being applied for heparin and LMWH quantitative 
analysis (Guerrini et al, 2005 and 2007).   
Selected values, expressed as percent moles of typical residues, are reported in Table 3.3.  
The content of I2S residues, components of the regular TSD sequences (Casu B., 2005), is 
~90% of total uronic acids for gs-PMH and even higher for gs-BMH (~94%) and gs-BLH 
(~99%). The I2S content is lower (about 87%) for gs-OMH, and especially for the gs-heparin 
variant HI-3 (62.6%) derived from a partially 2-O-desulfated PMH. The contents of total gs 
uronic acids (gsI + gsG) were correspondingly in the order: gs-BLH (1.0) < gs-BMH (5.6) < 
gs-PMH (10.3) < gs-OMH (13.3) < HI-3 (37.4). The obtained values are in accord with the 
sulfation degree of the starting heparin (for example, the total content of non-sulfated uronic 
acids followed the order BLH (4.8) < BMH (23.8) ~ PMH (26.7) < OMH (35.5)). However, it 
is necessary to consider that partial hydrolysis may affect the results. Except for HI-3, the 
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decrease of gsI was more significant than that of gsG, suggesting that the hydrolysis of the first 
residue is likely to be facilitated with the respect to its isomer. 
 
Table 3.3. Compositional quantitative NMR analysis of parent and glycol-split heparins  
Uronic acids  Hexosamines 
I2S  I  G  GalA  ANS  ANAc  A6S Parent heparins 
H1/C1  H2/C2  H6/C6 
PMH  73.5  9.8  16.9  < LOD b  87.0  12.9  80.8 
BMH  79.9  9.1  14.7  < LOD b  92.4  7.7  68.5 
OMH  64.5  6.7  20.2  8.6  94.7  5.3  90.3 
BLH  95.2  2.7  2.1  < LOD b  99.9  < LOQ b  92.4 
Uronic acids  Hexosamines 
I2S  gsI  gsG  ANS  ANAc  A6S Glycol‐split heparins 
H1/C1  H2/C2  H6/C6 
gs‐PMH  89.5  2.0  8.3  90.4  9.6  77.0 
gs‐BMH  94.4  < LOQ b  5.6  94.8  5.2  69.5 
gs‐OMH  86.7  4.4  8.9  95.0  5.0  80.0 
gs‐BLH  98.9  < LOQ b  1.0  99.9  < LOQ b  87.9 
Extensively 
gs‐heparin HI‐3a  62.6  26.7  10.7  89.7  10.3  65.7 
Data are expressed in moles percent (Guerrini et al, 2005); I2S –iduronic acid 2-O-sulfate; gsI/gsG – glycol-split 
iduronic/glucuronic acids (not including gsG of LR, if present); GalA – galacturonic acid; ANS – glucosamine-N-
sulfate (including the cross-peak of trisulfated glucosamine ANS3S6S)); ANAc – N-acetylated glucosamine 
Uronic acids compositional analysis was performed by integrating peak volumes of the anomeric region; total N-
sulfation/N-acetylation of glucosamine was performed by integrating the signals H2/C2 of the ring, while 6-O-
sulfation was determined by integration of the corresponding H6/C6 cross-peaks. Galacturonic acid was present 
in the ovine mucosal heparin contributing to the final content of gsG residues. 
a) Obtained from ~40% 2-O-desulfated PMH 
b) LOD – limit of detection, LOQ – limit of quantification 
 
Though at somewhat lower overall levels, contents found for the ANS residues practically 
follow the same order observed for the I2S residues. Table 3.3 reports the values for all the N-
sulfated glucosamines, including 3-O-sulfated ANS3S(6S) residues (4.5-6.8 %). Complement to 
100% of total glucosamines is accounted for by ANAc residues (from practically zero for gs-
BLH up to 9.6% for gs-PMH and 10% for HI-3). Notably, ANAc contents found in gs-samples 
are lower than those found for unmodified heparins (Table 3.3). This result is probably 
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associated with particular hydrolytic side reactions affecting the N-acetylated regions in higher 
degree than the N-sulfated sequences. Such an observation is in agreement with the appearance 
of ANAcα/β anomeric cross-peaks upon glycol-splitting. Islam and co-workers observed the 
disappearance of N-acetylated residues as a result of the work-up (acidic treatment) after 
periodate oxidation, used in order to obtain LMW products (2002).  
 
III.3. Determination of hydrodynamic properties of glycol-split heparins by SEC-
TDA 
Mark-Houwink parameters a and logK were also obtained for all the samples. Hereafter, 
the trends observed for the parameter a are discussed, while complete data, containing logK 
values, are shown in Annex 3. The analyses were repeated using 0.01 M NaNO3 solution as 
eluent, because under the experimental conditions used for molecular weight measurements 
(eluent 0.1 M NaNO3) the effect of the gs residues within the heparin chains is suppressed due 
to the high ion strength. Several trends can be observed from the obtained data. First of all, the 
Mark-Houwink plot is not linear and 3-4 distinct linear ranges may be observed for each 
heparin/gs-heparin sample, suggesting the conformational diversity between oligosaccharides 
of different length. An example for PMH is shown in Fig. 3.8. It is worth noting that internal 
slices (13-16 and 16-21 kDa in Fig.3.8) of the molecular weight distribution may be influenced 
by two well-defined adjacent linear regions (9-13 and 21-36 kDa in Fig. 3.8). We characterized 
these regions separately because of their close proximity to Mn and Mw values (Fig. 3.8). 
The higher the molecular weight, the lower the a value. Accordingly, they are in the 
range of typical flexible polymers in random coil form for higher masses, while appeared very 
high for shorter oligosaccharides, indicating more rigid structures. Different chain length and 
sulfation degree as well as different flexibility of iduronic and glucuronic acids may contribute 
to the conformational equilibrium. It is likely that sulfation degree may provide a significant 
impact. The longer chain oligosaccharides statistically contain longer undersulfated domains 
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and random coil formation is favored, while shorter chains likely contain highly sulfated 
negatively-charged sequences that may impair their flexibility.  
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Fig.3.8. Mark-Houwink plot for PMH obtained by SEC-TDA using 0,01 M NaNO3 as eluent 
Parameter a was determined for each linear region (kDa), except for the “critical” zones where sample 
concentration is low (under 5%) 
 
 
Interestingly, the number of regions characterized by distinct a values was found 
different for different parent heparins (Fig. 3.9). In Table 3.4 the fraction weight corresponding 
to each defined molecular weight range and the determined a value are shown. Another 
evident trend is that the a value decreases for gs-samples, suggesting the glycol-splitting-
induced higher flexibility (Fig. 3.10, Table 3.4). The flexibility of BLH chains containing very 
low amount of non-sulfated I and G susceptible to periodate, was less affected by glycol-
splitting (Fig. 3.10, Table 3.4). 
 
 59 
Table 3.4. Mark-Houwink parameter a obtained for heparins of different animal sources and their glycol-split derivatives  
NMR (mol.%) 
Sample 
I2S  ANS  A6S 
Range, kDa  %  a  Range, kDa  %  a  Range, kDa  %  a  Range, kDa  %  a 
PMH  73.5  87.0  80.8  9 – 13  28  1.37  13 – 16  21  0.94  16 – 21  17  0.66  21 – 36  17  0.57 
BLH  95.2  99.9  92.4  8 – 10  24  1.32  10 – 12  15  0.99  12 – 23  28  0.74  23 – 37  10  0.63 
OMH  64.5  94.7  90.3  6 – 7  12  1.41  7 – 14  50  0.99  14 – 32  31  0.66  > 32  nd  nd 
H
e
p
a
r
i
n
s
 
BMH  79.9  92.4  68.5  < 8  nd  nd  8 – 17  60  1.08  17 – 22  13  0.74  22 – 35  14  0.63 
         
gs‐PMH  89.5  90.4  77.0  3.5 – 4.5  15  1.44  4.5 – 8.5  38  0.90  8.5 – 22  36  0.53  > 22  nd  nd 
gs‐BLH  98.9  99.9  87.9  < 4.5  nd  nd  4.5 – 8  43  1.20  8.0 – 23  44  0.55  > 23  nd  nd 
gs‐OMH  86.7  95.0  80.0  2.5 – 3  20  1.33  3 – 6.5  42  0.71  6.5 – 17  29  0.55  > 17  nd  nd 
G
s
‐
h
e
p
a
r
i
n
s
 
gs‐BMH  94.4  94.8  69.5 
 
< 3  nd  nd 
 
3 – 7.5  51  0.97 
 
7.5 – 21  38  0.56 
 
> 21  nd  nd 
% - the fraction weight in mass.%, for each selected molecular weight range. The columns, better showing the trends discussed in III.3, are in yellow. 
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Fig. 3.9 Mark-Houwink plots obtained for heparins of different sources 
BMH – black, OMH – red, BLH – blue, PMH – green  
Fig.3.10. Mark-Houwink plots obtained for PMH (green) and its 
gs-derivative (black) 
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III.4. LC-MS analysis for structural characterization of gs-heparins and their 
starting materials 
As mentioned in the Introduction, to better study heparin sequences and unravel minor 
modifications of such a microheterogeneous polysaccharide, enzymatic depolymerisation 
followed by LC-MS analysis of the obtained mixture is often necessary. Among the other 
chromatographic techniques IPRP-HPLC has important advantages, first of all, it is easy to 
couple with MS, permitting the separation and identification of oligosaccharides in complex 
heparin-derived mixtures. This application demands the use of a mass spectrometer of high 
resolution and accuracy in mass determination. In the present work ESI-Q-TOF MS was 
chosen. The potential of the developed LC-MS method for qualitative and quantitative analysis 
of different gs-heparins has been studied. The obtained results were compared with NMR data. 
A previous exhaustive digestion with heparin lyases (heparinases) was performed in 
order to simplify the analyzed mixture. Given the high specificity of heparinases that 
preferentially cleave glycosidic bonds of unmodified heparin sequences (see I.1.4.2), these 
enzymes were expected to be unable to cleave bonds between glucosamine and gs-uronic acid 
residues. Exhaustive digests of gs-heparins with heparin lyases I, II, and III are accordingly 
expected to consist prevalently of disaccharides generated from unmodified heparin chains, as 
well as of several small oligosaccharides containing gsG/gsI residues (Fig.3.11). The 
combined approach of analyzing both non-glycol-split and glycol-split heparins should provide 
more detailed structural information on sequences of unmodified heparin (for example, on the 
number of subsequent non-sulfated uronic acids) with respect to the traditional method based 
on analysis of enzymatic digests of unmodified heparins. 
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Fig. 3.11. Generation of gs-oligosaccharides by exhaustive heparinases-digestion of gs-
heparins 
Green arrows indicate glycoside bonds that can be cleaved by heparinases; grey arrows show glycosidic bonds 
supposed to be resistant to enzymes because of the glycol-splitting induced modifications 
  
A specific nomenclature reflecting the first-level structure obtained by LC-MS analysis 
of heparin oligosaccharides was used. The abbreviation system is similar to that of Henriksen 
and co-workers (2004) and indicates the number of monosaccharide residues, sulfate groups, 
and N-acetyl groups. In our case, a number and the symbol “gs” were also added to indicate 
the number of the gs-residues. “Remnants” of the hydrolyzed internal gs residues were 
indicated by the symbol R (see Fig. 1.19e). Symbol ΔU and A indicate a 4,5-unsaturated 
uronic acid and a glucosamine residue, respectively, at the NRE. 
 
III.4.1. Optimization of IPRP-HPLC/ESI-Q-TOF method  
For optimizing separation and detection parameters, gs-PMH was chosen as a model 
sample. Firstly, ESI-Q-TOF parameters (capillary voltage and transfer line voltages) were 
optimized to avoid desulfation and significant adduct formation (first of all, with an ion-pair 
amine present in high concentration in the eluent). Both positive and negative ion mode were 
tested. The positive one was more sensitive, however, led to the formation of numerous adducts 
with dibutylamine (DBA) used as ion-pair agent. For this reason, negative ion mode, providing 
less complex spectra, was chosen. Values slightly lower than the typical ESI voltages were 
chosen as a compromise (see Experimental). A more crucial decrease of these voltages leads to 
the sensitivity “fall”, whereas higher values may cause significant desulfation.  
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As expected, enzymatic digests of gs-heparins are mainly constituted by disaccharides 
and by a number of tetra- and higher saccharides containing undigested gs-residues (Fig.3.12).  
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Fig. 3.12. LC-MS (a) and LC-UV 
(b) chromatograms of heparinase-
digest of glycol-split porcine 
mucosal heparin under the 
optimized conditions 
HPLC-UV Conditions: Column C18 
100x2.1 mm, 2.6 μm; eluents A and B – 
10 mM DBA and 10 mM CH3COOH in 
water-methanol = 9:1 (v/v) and methanol, 
respectively; multi-step gradient: 0 min – 
17%B, 10 min – 17%B, 30 min – 42%, 50 
min – 50%B, 65 min – 90%B, 75 min – 
90%B, 76 min – 10%B, 90 min – 10%B; 
flow-rate – 100 µl/min; UV detection – 
232 nm 
ESI-Q-TOF-MS conditions: negative ion 
mode, capillary voltage – 3.2 kV, 
nebulizer gas – 0.9 bar, drying gas – 7.0 
l/min, 180°C, m/z range 200-2000 
 
 
Optimization of chromatographic conditions was focused on the simultaneous separation 
of disaccharides and other peculiar oligosaccharides. Different aliphatic amines, among which 
dibutyl-, n-pentyl and n-hexylamine, have been tested in their acetate salt form, compatible 
with ESI-MS, as ion pair agents. The other amines that were historically used in IPRP mode are 
tri- and tetra-butylamines. However, these molecules are strongly adsorbed on the C18 
stationary phase, increasing the total analysis time. To compensate this effect, higher 
concentration of the organic solvent should be used, that, unfortunately, leads to worse 
resolution and signal suppression (Langeslay et al, 2013). DBA was chosen because it has been 
successfully used for the analysis of HS oligosaccharides (Wu and Lech, 2005; Kuberan et al., 
2002) and for pentasaccharidic and octasaccharidic heparanase substrates and their heparanase-
cleaved products (Bisio et al., 2007). n-Pentyl- and n-hexylamines have been chosen to be 
compared with DBA, since their effectiveness in the IPRP separations of some 
oligosaccharides has been recently demonstrated (Doneau et al., 2009, Langeslay et al, 2013). 
 63
A linear gradient of methanol was applied to compare the resolution provided by different 
amines (their concentration was kept constant, 10 mM). However, only the DBA acetate salt 
provided both the simultaneous separation of di- and oligosaccharides and a good resolution of 
positional isomers including gs species. Probably, it is more “selective” for the interaction with 
sulfate groups of different positional isomers than its mono-alkyl-analogs due to higher 
stereochemical hindrance. It should be noted that our results do not contradict the work of 
Doneau and co-workers (2009), where mono-alkyl-amines provided better results. The authors 
were focused on the sensitivity improvement of the MS detection for oligosaccharides with 
high polymerization degree (up to dp 22), while in our study we put special emphasis on the 
separation of short oligosaccharides, including isomeric components. For this reason, DBA was 
chosen for a further optimization of separation conditions. The dependence of the resolution of 
gs tetra- and hexasaccharides generated from gs-PMH by enzymatic cleavage, the DBA 
concentration in eluents has been investigated using a linear gradient changing from 10% B to 
90% B in 90 min. It has been shown that the change of the ion pair agent concentration from 5 
to 10 mM was crucial for the chromatographic resolution of gs oligosaccharides, while further 
increase of its concentration up to 15 mM did not influence significantly the chromatographic 
separation (Fig.3.13) but led to an essential decrease (~ 2 times) of MS detection sensitivity and 
to an increase of the total analysis time. In Fig.3.13 the resolution coefficients Rs as function of 
DBA concentration are shown for pairs of oligosaccharides with similar structure and, 
consequently, similar chromatographic behavior (in other words, difficult to be separated). The 
mass spectra interpretation and compositional analysis of gs-heparin digests with all the 
identified oligosaccharides are discussed below. For the species shown in Fig.3.13 see the 
abbreviation system in the footnote.  
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Fig.3.13. Dependence of the resolution 
coefficient (Rs) between target pairs of 
analytes on DBA concentration in eluent 
 
Conditions: Column C18 100x2.1 mm, 2.6 μm; 
eluents A and B – x mM DBA and x mM 
CH3COOH (x = 5, 10, 15 mM) in water-methanol = 
9:1 (v/v) and methanol, respectively; linear gradient: 
0 min – 10%B, 90 min – 90%B at 100 µl/min; UV 
detection – 232 nm 
 
Abbreviation system includes the number of 
monosaccharide residues, sulfate and N-acetyl 
groups, and the number of gs-residues. Symbol ΔU 
indicates 4,5-unsaturated uronic acid at the NRE. 
 
 
Having found the optimal concentration of DBA (10 mM), the gradient has been adapted 
to achieve better resolution for the simultaneous separation of di-, tetra- and hexasaccharides 
(Fig.3.12). The resolution coefficients (Rs) for six oligosaccharide pairs, components of 
heparinase digests of gs-PMH, were found to be 1.67 for ΔU4,4,0,1gs/ΔU4,4,1,1gs, 1.30 for 
ΔU4,6,0,1gs/ΔU6,6,1,1gs, 1.33 for ΔU6,6,1,2gs/ΔU6,6,1,1gs(1), 1.21 for 
ΔU6,6,1,1gs(1)/ΔU6,6,1,1gs(2), 1.55 for ΔU6,7,1,2gs/ΔU6,7,1,1gs(1) and 1.33 for 
ΔU6,7,1,1gs(1)/ΔU6,7,1,1gs(2). This resolution is sufficient for fingerprinting the enzymatic 
digests obtained from gs derivatives of different heparin samples through their LC-MS profiles.  
Inter-day variations have been also evaluated for the twelve target compounds (di-, tetra-, 
and hexasaccharides) eluted from the chromatographic column with different retention times in 
the range from 8 up to about 60 min. As shown in the Table 3.5, the value of day-to-day 
variability (RSD) does not exceed 1.1 % for each target compound.  
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Table 3.5.  Retention times (RT) and inter-day variability (RSD) for 
the target analytes 
RT, min  
(inter‐day measurements, n=3, P=0.95) Analyte 
x ± Δx   
ΔU2,2,0  9.0 ± 0.2  1.1 
ΔU2,3,0  26.0 ± 0.6  1.0 
ΔU4,3,1,1gs (1)  33.2 ± 0.7  0.8 
ΔU2,3,0‐R  35.6 ± 0.7  0.8 
ΔU4,4,0,1gs  37.8 ± 0.7  0.7 
ΔU4,4,1,1gs  38.8 ± 0.8  0.8 
ΔU4,5,0,1gs  42.5 ± 0.9  0.8 
ΔU6,6,1,2gs  47.4 ± 1.0  0.9 
ΔU4,6,0,1gs  47.8 ± 0.9  0.8 
ΔU6,7,1,2gs  52.7 ± 1.0  0.8 
ΔU6,7,1,1gs (1)  53.7 ± 1.0  0.8 
ΔU6,7,1,1gs (2)  54.8 ± 0.9  0.7 
The abbreviation system includes the number of monosaccharide residues, sulfate 
and N-acetyl groups, and the number of gs-residues, when present. Symbol ΔU 
indicates 4,5-unsaturated uronic acid at the NRE. Symbol R is used to indicate the 
presence of a remnant of gsG/gsI unit at the RE 
 
 
III.4.2. Mass spectra interpretation and identification of oligosaccharides 
By exact mass, each analytical signal has been identified as “first-level” structure, 
including the number of monosaccharide residues, sulfates, acetyl groups, and gs-units when 
present (Table 3.6). Three examples of negative ESI mass spectra, characteristic for sulfated 
oligosaccharides by loss of one or more sulfate groups and formation of dibutylamine adducts, 
are shown in Fig. 3.14 for ∆U2,3,0 (a), ∆U4,5,0,1gs (b), ∆U6,7,1,2gs and ∆U6,7,0,2gs (c).  
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Fig. 3.14. Mass spectra of the major disaccharide ∆U2,3,0 (a), gs-tetrasaccharide ∆U4,5,0,1gs 
(b), and gs-hexasaccharides ∆U6,7,1,2gs and ∆U6,7,0,2gs (c) observed by IPRP-HPLC/ESI-Q-
TOF 
HPLC-UV/ESI-Q-TOF-MS conditions: see Fig.3.12 
The abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE.  
 
Retention times, molecular formulae, monoisotopic exact masses and corresponding first-
level structures of the major components of heparinase digests of gs-PMH are reported in Table 
3.6. Some components with the same “monoisotopic exact mass” values, corresponding to 
different isomers, are present in the heparinase-digests of gs-heparins. 
Their formula was only accepted if the m/z of the candidate analyte matched the 
theoretical value within 5 ppm. The presence of gs-residues can be detected by the increase of 
the mass values by two daltons. 4,5-unsaturation of the uronic acids (typical for the heparinase-
generated oligosaccharides, see Fig.1.11), detectable by the loss of 18 Da (corresponding to one 
water molecule), causes the absorption of the UV-light at 232 nm. This property was used as a 
control during the structure assignment.  
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Table 3.6. Major fragments in heparinase-digests of gs-PMH found by LC-MS 
 Monoglucosamines Disaccharides Trisaccharides 
First-level structure A1,2,0 A1,3,0 (A*) ∆U2,2,0 ∆U2,3,0 ∆U2,3,0-R A3,5,0,1gs ∆U3,4,0-ol ∆U3,5,0-Ram 
Formula C6H13N1O11S2 C6H13N1O14S3 C12H19N1O16S2 C12H19N1O19S3 C16H25N1O23S3 C18H34N2O30S5 C18H29N1O28S4 C22H35N1O34S5 
Exact mass 338.9930 418.9498 497.0145 576.9713 694.9979 917.9800 834.9759 1016.9644 
Retention time, min 4.4 9.9 8.9 25.9 35.5 38.8 40.8 43.8 
 Glycol-split tetrasaccharides 
First-level structure ∆U4,3,1,1gs ∆U4,4,1,1gs ∆U4,4,0,1gs ∆U4,5,0,1gs ∆U4,5,0,1gs-R ∆U4,6,0,1gs 
Formula C26H42N2O30S3 C26H42N2O33S4 C24H40N2O32S4 C24H40N2O35S5 C28H46N2O39S5 C24H40N2O38S6 
Exact mass 958.0985 1038.0553 996.0447 1076.0015 1194.0281 1155.9583 
Retention time, min 
(1) 33.0 
(2) 34.0 
38.6 37.7 42.3 46.0 47.8 
 Glycol-split hexasaccharides 
First-level structure ∆U6,5,1,1gs ∆U6,6,1,1gs ∆U6,6,1,2gs ∆U6,7,0,2gs ∆U6,7,1,1gs ∆U6,7,1,2gs ∆U6,8,0,1gs ∆U6,8,0,2gs 
Formula C38H61N3O46S5 C38H61N3O49S6 C38H63N3O49S6 C36H61N3O51S7 C38H61N3O52S7 C38H63N3O52S7 C36H59N3O54S8 C36H61N3O54S8 
Exact mass 1455.1130 1535.0698 1537.0854 1575.0317 1615.0266 1617.0423 1652.9729 1654.9885 
Retention time, min 
(1) 43.8 
(2) 44.5 
(3) 45.3 
(1) 48.4 
(2) 49.1 
(3) 49.9 
47.4 
(1) 47.9 
(2) 51.8 
(1) 53.6 
(2) 54.8 
52.4 
(1) 59.3 
(2) 60.3 
57.9 
 
 * Abbreviation system for the “first-level structures” includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the number of gs-residues. Symbol ΔU 
indicates 4,5-unsaturated uronic acid at the NRE. Symbol R is used to indicate the presence of a remnant of gsG/gsI residue at the RE. Ram indicates a remnant formed by splitting 
and further hydrolysis of RE glucosamine residues (described in Chapter IV.4)
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The comparison of the experimentally obtained isotope pattern with the theoretical one 
was also used to confirm the assigned structure. This is possible due to the specific sulfur 
isotope abundance in nature. It exists mainly in two forms, 32S (95.02%) and 34S (4.21%). An 
example is shown in Fig.3.15. Oligosaccharides ∆U4,6,0,1gs and ∆U4,4,1,1gs-R, having the 
same nominal molecular mass (1156 Da) can be only distinguished by the accurate 
determination of monoisotopic m/z value and comparison of the experimental isotope pattern 
with the theoretical one. 
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Fig.3.15. Experimental and simulated isotope patterns of ∆U4,4,1,1gs-R (a,b) and 
∆U4,6,0,1gs (c,d) 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol R is used to 
indicate the presence of a remnant of gsG/gsI residue at the RE 
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II.4.3. Comparison of heparinase-digests of porcine mucosal heparin and its glycol-split 
derivative 
After having optimized the separation conditions and identified each analytical signal, the    
LC-MS profile of the gs-PMH heparinase-digest was compared with the corresponding digest 
of the unmodified PMH (Fig.3.16) in order to better characterize the gs-sample. 
 
Fig.3.16. Comparison of LC-MS profiles of PMH (upper chromatogram) and its glycol-split 
derivative (lower chromatogram) after exhaustive enzymatic digestion 
In the figure only major compounds are shown. 
HPLC-UV/ESI-Q-TOF-MS conditions: see Fig. 3.12. 
Abbreviation system for the “first-level structures” includes the number of monosaccharide residues, sulfate and 
N-acetyl groups, and the number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. 
Symbol R is used to indicate the presence of a remnant of gsG/gsI residue at the R 
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Most of the peaks generated upon enzyme treatment by both PMH and gs-PMH are 
attributable to oligomers initiating with a ΔU2S residue (Table 3.6). Even if with different 
relative intensities, only the major unsaturated trisulfated disaccharide ΔU2S-ANS6S (ΔU2,3,0), 
characterizing the regular highly sulfated TSD sequences (Fig.1.19), and the minor disulfated 
unsaturated disaccharide ΔU2S-ANS (ΔU2,2,0) are common components of the digestion 
products of both unmodified and gs-species.  
Two isomers ΔU2,2,0, characterized by slightly different retention time values (8.2 and 
8.6 min), were distinguished using the corresponding standard solutions independently by 
monitoring LC-UV chromatogram (see below, Fig.3.20). The resolution in LC-MS was lower 
(Fig. 3.16) because of a possible mixing of isomers in the tube connecting UV and MS 
detectors. While ΔU2S-ANS is preserved, its positional non-2-O-sulfated isomer ΔU-ANS6S 
(ΔU2,2,0) as well as ΔU-ANS (ΔU2,1,0) and ΔU-ANAc6S (ΔU2,1,1) disappear completely in the 
gs-PMH digest due to the splitting of non-sulfated uronic acids residues. The disaccharides that 
disappeared upon glycol-splitting were expected to be incorporated in the longer 
oligosaccharides containing the generated gs-residues. Indeed, heparin digests do not contain 
oligosaccharides longer than tetramers, while gs-heparin digests contain disaccharides 
preserved after glycol-splitting, gs-tetrasaccharides and gs-hexasaccharide fragments 
(Fig.3.16). Also traces of several gs-octasaccharides with three gs-residues were observed in 
the gs-PMH digest (not shown, see Discussion). 
The most prominent oligosaccharide peak of gs-PMH corresponds to the pentasulfated 
ΔU4,5,0,1gs containing a TSD unit followed by a gs-residue and ANS6S (Fig.3.17a). It is a 
marker of the TSD units that were adjacent to non-sulfated uronic acids in the original heparin 
chains. This component was isolated and its structure was confirmed by NMR (Fig. 3.17b). The 
corresponding unmodified tetrasaccharide ΔU2S-ANS6S-G-ANS6S was previously found by Xiao 
et al. (2011). 
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Fig. 3.17. Structure of the major gs-tetrasaccharide ΔU4,5,0,1gs of the heparinase-digest of gs-
heparins and its partial HSQC NMR spectrum 
 
It is worth noting that in several cases it was possible to determine the exact structure of 
components of the enzymatic digest, as for example oligosaccharides derived from the ATBR. 
The resistance to enzymatic cleavage of the glycosidic bond between glucosamine and 
glucuronic acid when this latter is followed by a 3-O-sulfated glucosamine is well known (see 
I.1.4.2). Accordingly, the most prominent tetrasaccharide peak ΔU4,4,1 (∆U-ANAc6S-G-ANS3S6S) 
in the heparin digest is derived from the ATBR (Fig.3.16a, Viskov and Mourier, 2004). Gs 
residues induced an additional resistance to heparinase leading to the formation of a 
monoacetylated hexasaccharide with two internal gs-residues ΔU6,7,1,2gs (Fig.3.16b). The 
intensity of this signal increased in the gs-derivative of the heparin fraction with high affinity 
towards AT (fraction enriched in the sequences containing the active site), confirming the 
proposed structure (Fig.3.18).  
The obtained results show also that ΔU4,4,1,1gs is not associated with the ATBR 
sequence (it is incorporated in the ΔU6,7,1,2gs), but should correspond to the sequence ∆U2S-
ANS6S-gsG/gsI-ANAc6S. 
 
 
 72
0
2
4
6
8
10
gs-PMH gs-HA PMH
A
re
a 
ra
tio
S(
∆U
6,
7,
1,
2g
s)
/S
(∆U
2,
3,
0)
, %
O
OH
CO2
-
OH
O O
O
NHAc
OH
CH2OSO3
-
CO2
O
OHOH
O
CH2OSO3
-
NHSO3
OSO3-O O
-
-
O
OSO3
-
OH O
O
NHSO3
-
OH
CH2OSO3
-CO2
-
OH
∆U6,7,1,2gs 
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Normalization to ∆U2,3,0 peak area was done in order to both 
evaluate the ATBR content with respect to regular highly sulfated 
TSD-sequences and to avoid errors associated with the stability of 
MS detector 
 
As detailed in Table 3.6 for gs-PMH, heparinase-digestion of gs-heparins generate also 
minor, small-size fragments such as the monosaccharides A1,2,0 and A1,3,0(A*) (where A is 
ANS6S and A* is a 3-O-sulfated ANS3S6S) and disaccharide ΔU2,3,0-R (where R is the remnant at 
the RE, Fig.3.19). All these compounds are markers of a hydrolytic process at the level of gs-
units. For example, monosaccharides A1,2,0 and A1,3,0(A*) are usually present in the digest 
of PMH (indicating that several heparin chains have A at the NRE), but in low amount 
(unpublished observation from our laboratory). This is in agreement with NMR data, where 
the formation of A*NRE upon glycol-splitting was observed (discussed in III.2). Trisaccharide 
ΔU3,4,0-ol (assigned to a compound terminating with a reduced uronic acid, Fig.3.19) is likely 
to be generated from the heparin chains bearing uronic acid at the RE. The presence of A and U 
at the NRE and RE, respectively, is in agreement with the possible depolymerization of the 
macroheparin precursor by heparanase.  
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III.4.4. LC-MS differentiation of gs-heparins obtained from heparins of different sources 
After having identified all components of the heparinase-digests of PMH and gs-PMH, 
the developed approach has been applied for profiling gs-heparins of other sources (gs-OMH, 
gs-BMH, gs-BLH), including gs-derivatives of a ~40% glycol-split derivative of PMH (HI-3) 
to verify the sensitivity of the approach for detecting structural differences within gs-heparins 
chains. For comparing these samples, we focused our attention on three aspects: (1) 
comparison of the disaccharides composition, (2) comparison of tetra- and hexasaccharide 
fractions and, (3) finally, the absence or presence of octasaccharidic components. 
 
Comparison of the disaccharides composition by quantitative LC-MS analysis 
As opposed to tetra- and hexasaccharides, the whole series of disaccharide standards are 
commercially available, thus permitting their quantitative analysis. Because the enzymatically 
generated disaccharides have a chromophore group absorbing at a characteristic wavelength 
(232 nm), the quantitative analysis using both MS (Fig.3.16) and UV (Fig.3.20) detector was 
performed. The regression equations, correlation coefficients, limit of detection (LOD), limit of 
quantification (LOQ) and area variability (RSD) for the major disaccharides present in gs-
heparin digests (∆U2S-ANS and ∆U2S-ANS6S) are given in Table 3.7.  
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Fig. 3.20. LC-UV chromatograms (232 nm) of heparinase-digests of PMH (a) and gs-PMH (b) 
Arrows evidentiate that glycol-splitting induced disappearance of disaccharides 1, 2 and 3 originally containing 
non-sulfated G/I. Upon glycol-splitting, these heparin units become part of tetra- and hexasaccharides containing 
gs residues. 1 – ΔU2,1,0 (ΔU–ANS), 2 – ΔU2,1,1(ΔU–ANAc6S), 3 – ΔU2,2,0 (ΔU–ANS6S), 4 – ΔU2,2,0 (ΔU2S–ANS), 
5 – ΔU2,2,1 (ΔU2S–ANAc,6S), 6 – ΔU2,3,0 (ΔU2S–ANS6S), 7 – ΔU4,3,1,1gs, 8 – ΔU2,3,0-R, 9 – ΔU4,4,1, 10 – 
ΔU4,4,1,1gs, 11 – ΔU4,5,0,1gs, 12 – ΔU4,5,0. 
 
Table 3.7. Regression equations, correlation coefficients (R2), limit of detection (LOD), limit 
of quantification (LOQ) and area variability (RSD) for ΔU2S-ANS and ΔU2S-ANS6S detected by UV 
and MS 
UV (232 nm) 
 Regression equation 
(y – S·10-1, mAU; x – C, μg/ml) R
2 LOD, μg/ml LOQ, μg/ml Area RSD*,% 
ΔU2S-ANS y = 2.137x – 0.120 0.9994 4.3 21.0 0.3 
ΔU2S-ANS6S y = 1.621x – 0.122 0.9991 5.2 40.2 0.3 
MS (neb. 0.9 bar, dry gas 7 ml/min, 180ºC; +3.2 kV; m/z 200 – 2000 Da; flow-rate 100 μl) 
 Regression 
(y – S·10-4, mAU; x – C, μg/ml) R
2 LOD, μg/ml LOQ, μg/ml Area RSD*,% 
ΔU2S-ANS y = 7.682x – 1.005 0.9989 0.13  0.24  3.5 
ΔU2S-ANS6S y = 7.839x - 1.447 0.9989 0.11 0.20 3.4 
 *  inter-day measurements, n=3, P=0.95 
  S – peak area 
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For the major trisulfated disaccharide ΔU2S-ANS6S the dynamic range of the calibration 
curve (range between LOQ and limit of linearity (LOL)), was from 40 to 1500 µg/ml when 
using UV detection at 232 nm and from 0.20 up to 550 μg/ml for MS detection. Because the 
ΔU2S-ANS6S concentration in digested gs-heparins varied from 300 to 600 μg/ml, each sample 
was diluted two times before LC/UV/MS analysis in order to avoid saturation of the MS 
detector and the chromatographic column. Injection of higher amounts of sample occasionally 
led to lower accuracy of quantitative analysis as well as peak broadening and decreasing 
efficiency. Both UV and MS calibration curves obtained for the less abundant   ΔU2S-ANS were 
linear in the whole concentration range typical for non-modified and gs-heparins, namely         
3 – 100 μg/ml. The lower limit of the dynamic range (LOQ) was found equal to 21.0 µg/ml for 
the UV detector and 0.24 μg/ml for the MS detector. As expected, the area variability (RSD) 
for UV detection is lower than for the MS (Table 3.7). So, for quantitative analyses, the 
calibration curves obtained with UV detector have been chosen. The MS detection cannot be 
used, especially, when saturated disaccharides, such as the trisulfated disaccharide 2,3,0      
(I2S-ANS6S, RT 24.8 min) which partially overlaps with its unsaturated analog ΔU2,3,0           
(RT 26.0 min, Table 3.5), are present. While they did not absorb at 232 nm, the MS detector is 
sensitive to these analytes that may lead to incorrectly higher results. 
For PMH the ΔU-ANS6S, ΔU-ANAc6S, ΔU-ANS (absent in gs-PMH due to their 
incorporation into longer chain oligosaccharides) were also evaluated. Since the extinction 
coefficient at 232 nm for all mentioned disaccharides were the same under the applied 
analytical conditions, it was possible to use the calibration curve obtained for ΔU2S-ANS for 
calculating the total amount of two positional isomers (ΔU2S-ANS and ΔU-ANS6S), that are 
eluted at the same retention time, and of ΔU-ANAc6S, ΔU-ANS.  
The contents of disaccharides in digests of gs-heparins obtained from starting materials of 
different origin are reported in Table 3.8. The values are expressed as a percentage of the 
digested heparin or gs-heparin material (100 μg). Such an expression permits not only to 
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compare the different samples, but also to evaluate the content of the regular highly sulfated 
sequences, not adjacent to non-sulfated uronic acids, within heparin chains.  
Table 3.8. Disaccharide compositional analysis determined by HPLC/UV, of PMH and 
different gs-heparins (normalized to quantity of digested material)* 
x ± ∆x, % mass. 
∆U-ANS ∆U-ANAc6S ∆U-ANS6S ∆U2S-ANS ∆U2S-ANS6S 
 
RT  4.3 min RT 4.4 min RT 8.2 min RT 8.6 min RT 25.6 min 
PMH 7.7 ± 0.3 17.5 ± 0.3 # 66.7 ± 0.9 
gs-PMH < LOD < LOD < LOD 4.8 ± 0,2 49.2 ± 0.9 
gs-OMH < LOD < LOD < LOD 2.1 42.3 
gs-BMH < LOD < LOD < LOD 9.5 45.9 
gs-BLH < LOD < LOD < LOD 3.9 80.4 
HI-3 < LOD < LOD < LOD 2.7 32.0 
*Analyses of digests of PMH and gs-PMH were performed in duplicate (n=2, P=0.95), for other samples single 
analyses were performed. The RT values shown in this table were obtained using UV detector.  
LOD = limit of detection. 
# The total amount of these two isomers was determined using the calibration curve obtained for ΔU2S-ANS, the 
isomer that is preserved in gs-heparins. Even if ΔU-ANS6S is characterized by an extinction coefficient somewhat 
higher that of its isomer leading to an overestimated value, the percentage found for the sum of the two isomers is 
in agreement with the results obtained by other authors (Wang et al., 2012) 
As expected, since the glycol-splitting reaction converts the non-sulfated uronic acids to 
glycol-split residues, only ΔU2S-ANS and ΔU2S-ANS6S are preserved during gs-reaction and, 
consequently, gs-heparin digests showed an overall content of disaccharides lower than 
unmodified heparin. Also, with the exception of gs-BLH, the total disaccharide content in 
digested gs-heparins of different type (43-55%) is consistently lower than for PMH (~92%). 
The latter sample contains, as opposed to the digests of the gs-heparins, non-2-O-sulfated 
disaccharides as well as a higher quantity of the 2-O-sulfated ones. The lower content of ΔU2S-
ANS and ΔU2S-ANS6S in the gs-heparin digests with respect to the PMH digest is explained by 
their incorporation into tetra- (for example, ΔU4,5,0,1gs in Fig. 3.17) and higher 
oligosaccharides containing gs-residues. The high disaccharide content of gs-BLH (~85%) 
correlates with its high sulfation degree reported in the literature (Guerrini et al., 2001). The 
extensively gs-PMH variant (HI-3) shows the lowest content of disaccharides (~35%) due to 
the highest non-sulfated uronic acid content in the starting material. 
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Comparison of tetra- and hexasaccharide fractions 
The second step consisted in the comparison of the tetra-and hexasaccharide contents. As 
illustrated in Fig.3.21, the LC-MS profiles of tetra- and hexasaccharide regions of the 
heparinase digests of gs-heparins, obtained from heparin samples of different tissue/species, 
significantly differ from each other.  
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Fig.3.21. LC-MS profiles of heparinase digested tetra- and hexasaccharides of glycol-split-
heparins of different animal and organ sources including HI-3 derived from partially 2-O-
desulfated PMH. In panel (c) extraction ion chromatograms (EICs) of octasaccharides with three 
gs residues found in gs-PMH and HI-3 digests are shown.  
HPLC-UV/ESI-Q-TOF-MS conditions: see Fig.3.12. 
 
 
Even if most of the fragments contain gs residues, the relative proportion of peaks varies 
for the different heparins and their overall profiles constitute characteristic fingerprints. The 
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chromatogram of gs-BLH digest displays the largest differences with respect to those of 
reference gs-PMH. Generally, the signal intensities of the oligosaccharidic region of the 
chromatogram, where most of the peaks of gs-compounds are observed, are the lowest for gs-
BLH (Fig. 3.21). This is in agreement with the high sulfation degree of gs-BLH showed by 
NMR and the high content of ΔU2,3,0 determined by LC-MS quantitative analysis (Table 3.8). 
The low N-acetylation degree of BLH is also reflected in the relative content of tetrasulfated 
tetrasaccharides ΔU4,4,0,1gs and ΔU4,4,1,1gs (Fig. 3.22). In the gs-PMH the N-acetylated 
form appeared much more intense, while their intensities are inverted in gs-BMH, and, finally, 
in the highly sulfated gs-BLH the acetylated tetrasaccharide appeared only in trace. This was 
found to be in total agreement with the quantitative NMR data about the content of the ANAc. In 
the HI-3 digest the relative content of ∆U4,4,0,1gs increases with respect to ∆U4,4,1,1gs (when 
comparing with their contents in the gs-PMH digest) because of the higher content of non-
sulfated uronic acids within its chains. 
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Fig. 3.22.  Peak area ratio of 
mono-gs-tetrasaccharides 
∆U4,4,0,1gs and ∆U4,4,1,1gs 
found in the enzymatic digests of 
gs-heparins of different sources 
 
Normalization to ∆U2,3,0 peak area was 
done in order to both evaluate the gs-
tetrasaccharide content with respect to 
regular highly sulfated TSD-sequences 
and to avoid errors associated with the 
stability of MS detector. 
 
ANAc content (molar %) determined by 
quantitative 2D NMR is shown for each 
sample (Table 3.2). 
 
One of the most interesting difference observed for gs-BLH is a low content of ATBR 
derived hexasaccharide ∆U6,7,1,2gs (Fig.3.21), even if NMR data showed a content of the 
trisulfated glucosamine ANS3S6S (6.6 molar %) comparable with that of gs-PMH (5.8 molar %). 
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This apparent disagreement, can be explained by different sulfation/N-acetylation pattern of the 
ATBR of the highly sulfated bovine lung heparin, which is known to contain N-sulfated 
glucosamine (ANS6S-G-ANS3S6S-I2S-ANS6S) instead of the N-acetylated one, that, unlike in PMH, 
is preceded by 2-O-sulfated iduronic acid (Loganathan et al., 1990). Combination of glycol-
splitting and enzymatic digestion generates this tetrasaccharide, instead of the hexasaccharide 
found in gs PMH digest (Fig.3.23). Accordingly, a significant increase of ΔU4,6,0,1gs 
(Fig.3.21), corresponding to the highly sulfated ATBR of BLH, is observed. 
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Fig. 3.23. Scheme of 
generation of ∆U6,7,1,2gs 
(a) and ΔU4,6,0,1gs (b) 
from different types of 
ATBR-sequences by 
exhaustive enzymatic 
digestion of gs-heparins 
 
The first type (a) is 
characteristic for PMH, while 
the second type (b) is typical 
for highly sulfated BLH  
In contrast to gs-BLH, the chromatographic profile of HI-3 (extensive gs-PMH with 
~40% of gs-residues) is characterized by the higher intensities of tetra- and hexasaccharide 
fractions with respect to PMH (Fig. 3.21). This result correlates with the quantitative data on 
the disaccharide content (Table 3.8). The detectable hexasaccharides of HI-3 are mainly those 
that contain two gs residues.  
Some octasaccharides containing three gs residues were detectable in the enzymatic 
digests of gs-heparins only in trace, however, their content increases in HI-3 (Fig. 3.21c). Also 
higher masses (dp > 8) were not detectable in the gs-PMH digest, but were observed in trace 
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amounts in HI-3. Their identification became feasible only after previous isolation of the 
corresponding fractions by SEC from the exhaustive enzymatic digest of HI-3 (Fig.3.24, see 
Discussion). 
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Fig.3.24. Extracted ion chromatogram of the decasaccharide fraction obtained 
by SEC-fractionation of HI-3 heparinase-digest 
The work is in progress (see Chapter V). Only major components are shown in these 
preliminary results. Abbreviation system includes the number of monosaccharide residues, 
sulfate and N-acetyl groups, and the number of gs-residues. Symbol ΔU indicates 4,5-
unsaturated uronic acid at the NRE. 
 
III.5. Sensitivity of the developed approach to the glycol-splitting reaction 
conditions 
Having analyzed all the gs-heparin samples, it appeared evident that the reaction 
conditions led to partial hydrolysis of heparin chains. The Mw decreases substantially for each 
heparin sample after glycol-splitting reaction (see III.1). Moreover, the quantity of generated 
gs residues obtained by 2D NMR was lower than the original amount of non-sulfated uronic 
acids in the starting materials (see III.2). LC-MS analysis of the digested gs-heparins showed 
the presence of species bearing remnant of gsU residues, indicating a partial hydrolysis at the 
level of gs-residues. We supposed that the addition of 0,1 M HCl solution for pH 
neutralization after borohydride treatment might create locally very strong acidic conditions 
causing Smith degradation.  
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In order to improve the reaction procedure and minimize partial hydrolysis, HCl could be 
substituted with a mild organic acid. As previously, PMH was chosen as a model and its gs-
derivative was prepared using 5% acetic acid for pH neutralization, and then characterized by 
the developed method. As expected, the obtained sample had higher Mw (16.6 kDa) and 
content of gs-units (22.5 %). SEC-TDA and NMR data obtained for the two gs-PMH prepared 
by different methods are shown in Table 3.9. The NMR spectrum of the less hydrolyzed gs-
PMH shows higher amounts of gs residues, and even gsG followed by trisulfated glucosamine 
became detectable (Fig.3.25b). The marker of hydrolysis ΔU2,3,0-R appeared in LC-MS 
chromatogram of the digest gs-PMH prepared under mild conditions only in trace amounts 
(Fig.3.26).  
Table 3.9. Main parameters (Mw, gs uronic acid content and the relative content of the 
hydrolysis marker ΔU2,3,0-R) that can be affected by glycol-splitting reaction conditions 
SEC‐TDA    2D HSQC NMR (%)    LC‐MS 
 
Mw, kDa 
 
I2S  gsI gsG ANS/NAC-(R) 
 
 
 
Area ratio (%) 
ΔU2,3,0-R/ΔU2,3,0  
gs-PMH (a)  10.8    89.5  2.0  8.3  +    4.4 
gs-PMH (b)  16.6    77.5  9.6  12.9  trace    0.4 
(a) obtained by adding a 0,1M HCl solution at the step of pH adjustment 
(b) obtained by adding a 5% (v/v) CH3COOH solution at the step of pH adjustment 
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Fig.3.25. Comparison of HSQC spectra of two gs-PMH prepared under slightly different 
conditions: (a) using 0.1 M HCl, (b) using 5% (v/v) CH3COOH for pH adjustment at the last step 
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Fig. 3.26. LC-MS profiles of heparinase-digested gs-PMH samples prepared under slightly 
different conditions: (a) using 0.1M HCl, (b) using 5% (v/v) CH3COOH for pH adjustment 
at the last step  
The main observed difference is the decreased content of hydrolysis marker ΔU2,3,0-R 
 
III.6. Discussion 
Structural characterization of gs heparins is of high interest because their potential anti-
cancer and anti-inflammatory activity is likely affected by location of gs-residues along the 
sulfated polysaccharide chains as well as by any modification in the original heparin 
sequences. Such a characterization is especially difficult because of problems associated with 
intrinsic microheterogeneity and polydispersity. In the present work, these problems have been 
faced by converging utilization of advanced NMR, SEC-TDA and LC-MS methods.  
The performed NMR studies have permitted to assign for the first time all the cross peaks 
associated with gs residues in the 2D HSQC NMR spectra of gs-heparins prepared from 
heparins of different animal and tissue sources. The obtained NMR spectra, especially their 
anomeric regions, appeared highly characteristic for gs-heparins (Fig. 3.7). Their NMR 
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quantitative analysis was also performed relying on the required condition that the coupling 
constants 1JC-H for gs-residues were almost the same than those of the unmodified uronic acids. 
It permitted the structural characterization of individual gs-samples as well as to distinguish 
and to compare them in terms of monosaccharide composition.  
Notably, different types of gs-containing sequences, including gs uronic acids followed 
by a trisulfated glucosamine (the recognized marker of ATBR) can be distinguished by 2D 
HSQC NMR (Table 3.2, Fig.3.25). A similar signal was observed also in HI-3 spectrum 
(Fig.3.3a) but with slightly different chemical shift (4.94/103.1 ppm). Since it becomes visible 
in the spectrum of the gs-product derived from partially 2-O-desulfated heparin, we supposed 
it corresponded to gsI-(A*). This result confirms that there are some I2S-ANS3S6S units outside 
the ATBR of original heparin chains and could explain the fact that the G-(A*) content was 
found almost always lower than total A* content for unfractionated heparins (Rudd et al, 
2012). The presence of ΔU2,4,0, corresponding to ΔU2S-ANS3S6S, in heparinase-digested 
heparins (unpublished observation of our group), is also in agreement with the observed data. 
Also the residues of the linkage region in gs-heparins were identified by NMR. Such a 
sequence is present in most of the unmodified heparins (Iacomini et al., 1999) as well as in 
some LMWHs (Bisio et al., 2009). Two residues of the LR, i.e., the GLR and the terminal Xyl 
(when not lost in the purification/bleaching treatments of the pharmaceutical grade 
polysaccharide) have been shown to be susceptible to glycol-splitting. In the HSQC NMR 
analysis of the anomeric region in gs-heparins (Fig. 3.1, 3.7), their glycol-splitting is clearly 
reflected by the corresponding signals at 4.92/107.7 and 4.75/105.9 ppm (Table 3.2, Fig.25b). 
Additionally, the spectra contain several signals that may be used as markers of both 
glycol-splitting reaction completeness (by monitoring the anomeric signals of unmodified I 
and G as well as H2/C2 cross peak of G, Fig. 3.1) and hydrolytic processes (anomeric signals 
of ANS/NAc bearing a remnant of gsG/gsI, Fig.3.6a, H2/C2 cross peaks of trisulfated 
glucosamine at the NRE, Fig.3.1d).  
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The obtained results show that uncontrolled reaction conditions, first of all uncontrolled 
pH value, may lead to different hydrolysis processes, at the level of either gs-units (Fig.1.19, 
Conrad et al., 1992) or glycosidic bonds (Jandik et al, 1996). Moreover, it was observed that 
gsI are hydrolyzed to a higher degree with respect to the gsG. The characteristic cross peaks of 
ANS and ANAc bearing the generated remnant (R) in HSQC spectra were also assigned. Another 
marker of the hydrolysis is the formation of glucosamine at the NRE, as shown in Fig.1.19e. 
While the cross peaks of N-sulfated and N-acetylated NRE glucosamines overlap with those of 
the same units inside the internal sequences, the trisulfated glucosamine formed at the NRE 
can be easily detected by monitoring the H2/C2 signals of A* and A*NRE (Fig. 3.1d). The 
A*/A*NRE ratio in the ring region of the HSQC spectrum may be used as a marker for 
evaluation of hydrolysis degree of A*-containing sequences (including gs-ATBR). 
A set of NMR signals, associated with the terminal reducing aminosugars (such as α- and 
β-anomers of ANAc were observed, Fig.3.7), are clearly evident in the HSQC spectra of gs-
heparins, but not significantly present in the parent heparin spectra. We have shown that also 
hydrolysis of the glycosidic bonds may occur under strong acid conditions, leading to the 
formation of RE amino sugars (Fig.3.6). The present study indicated that the major terminal 
reducing glucosamine in gs-heparins is N-acetylated, with typical signals at 5.16/92.7 ppm for 
α anomer and 4.77/97.5 for β one (Guerrini et al., 2008). A substantial loss of N-acetylated 
glucosamine-containing sequences upon periodate oxidation, followed by treatment with base, 
was reported for heparin chains with high affinity for AT and shown to occur preferentially at 
the level of the active site for AT (-I-ANAc(6S)-G-ANS3S6S-I2S-ANS6S-) (Islam et al., 2002).  
Evidently, these results should be taken into account for monitoring the conditions for 
the preparation of gs products. Both NMR and SEC-TDA represent attractive tools for this 
aim. However, minor modifications, including side products, can be unraveled only through 
careful cleavage of gs-heparin chains and identification of the generated di- and 
oligosaccharide fragments by LC-MS analysis. 
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The assumption, at the basis of the present work that digestion of glycol-split heparins 
with a mixture of heparin lyases I, II and III would generate small oligosaccharides containing 
glycol-split residues was correct. The combination of glycol-splitting and enzymatic digestion 
leads to the skipping of the units containing gs residues and generation of longer 
oligosaccharides with internal gs residues (Fig. 3.11). As exemplified in Fig.3.16 and 
summarized in Table 3.6 for the gs-derivative of a sample of the most common heparin (gs-
PMH) and illustrated in Fig.3.21 for gs-heparins of different origin, the LC-MS analysis 
indicates that, in addition to “normal” disaccharides as expected major products, heparinase 
digests of gs-heparins are largely constituted by tetra- and hexasaccharides containing one or 
two glycol-split residues. Most of fragments in the heparinase digests of gs-heparins are even-
numbered and start at their NRE with an unsaturated, 2-O-sulfated uronic acid residue. Odd-
numbered fragments are only present in very minor amounts.  
Analyses based only on mass values do not permit to discriminate among all the different 
sequences of isomeric oligosaccharides. However, reasonable assumptions on the actual 
sequences of fragments containing gs residues can be made by comparison with structures 
established for the major oligosaccharides obtained from heparin lyase digests of unmodified 
heparins. The structure of gs-containing oligosaccharides expected on the basis of the major 
PMH oligosaccharides isolated and identified thus far (Xiao et al., 2011,Yamada et al., 1998) 
are compared in Table 3.10 with the major fragments identified in the present work for gs-
PMH. Clearly, fragments containing gs residues derive from non-sulfated G and/or I of 
heparin sequences. 
Even if the initial aim of the work was to structurally characterize gs-heparins, the 
developed method appeared a powerful tool for characterizing the starting heparin material. As 
an example, different types of ATBR sequences, differing by sulfation/N-acetylation pattern, 
were found in gs-heparin digests (Fig. 3.23).  
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Table 3.10.  Several major G- and I-containing tetra- and hexasaccharide fragments obtained 
from PMH (literature data) and the corresponding gs-oligosaccharides found in this work 
Literature data Present work 
ΔU4,4,1  ΔU2S‐ANAc6S‐G‐ANS6S  ΔU4,4,1,1gs  ΔU2S‐ANAc6S‐gsG‐ANS6S 
ΔU4,4,0 (1)  ΔU2S‐ANS‐G‐ANS6S   ΔU4,4,0,1gs  ΔU2S‐ANS‐gsG‐ANS6S 
ΔU4,4,0 (2)  ΔU2S‐ANS6S‐G‐ANS  ΔU4,4,0,1gs  ΔU2S‐ANS6S‐gsG‐ANS 
ΔU4,5,0  ΔU2S‐ANS6S‐G‐ANS6S  ΔU4,5,0,1gs  ΔU2S‐ANS6S‐gsG‐ANS6S 
ΔU4,6,0  ΔU2S‐ANS6S‐G‐ANS3S6S  ΔU4,6,0,1gs  ΔU2S‐ANS6S‐gsG‐ANS3S6S 
ΔU6,6,1 (1)   ΔU2S‐ANS6S‐I‐ANAc6S‐G‐ANS6S  ΔU6,6,1,2gs  ΔU2S‐ANS6S‐gsI‐ANAc6S‐gsG‐ANS6S   
ΔU6,6,1 (2)  ΔU2S‐ANS6S‐I‐ANAc6S‐G‐ANS3S  ΔU6,6,1,2gs  ΔU2S‐ANS6S‐gsI‐ANAc6S‐gsG‐ANS3S 
ΔU6,7,0   ΔU2S‐ANS6S‐G‐ANS6S‐G‐ANS6S  ΔU6,7,0,2gs  ΔU2S‐ANS6S‐gsG‐ANS6S‐gsG‐ANS6S 
ΔU6,7,1   ΔU2S‐ANS6S‐I‐ANAc6S‐G‐ANS3S6S  ΔU6,7,1,2gs  ΔU2S‐ANS6S‐gsI‐ANAc6S‐gsG‐ANS3S6S 
Oligosaccharides from unmodified heparin were identified from Linhardt’s group upon exhaustive digestion 
with heparinase I, II, or III (Xiao et al., 2011) and partial digestion only with heparinase I (Xiao et al, 2011). 
Hexasaccharides were obtained from pig mucosal heparin by Sugahara group (Yamada et al, 1998) from a 
“hexasaccharidic fraction” isolated by gel-filtration on Bio-Gel P-10 and sub-fractionated on a column of amine-
bound silica under a sodium phosphate gradient. Tetrasaccharide ΔU2S-ANS6S-G-ANS3S6S was isolated from 
bovine lung heparin (Loganathan et al., 1990). 
 
Interestingly, also octasaccharides with three gs units, even if as trace components, were 
found in the heparinase-digests of gs-heparins (Fig.3.21c), indicating that the sequences with 
up to three subsequent non-sulfated uronic acids may exist within the original heparin chains. 
The observed octasaccharides should contain N,6-O-sulfated glucosamines, suggesting that 
sequences with subsequent non-sulfated uronic acids are still highly sulfated. This result may 
suggest that the internal undersulfated domain of heparin chains is very short.  
Longer chain oligosaccharides were observed only in the HI-3 enzymatic digest after 
SEC-fractionation. Several decasaccharides with four gs-residues were observed (Fig.3.24). 
These compounds differ not only by their sulfation degree, but also by different number of     
N-acetyl-glucosamines (from 0 up to 2) in their structures. In contrast to the found gs-
decasaccharides, octasaccharides with three gs-residues containing more than one N-acetyl-
group were not found (except for the sequences close to the LR, see Chapter IV) in the gs-
heparin digests, nor in the HI-3 digest. It is likely that two N-acetyl-glucosamines do not exist 
within the sequences shorter than decasaccharides and they are separated by at least three        
N-sulfated disaccharide units within heparin chains. 
 87
Although the main scope of this study was the identification and profiling of the major 
components of glycol-split heparins, some minor mono- and tri-saccharide components of the 
enzymatic digests were also identified (Table 3.6). These small fragments may provide 
information on end-groups in the original heparin and/or on those generated by some 
fragmentation associated with the glycol splitting reaction. Thus, the finding of monomeric 
glucosamine fragments 1a (A1,2,0) and 1b (A1,3,0(A*)), where A* indicates that the 
aminosugar is 3-O-sulfated, rises the question whether they can be taken as a proof of concept 
that heparin molecules essentially as used in clinics are the result of cleavage, by an endo-β-D-
glucuronidase of consistently longer chains of a proteoglycan biosynthetic precursor 
(“macromolecular heparin”) (Gong et al., 2003). That enzyme is essentially a heparanase and 
would cleave the heparin chains at the level of G residues (Sandbäck-Pikas et al., 2008) 
generating shorter chains terminating with an aminosugar at their non-reducing end. Exhaustive 
cleavage with heparinases of these chains could then release glucosamine monomers as found 
in the present work (Fig.3.16) and in a number of other heparin preparations (unpublished data 
from our laboratories). However, an alternative explanation, namely the hydrolysis of the 
glycosidic bond between G and ANS3S6S within the ATBR (Islam et al., 2002) should be 
considered. In fact, gsG-A* appeared as a low signal in the NMR spectra, along with the 
generation of A* at the NRE (discussed above).  
As by NMR, also LC-MS analysis revealed partial Smith degradation, i.e., cleavage of gs-
heparins at the level of gs-residues as previously observed (Conrad and Guo, 1992): several 
hydrolysis marker fragments (such as ΔU2,3,0-R and ΔU4,5,0,1gs-R, Fig.3.19, Table 3.6) 
terminating with the remnant (R) of a glycol-split and hydrolyzed uronic acid, were identified 
for some gs preparations. Such a cleavage may occur under relatively mild acid conditions 
(Conrad and Guo, 1992). In addition, borohydride reduction could modify some of the residues 
at the reducing end, converting them into the corresponding alditols, such as ∆U3,4,0-ol (Fig. 
3.19, Table 3.6). 
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III. 7. Conclusions 
Glycol-split heparins from different animal sources have been characterized for the first 
time by the combined NMR and LC-MS analysis. While 2D HSQC NMR permits to evaluate 
the average monosaccharide composition, HPLC/MS analysis of glycol-split heparins, obtained 
from commercial and chemically modified heparins under the optimized conditions of the 
present work, permits to profile their di-, tetra-, and hexasaccharide composition in a way that 
is characteristic of the structure of the starting materials and especially emphasizes the extent of 
their glycol-splitting. The combined analytical approach is also suitable to distinguish glycol-
split heparins obtained from heparins of different animal and tissue origin. It is also attractive 
to think that, in parallel with an analysis of the parent heparins, analysis of their glycol-split 
derivatives could permit to extend structural information to the original unmodified heparins, 
especially regarding sequences containing non-sulfated G and I residues. It has been shown that 
this method may permit to characterize the sequences with subsequent non-sulfated uronic 
acids, and their length, as well as the distribution of N-acetyl-glucosamines within heparin 
sequences. As additional analytical tool, size-exclusion chromatography coupled with triple 
detector array, not requiring the use of oligosaccharide standards, permits both to characterize 
molecular weight distribution and to determine hydrodynamic parameters for heparin-related 
samples. In the case of gs-derivatives the modifications in flexibility of heparin chains, that 
may be important for understanding their biological activity, can be monitored. Combined 
together NMR, LC-MS and SEC-TDA proved to be a powerful tool for reaction monitoring 
and controlling both glycol-splitting completeness and hydrolytic side reactions that can 
contribute to additional microheterogeneity of the final gs-product. 
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CHAPTER IV: STRUCTURAL FEATURES OF GLYCOL-SPLIT                                  
LOW-MOLECULAR WEIGHT HEPARINS 
Most of the present results have been published in:  
 Alekseeva A., Casu B., Cassinelli G., Guerrini M., Torri G., Naggi A. Structural features of 
glycol-split low-molecular-weight heparins and their heparin lyase generated fragments. 
Analytical and Bioanalytical Chemistry. 406 (2014) 249-265. 
 Alekseeva A., Elli S., Cosentino C., Torri G., Naggi A. Susceptibility of enoxaparin reducing end 
amino sugars to periodate oxidation. Carbohydrate Research. 400 (2014) 33-43. 
 
As mentioned in the Introduction, gs-derivatives are currently being developed mainly 
starting from LMWHs (Zhou et al, 2011; Leitgeb et al., 2011; Ritchie et al, 2011) due to their 
better bioavailability, however, their structural features have not been reported yet. Additional 
microheterogeneity of the starting material induced by specific depolymerization reactions 
makes the analysis of gs-LMWHs even more complex than for gs-heparins. The present 
chapter describes the structural features of gs-derivatives prepared from three commercially 
available LMWHs, tinzaparin, dalteparin and enoxaparin, revealed by the approach developed 
and discussed in Chapter III.  
Based on results reported in section III.5, their gs-derivatives were prepared using mild 
acidic conditions (diluted acetic acid at the last step of preparation, with pH adjustment after 
borohydride reduction) for minimizing hydrolytic side reactions. The results on the molecular 
weight distribution, obtained by SEC-TDA analysis, show that mild conditions do prevent 
significant hydrolysis, even if slight chain shortening was still observed (Table 4.1). The 
hydrodynamic radius Rh (Table 4.1) and Mark-Houwink a and logK parameters (Annex 3) 
were also determined. As for unfractionated heparins, the presence of the gs-residues favors 
the random coil formation. This trend is more evident for longer chain oligosaccharides.  
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Table 4.1. Average molecular weight (Mw), polydispersity (D), hydrodynamic radius (Rh) and 
fractions weights for fractions with molecular weight < 2 kDa and >8 kDa, obtained for parent 
LMWHs and their glycol-split derivatives by SEC-TDA 
Fraction weight, % mass 
Sample  Mw, kDa  D  Rh*, nm 
< 2 kDa  > 8 kDa 
Tinzaparin  7.9  1.5  2.2  0.4  24 
Dalteparin  7.5  1.2  2.3  nd  18 Parent LMWHs 
Enoxaparin  5.2  1.4  1.8  18  14 
             
gs‐Tinzaparin  7.2  1.4  2.0  7  22 
gs‐Dalteparin  6.4  1.2  2.2  – *  – * Glycol‐split LMWHs 
gs‐Enoxaparin  4.7  1.3  1.8  20  9 
Mw and D were measured using 0.1M NaNO3 as eluent to avoid aggregation 
Rh and fraction weight (% mass) were determined using 0.01M NaNO3 as eluent 
* Fraction weight for gs-dalteparin fractions with molecular weight <2 kDa and > 8 kDa were not determined 
because of formation of aggregates, whose response disturbs the chromatographic profile  
 
IV.1. Two-dimensional HSQC NMR analysis of gs-LMWHs  
As in the case of gs-UFHs, for LMWHs (blue spots) and gs-LMWHs (red spots), signals 
for typical residues are located in subregions of the spectrum (Fig.4.1). The most intense 
signals are those of the TSD sequences for both starting materials and gs-products. Cross peaks 
of non-sulfated I/G and those associated with these residues (amino sugars preceding them) 
disappeared, while new ones corresponding to gs units appeared in the spectrum (Fig.4.1) at 
positions similar to those obtained for gs-UFHs (Table 3.2). 
Table 4.2 reports the relative content of typical monosaccharide residues for the three 
prepared gs-LMWH samples measured from the signal volumes as described in Chapter III. 
For comparative purposes also the data for the parent LMWHs are reported. As for gs-heparins, 
differences in relaxation times may lead to the overestimation of some gs-residues, so that the 
currently obtained data should be taken in consideration as preliminary.  
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Fig.4.1. Anomeric (left panel) and “ring” (right panel) regions of the 1H/13C HSQC NMR 
spectra of gs-tinzaparin (a), gs-enoxaparin (b) and gs-dalteparin (c) (red spots) superimposed 
on the spectra of the corresponding unmodified LMWH (blue spots) 
Symbols for typical end-group signals are framed with rectangles. A – glucosamine, A* – glucosamine-N,3-O,6-
O-trisulfate, MNS – mannosamine-N-sulfate, 1,6ANS/1,6aMNS – 1,6-anhydro-glucosamine-N-sulfate and 1,6-
anhydro-mannosamine-N-sulfate, aM.ol – 2,5-anhydro-mannitol, ΔU(2S) – 4,5-unsaturated (2-O-sulfated) uronic 
acid, I/G – iduronic and glucuronic acids, GLR – glucuronic acid of the LR sequence, GalA – galacturonic acid, 
gsI/gsG – gs iduronic and glucuronic acids, gsU – gs uronic acids, Gal – galactose, Xyl – xylose, Ser – serine,    
nr – non-reducing end, Rc – ring contracted residues (Fig.1.17) 
 92
Table 4.2. Relative content (molar ratios) of the major individual residues of LMWHs and the 
corresponding gs-LMWHs 
 Tinzaparin gs-Tinzaparin Enoxaparin gs-Enoxaparin Dalteparin gs-Dalteparin 
REPEAT SEQUENCE 
ANS(total)a 88.2 86.8  91.5  89.6 91.9 93.9 
ANAc(total)a 11.8 13.2 9.5 10.4 8.1 6.1 
A* b 2.0 1.7 3.3 4.2 4.2  6.3 
I2S 60.0  67.5 53.3 53.2 76.8c 79.8 
I 8.3 <LOD 6.1 <LOD 7.3 <LOD 
G 14.7 <LOD 13.6  <LOD 10.3 <LOD 
G-(A*) b 1.7 <LOD 3.1 <LOD 4.1 <LOD 
gsI – 7.7 – 9.9 – 9.2 
gsG – 8.7 – 10.1 – 7.7 
gsG-(A*) b – <LOD – 1.6 – 3.3 
NON-REDUCING END GROUPS 
ΔU2S 14.9 11.8 16.4 18.2 – – 
ΔU – – 1.3 <LOD – – 
REDUCING END GROUPS 
Ared 12.3 <LOD 11.6 <LOD <LOD  <LOD 
1,6aA – – 4.1 2.5 – – 
aM.old – – – – 12.7 7.3 
LINKAGE REGION (LMWHs) 
GLR+Gal1 3.0 <LOD 2.6 <LOD 1.9 <LOD 
Gal2 1.6 <LOD 1.3 <LOD 1.3 <LOD 
Xyl-(Ser) 1.6 <LOD <LOD <LOD <LOD <LOD 
Xyl-(oxSer) <LOD <LOD 0.8 <LOD 0.9 <LOD 
LINKAGE REGION (gs-LMWHs) 
gsGLR – 2.6 – 1.6 – 2.0 
Gal1 – 2.2 – 1.2 – 1.1 
Gal2 – 2.1 – 0.9 – 1.1 
gsXyl – 1.0 – 1.9 – 2.1 
 LOD – limit of detection;  “–“ – for residues atypical for the type of LMWH  
a  calculated from the cross peaks of H2/C2 ANS, H2/C2 ANAc, H2/C2 ANS3S6S and for enoxaparin H2/C2 
1,6aANS/1,6aMNS 
b A* = ANS3S(6S) 
c  including I2S-(aM.ol) and I(nr) residues 
d  calculated as sum  of the cross peaks (C-2 aM.ol6S + C-4 aM.ol6S + C-2aM.ol6OH + C-4aM.ol 6OH) divided 
2*(total amines) 
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As in the spectra of the parent LMWHs, the gsGLR signal intensity indicates that the 
content of LR in gs-tinzaparin is higher than in gs-enoxaparin, while almost absent in gs-
dalteparin (Fig.4.1c, Table 4.2). The integration of the signals of the gsLR sequence should be 
taken in account with a caution, because longer relaxation times T2 for terminal sequences may 
lead to a notable overestimation. In fact, the quantitative values obtained for the gsLR residues 
(especially, gsGLR and gsXyl, Table 4.2) seem to be overestimated. 
Notably, cross-peak G-(A*) at 4.62/103.9 ppm, taken as a marker of the ATBR (Bisio et, 
2009), is common to the three unmodified LMWHs but disappears upon glycol-splitting. Signal 
gsG-(A*) (at 4.90/103.2 ppm) is clearly observed only in the spectrum of gs-dalteparin 
(Fig.4.1c), but can be also detected in the expanded scale spectrum of the other gs-LMWHs. 
The signal is at the position similar to gsG-(A*) in the gs-derivative of the synthetic 
pentasaccharide ANS6S-gsG-ANS3S6S-I2S-ANS6S (4.93/103.5 ppm) (Table 3.2). The assignment 
has been confirmed by TOCSY experiments, indicating a correlation of the signal at 4.90/103.2 
ppm with the primary alcohol group of gsU residues (Fig. 4.2). Different contents of the gsG-
(A*) reflect different contents of ATBR sequence in the original LMWHs Table 4.2.  
Notably, end-groups are evident in the NMR spectra of all the LMWHs (Fig.4.1). 
Chemical shifts of the terminal groups typical for each LMWHs are listed in Annex 4. The 
NMR spectrum of dalteparin shows its relative structural homogeneity, with I2S at the NRE and 
aM.ol at the RE, this latter residue well-identifiable in the “ring region” of the NMR spectrum 
(Fig.4.1c). Enoxaparin appears the most heterogeneous due to the variety of RE amino sugars 
(Fig.4.1b). 
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p p m
2 .53 .03 .54 .04 .55 .05 .5 p p m
6 0
7 0
8 0
9 0
1 0 0
1 1 0
2 .53 .03 .54 .04 .55.05.5 ppm
3 .5
4 .0
4 .5
5 .0
5 .5
ppm
4.90/103.2 ppm
(a)
(b)
gsG‐(A*)
H1/C1
gsU
H2/C2
gsG‐(A*)
gsGgsI
 
Fig. 4.2. HSQC (a) and 2D-TOCSY (b) spectra of gs-dalteparin 
Correlation of H1/C1 and H2/C2 signals of gsG-(A*) are shown by red line 
 
NMR data (Fig.4.1) show that not only internal sequences but also several end-groups are 
susceptible to glycol-splitting and/or reduction. The enoxaparin minor cross-peaks of ΔU at the 
NRE are among those that disappear upon periodate oxidation/borohydride reduction because 
of the presence of vicinal OH groups. The cross-peaks of both α and β anomers of aminosugars 
and uronic acids at the RE typical for unmodified tinzaparin (ANSα, ANSβ, Fig.4.1a) and 
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enoxaparin (ANSα, ANSβ MNSα, MNSβ, I2Sα, I2Sβ, see Fig.4.1b) disappeared after the gs-reaction. 
The resulting RE-alditols (A-ol) are not detectable in the complex “ring region” of the NMR 
spectra due to signal overlapping with the free primary hydroxyl groups at C-6 of glucosamine 
and those at C-2 and C-3 of gs-uronic acids (Fig.4.1). However, I2S followed by A-ol can be 
detected in both gs-tinzparin and gs-enoxaparin (Fig.4.1, 4.3). Its chemical nature was shown 
by HMBC NMR spectroscopy, where the long-range correlation of the anomeric H1/C1 
(5.34/103.1 ppm) signal and H5/C5 was clearly observed (Fig. 4.3). Its absence in gs-
dalteparin, with its resistant RE aM.ol residues, independently confirms this interpretation. The 
direct proof was obtained by borohydride reduction of the enoxaparin octasaccharide fraction: 
along with disappearance of the RE glucosamine cross-peaks (ANSα, ANSβ, MNSα), a new signal 
at 5.34/103.1 ppm appeared in the spectrum (Fig.4.3b).  
H5/C5
I2S
H1/C1
I2S
I2S
I‐(A6S)
G2S
G‐(ANS)
G‐(A*)
G‐(ANAc)
1,6aMNS1,6aANS
A*
∆U2S
(ANAc)‐G
(ANAc)‐G
ANAc tot
I2S‐(1,6aANS)
I2S‐(1,6aMNS)
ANSα
MNSα
ANSβ
I2S‐(A‐ol)
(a) (b)
 
Fig.4.3. (a) Superimposed HSQC (blue spots) and HMBC (orange spots) spectra of gs-
tinzaparin, (b) superimposed HSQC spectra of enoxaparin octasaccharide fraction before (red 
spots) and after borohydride reduction (grey spots) 
Correlated signals H1/C1 and H5/C5 of I2S in the HMDC spectrum (a) as well as the anomeric HSQC signals 
susceptible to reduction and a new signal of I2S-(A-ol) (b) are circled. 
 
Unexpectedly, also the enoxaparin cross-peaks related to 1,6aMNS disappeared upon 
periodate oxidation/borohydride reduction (Fig.4.1b). This anomalous behavior of 1,6aMNS has 
been studied independently and is discussed in section IV.4.2 of the present chapter. 
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IV.2. LC-MS profiling of heparinase-digested gs-LMWHs  
Mass spectra interpretation 
LC-MS analysis was carried out using the gradient and MS parameters optimized for gs-
heparin digests (Chapter III). The identification of oligosaccharide components was performed 
using the exact mass values and characteristic isotope patterns. Enoxaparin 1,6-anhydro- 
(1,6aA) oligosaccharides can be detected by the characteristic mass loss of 18 Da with respect 
to the regular oligosaccharides. Dalteparin aM.ol end-group can be easily detected by the 
difference of 15 Da with respect to the unmodified natural oligosaccharides. Minor dalteparin 
oligosaccharides containing both aM.ol and Rc residues (Fig.1.17) were detected due to a mass 
decrease of 15 Da in comparison with the oligosaccharides bearing only aM.ol residues. The 
chemical nature and provenience of the sample (such as depolymerisation process) were taken 
into consideration to confirm the identified structures.  
The abbreviation system was the same as that we used for gs-oligosaccharides 
generated by gs-heparins digestion and includes the number of monosaccharide residues, 
sulfate groups, N-acetyl groups, and gs residues when present (for example, ΔU4,5,0,1gs). 
Symbols ΔU, U and A indicate a 4,5-unsaturated uronic acid, a saturated one and a 
glucosamine unit, respectively, at the NRE. “Remnants” of the hydrolyzed internal gs residues 
were indicated by the symbol R (Fig.1.19e), and those at NRE as R(Unr). Symbol “ol” 
indicates the alditol form of terminal units at the RE; symbols aM.ol and Rc indicate 2,5-
anhydromannitol and internal contracted ring residues typical for dalteparin. Symbol 1,6aA 
was used for both epimers (1,6-anhydro-glucosamine and 1,6-anhydro-mannosamine) because 
it was not possible to distinguish them by MS data. As two particular cases, gs1,6a and Ram 
were used to indicate glycol-split 1,6-anhydro-amino sugar and remnant of an amino sugar. 
Their generation is discussed in section IV.4.2. 
An example of the interpretation of mass spectrum of a peak found in gs-enoxaparin 
digest is shown in Fig.4.4. 
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Fig.4.4. Experimental MS data (a) and the 
simulated ones for three overlapping 
oligosaccharides found in the gs-enoxaparin 
digest (b-d) 
A first-level structure was assigned to each signal. The 
assignment relies on the exact mass value and isotope 
pattern. The error values between experimental and m/z 
calculated for the proposed structure are reported in ppm. 
 
Abbreviation system includes the number of 
monosaccharide residues, sulfate and N-acetyl groups, and 
the number of gs-residues. Symbol ΔU indicates 4,5-
unsaturated uronic acid at the NRE. Symbol “ol” indicates 
the terminal sugars in alditol (reduced) form. Symbol 1,6aA 
indicates the terminal 1,6-anhydro-amino sugars in gs-
enoxaparin 
 
Sodium borohydride reduction was used to distinguish between internal gs-unit and 
alditol end residue. Species susceptible to borohydride reduction (i.e., those converted to 
alditol forms) were identified as oligosaccharides originally terminating with hexosamines 
and, consequently, bearing internal gs, while the reduction resistant oligosaccharides were 
considered to exist already in the alditol form. For example, the double-charged ion with m/z 
497.02 could correspond to both ΔU4,4,0,1gs and ΔU4,4,0-ol. After sodium borohydride 
reduction two peaks were observed: a) m/z 498.02, indicating that this oligosaccharide contains 
one internal gs-unit (gsU) and corresponds to the structure ΔU2S-ANS(6S)-gsU-ANS(6S), where 
only one of the two sulfate groups within parenthesis is present; b) unmodified m/z 497.02, 
which should correspond to ΔU2S-ANS-U2S-ANS-ol structure, having an internal 2-O-sulfated 
uronic acid (U2S).  
This approach was used also to distinguish two isomers ΔU4,6,0-ol (Fig.4.5) and 
ΔU4,6,0,1gs. The first tetrasaccharide represents the highly sulfated sequences at the RE of the 
original tinzaparin/enoxaparin chains, while the minor gs-tetrasaccharide is likely to be one of 
the markers of the N-sulfated ATBR (I2S-ANS6S-G-ANS3S6S-I2S-ANS6S), observed in the 
enzymatic digest of gs-heparin from bovine lung (see Chapter III). 
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The additional NaBH4 reduction of the gs-enoxaparin digest confirmed also the structure 
assigned to the minor tetrasaccharides terminating with an uronic acid remnant               
(ΔU4,4,1,1gs-R, m/z 577.03 for [M-2H]2- ion form, and ΔU4,5,0,1gs-R, m/z 596.01 for [M-
2H]2- ion form), for which the m/z values remained constant after the additional reduction. 
All the oligosaccharides in hemiacetal forms with internal gs-units had the same 
retention times as those observed in gs-heparin digests (Chapter III), confirming that they do 
not bear an alditol group (alditol formation induces a slight increase of the retention time, see 
Discussion).  
 
Structural features of gs-LMWHs by analysis of heparinase-generated gs-
oligosaccharides  
Like those of similarly digested gs-heparins, the LC-MS profiles of heparinase-digested 
gs-LMWHs essentially consist of disaccharides, gs-tetrasaccharide and gs-hexasaccharide 
fragments and very low amounts of some gs-octasaccharides (Fig.4.5).  
The major disaccharide ΔU2,3,0 (ΔU2S-ANS6S), the minor disaccharide ΔU2,2,0                 
(ΔU2S-ANS) and several tetrasaccharides resistant to the enzymatic cleavage (such as,            
ΔU4,6,0-ol in gs-tinzaparin, ΔU4,5,0-1,6aA in gs-enoxaparin, ΔU4,5,0-aM.ol in gs-dalteparin) 
are also present in the corresponding digests of LMWHs (unpublished observation of our 
group). Notably, no disaccharide in alditol form was detected in the gs-tinzaparin digest. The 
resistance to heparinases of the sequences with LMWH unnatural residues was previously 
observed for dalteparin and enoxaparin (Linhardt et al., 1990; Ozug et al., 2012; Viskov and 
Mourier, 2004).  
LC-MS profile of gs-enoxaparin enzymatic digest (Fig.4.5b) is definitely more 
heterogeneous, especially as regards end residues, than those of gs-tinzaparin and gs-dalteparin 
digests, making structural assignments more difficult. LC-MS chromatogram of the 
heparinase-digest of gs-dalteparin (Fig.4.5c) is less complex than those of the other two gs-
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LMWH digests, reflecting in part a rather homogeneous internal structure of the original 
LMWH and the fact that practically all chains in the original dalteparin terminate at the RE 
with aM.ol groups, resistant to glycol-splitting. Notably, the gs-dalteparin digests contain also 
octasaccharides U8,9,1,1gs-aM.ol and U8,9,1,2gs-aM.ol (both in traces), indicating that all 
the glycosidic bonds of these oligosaccharides are resistant to cleavage by heparinases (see 
Discussion). The heparinase-resistant aM.ol-containing hexasaccharides with the ring 
contracted residue (Fig.1.17), ΔU6,6,1,Rc-aM.ol and ΔU6,7,0,Rc-aM.ol (Fig.4.5) was 
observed at the first time in the present study. 
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Fig.4.5. LC-MS chromatogram of the heparinase-digests of gs-tinzaparin (a), gs-enoxaparin (b), 
gs-dalteparin (c) 
LC-MS conditions: see Fig.3.12 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the number 
of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates the terminal 
sugars in alditol (reduced) form. Symbols 1,6aA and aM.ol indicate the terminal 1,6-anhydro-amino sugars in gs-
enoxaparin and 2,5-anhydro-mannitol in gs-dalteparin, respectively. Rc indicates internal ring-contracted structures 
in gs-dalteparin. 
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Among gs-hexasaccharides, ∆U6,7,1,2gs, marker of gs-ATBR, is present in all the 
samples but in different amounts, correlating with NMR data of A* and G-(A*) contents in the 
original LMWHs (Table 4.2). Several octasaccharides with three gs uronic acids in contiguous 
disaccharide units were found in gs-LMWHs in trace amounts. This indicates that sequences 
with three subsequent non-sulfated uronic acids are present within the original LMWH chains. 
During the study of the gs-enoxaparin structure, a fraction containing highly sulfated mono-N-
acetylated octasaccharides with three gs units (ΔU8,7,1,3gs, ΔU8,8,1,3gs, ΔU8,9,1,3gs) was 
isolated from the gs-enoxaparin digest by SEC fractionation for detailed study (Fig.4.6). In 
order to distinguish between octasaccharides with two internal gs-residues and reduced 
terminal glucosamine (alditol form), having the same molecular mass, borohydride reduction 
of the total octasaccharide fraction was used. The species susceptible to borohydride were 
those with three gs-residues and hemiacetalic glucosamine at the RE, while unaffected 
oligosaccharides should bear already reduced glucosamine. The presence of both types of 
octasaccharides (those with three gs-units ΔU8,7,1,3gs, ΔU8,8,1,3gs, ΔU8,9,1,3gs (Fig.4.6) 
and those with two gs-units and a terminal alditol ΔU8,7,1,2gs-ol, ΔU8,8,1,2gs-ol, 
ΔU8,9,1,2gs-ol, ΔU8,10,1,2gs-ol) was revealed. Except for ΔU8,10,1,2gs-ol, alditol forms 
were found in trace (not shown in Fig.4.6). The cross-peak of the α-anomer of N-sulfated 
glucosamine (ANSα), observed in the 2D NMR spectrum of the digest before reductive 
treatment, also confirms the presence of octasaccharides with three gs units and a hemiacetalic 
N-sulfated glucosamine at the RE. It is worth noting that in the case of the octasaccharides 
with two gs residues their resistance to the enzymatic cleavage may be explained by the 
position of the 2-O-sulfated uronic acid (US) that is likely to be close to the alditol unit in the 
proposed structure ΔUS-A-gsU-A-gsU-A-US-A-ol (the resistance of the sequences with 
unnatural residues is noted above). 
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Fig. 4.6. LC-MS chromatogram (a) and HSQC NMR spectrum (b) of octasaccharide 
fraction of gs-enoxaparin digest obtained by SEC fractionation 
LC-MS conditions: see Fig.3.12 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and 
the number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” 
indicates the terminal sugars in alditol (reduced) form. gsLR – gsG-(Gal)2-gsXyl-Serox, gsLR(2) – gsG-
(Gal)2-CH(CH2OH)2  
The signal at 4.75/105.9 ppm (panel b) was attributed to gsXyl residue. It was the only additional signal 
to those assigned for gs-heparins in HSQC spectra (see Table 3.2), and its amount was found much higher 
in the fraction enriched by gsXyl-bearing oligosaccharides, shown in this figure (panel a). Moreover, the 
ratio of the intensities of GLR, Gal1, Gal2 and gsXyl in this fraction was 1:1:1:1. 
 
 
Longer sequences with more than three gs units were not detected, even after 
fractionation by SEC. The same results were obtained also for the sequences in the closest 
proximity to the LR: this undersulfated region, followed by gsLR, was found to vary from 
disaccharide to octasaccharide with three subsequent non-sulfated uronic acids. These data are 
reported in detail in section IV.4.1 and in the discussion of the present chapter. 
 
IV.3. Direct LC-MS analysis of gs-LMWHs  
While LC-MS analysis of the digested heparin-related samples allows also the detection 
of minor components, such as the end-residues in LMWHs, they do not permit to determine 
the primary composition of the oligosaccharide mixtures. Unlike UFHs, which have molecular 
weights too high to be directly analyzed by LC-MS, profiling of the intact LMWHs is possible 
(a) 
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due to their lower molecular weight (Langeslay et al., 2013). LC-MS analyses of gs-LMWHs 
in comparison with the starting LMW material were expected to provide additional 
information about individual components of tinzaparin, enoxaparin and dalteparin. 
 
IV.3.1. Method development 
Gradient optimization 
For profiling gs-LMWHs, the methanol gradient used for the analysis of the enzymatic 
digests did not permit to achieve simultaneously good resolution and detection of longer 
oligosaccharides. An attempt to improve the sensitivity by using n-pentyl- or n-hexyl-amines 
(Doneanu et al., 2009) was done, but it led to the decrease of the isomer resolution. 
Substitution of methanol in the DBA-containing mobile phases by acetonitrile permitted to 
improve chromatographic performance in lower total analysis time by decreasing column 
backpressure and consequent increase of the flow-rate (from 100 up to 250 µl/min). 
Acetonitrile-based eluents allowed detecting oligosaccharides up to dp 20 in enoxaparin and 
up to dp 22 in tinzaparin and in dalteparin. Comparable results were reported using 
pentylamine acetate as ion-pair agent for the UPLC separation of tinzaparin oligosaccharides 
(Langeslay et al., 2013) and in an earlier SEC-MS study of Henriksen (2004) oligosaccharides 
up to dp 18 were detected in tinzaparin. The optimized gradient conditions are reported in the 
experimental part (Chapter VI) and the obtained compositional LC-MS profiles are discussed 
below (section IV.3.2), while the complete chromatograms are reported in Annexes 5-7. 
 
Mass spectra interpretation 
For each peak a “first-level structure” was assigned using MS data and considering the 
chemical nature and mode of depolymerization used for LMWH preparation. The mass spectra 
interpretation was based on the same concepts applied for the digested gs-heparins and gs-
LMWHs. High accuracy and resolution of MS permit to accurately measure m/z and to obtain 
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characteristic isotope patterns (Fig.4.7-4.8). Their formula was only accepted if the m/z of the 
candidate analyte matched with the theoretical value within 5 ppm for oligosaccharides up to 
dp 8. For higher chain length oligosaccharides an error within 10 ppm was accepted.  
 
For gs-oligosaccharides, a 2 Da mass increase is expected for each internal gs residue 
with respect to the corresponding unmodified oligosaccharides, however, the susceptibility of 
the RE residues to reduction has to be taken in account for the structural assignment of 
oligosaccharides in gs-LMWHs. The “first” increment of 2 Da (“2H”) was assigned to the 
reduced RE residue (either glucosamine or uronic acid), and a further increase of the mass 
value of 2 or 4 Da was assigned to oligosaccharides (in the alditol form) with 1 or 2 gs 
residues, respectively. Because the dalteparin RE residues are exclusively constituted by 
aM.ol, which is not susceptible to glycol-splitting nor to borohydride reduction, the gs-
oligosaccharides present in gs-dalteparin are easier to be assigned on the MS basis, because 
each increment of 2 Da should indicate only the presence of one gs-residue. 
The abbreviation system was the same that for digested gs-LMWHs samples (see IV.2). 
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Fig.4.7. Example of MS interpretation 
using isotope pattern and exact mass: (a) 
simulated pattern for  [ΔU10,11,1-LR - 
3H + 4DBA]3- ion form, (b) experimental 
one  
 Fig.4.8. Mass spectra for aM.ol-oligosaccharides, 
regular chain decasaccharide in  [U10,13,0-aM.ol - 3H 
+ 6DBA]3- ion form  and another one containing internal 
Rc-unit [U10,13,0-Rc-aM.ol -3H+ 6DBA]3-. The errors 
between experimental m/z and calculated one are also 
shown 
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Evaluation of the method sensitivity to compositional differences 
As for UFHs, the method was tested in terms of its “sensitivity” to hydrolytic side 
reactions. Tinzaparin was chosen due to its relative simplicity among the commercially 
available LMWHs and its being the most similar to heparin. We prepared gs-tinzaparin using 
both hydrochloric and acetic acid at the last reaction step, and the differences in the hydrolysis 
degree were confirmed by 2D NMR, LC-MS and SEC-TDA (Table 4.3). LC-MS 
chromatograms under the optimized separation conditions of both gs-tinzaparin samples differ 
significantly (Fig.4.9): the sample prepared with 0,1M HCl acid solution appeared to contain a 
number of remnant (R) bearing species. Having shown that the present LC-MS method permits 
to observe and monitor such a hydrolysis process, it was applied for the profiling of LMWHs 
and their gs-derivatives.  
 
Table 4.3. Parameters differing between gs-tinzaparin prepared by different methods (Mw, 
uronic acid content and the relative content of hydrolysis marker ΔU2,3,0-R) 
SEC‐TDA    2D HSQC NMR (%)    LC/MS 
 
Mw, kDa 
 
ΔU2S I2S  gsI gsG ANS/NAC-(R) 
 
 
 
Area ratio (%) 
ΔU2,3,0-R/ΔU2,3,0  
gs-tinzaparin (a)  6.4    13.2  73.5  2.2  5.9  +    3.9 
gs-tinzaparin (b)  7.2    11.8  67.5  7.7  8.7  trace    < LOD 
(a) obtained by adding a 0,1M HCl solution at the step of pH adjustment 
(b) obtained by adding a 5% (v/v) CH3COOH solution at the step of pH adjustment 
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Fig.4.9. Total LC-MS chromatograms of two gs-tinzaparin preparations: (a) using 0.1M 
HCl or (b) 5% (v/v) CH3COOH for pH netralization 
Only major components are shown.  
LC conditions: column C18 100 x 2.1 mm, 2.6 µm; eluents A and B – 10 mM DBA and 10 mM CH3COOH 
in H2O-CH3CN = 9:1 (v/v) and CH3CN, respectively; gradient: 0 min – 5%B, 5 min – 5%B, 125 min – 
35%B, 130 min – 70%B, 135 min – 70%B, 138 min – 5%B, 160 min – 5%B; flow rate – 0.25 ml/min 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates 
the terminal sugars in alditol (reduced) form, while R indicates remnant of uronic acids (hydrolysis marker) 
 
 
IV.3.2. LC-MS profiling of gs-LMWHs 
To obtain compositional profiles of the gs-LMWHs, their samples were analyzed directly 
by the LC-MS method in comparison with those of the original unmodified LMWHs. 
Although a detailed analysis of unmodified LMWHs is outside the scope of this work, some 
general features of their LC-MS chromatograms are described here for comparison with the 
corresponding gs-derivatives (Fig.4.10-4.12). 
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Fig.4.10. LC-MS profiles of tinzaparin (a,b) and gs-tinzaparin (c,d) 
LC-MS conditions: see Fig.4.9.  
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates 
the terminal sugars in alditol (reduced) form. LR – linkage region, gsLR – gsG-(Gal)2-gsXyl-Serox, gsLR(2) – 
gsG-(Gal)2-CH(CH2OH)2  
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Fig.4.11. LC-MS profiles of enoxaparin (a,b) and gs-enoxaparin (c,d) 
LC conditions: column C18 100 x 2.1 mm, 2.6 µm; eluents A and B – 10 mM DBA and 10 mM 
CH3COOH in H2O-CH3CN = 9:1 (v/v) and CH3CN, respectively; gradient: 0 min – 0%B, 5 min – 0%B, 
130 min – 35%B, 140 min – 70%B, 145 min – 70%B, 148 min – 0%B, 170 min – 0%B; flow rate – 0.25 
ml/min 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates 
the terminal sugars in alditol (reduced) form. 1,6aA indicates both 1,6-anhydro-glucosamine and 1,6-anhydro-
mannosamine. 
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Fig.4.12. LC-MS profiles of dalteparin (a,b) and gs-dalteparin (c,d) 
LC conditions: column C18 100 x 2.1 mm,.2.6 µm; eluents A and B – 10 mM DBA and 10 mM 
CH3COOH in H2O-CH3CN = 9:1 (v/v) and CH3CN, respectively; gradient: 0 min – 10%B, 4 min – 10%B, 
15 min – 18%B, 30 min – 18%B, 115 min – 35%B, 133 min – 70%B, 138 min – 70%B, 140 min – 10%B, 
160 min – 10%B; flow rate – 0.25 ml/min 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates 
the terminal sugars in alditol (reduced) form. Symbols aM.ol and Rc indicate 2,5-anhydro-mannitol and ring-
contracted units. 
 
 
The present LC-MS method highlights both the structural heterogeneity of the analyzed 
samples and their different molecular weight distributions. For example, while the LC-MS 
chromatogram of enoxaparin appears highly heterogeneous (Fig.4.11), that of dalteparin 
(Fig.4.12), a LMWH known to be extensively purified by ion-exchange chromatography (Bisio 
et al, 2009), reflects a lower heterogeneity and a lower content of dp 4 and dp 6 fractions with 
respect to tinzaparin (Fig.4.10) and enoxaparin (Fig.4.11). The highly sulfated even-numbered 
oligosaccharides are prevalent in all three LMWHs. N-acetyl groups were observed more 
frequently within longer chains (Annexes 5-7). 
Peculiar residues typical for each LMWH are clearly observed in their LC-MS profiles. 
In tinzaparin and enoxaparin LC-MS chromatograms the major components absorb at 232 nm 
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due to the presence of 4,5-unsaturated uronic acid residues (ΔU2S/ΔU) at the NRE (Fig.1.15), 
formed as a result of the depolymerisation by β-elimination reaction. The enoxaparin LC-MS 
profile appears more complex due to the presence of oligosaccharides bearing at the RE either 
hemiacetalic or 1,6-anhydro (1,6aA) forms (Fig.4.11). Some dalteparin oligosaccharides with 
an internal contracted ring (Rc) residues were detected for the first time (Fig.4.12, Annex 8). 
Among the minor components, oligosaccharides with an odd number of residues and a 
glucosamine at the NRE are detectable in all three LMWHs (Fig.4.10-4.12), suggesting that 
some of the original heparin chains terminate with glucosamine units, as discussed in Chapter 
III. Odd-numbered oligosaccharides starting and terminating with uronic acid residues are 
minor components of tinzaparin (such as ΔU9,10,1, Fig.4.10) and in dalteparin (U5,6,0 and 
U5,7,0, Fig.4.12), but are well evident in the enoxaparin (∆U5,6,0 and ∆U5,7,0, Fig.4.11). 
These RE residues are likely to be present in original heparin chains, but their content in 
LMWHs may be increased during the depolymerisation process as a result of a peeling 
reaction (Viskov and Mourier, 2005).  
LC-MS profiles of gs-derivatives significantly differ from their parent LMWHs 
(Fig.4.10-4.12). LC-MS analysis shows that, together with internal gs-residues, glycol-
splitting-induced modifications involve several end-groups, confirming the NMR data and LC-
MS analysis of the digested gs-LMWHs. The major modifications occurring in the end-groups 
of LMWHs upon periodate/borohydride treatment are summarized in Fig.4.13.  
The most evident effect of the reduction step is the formation of alditol residues at the 
RE (involving a 2 Da mass increase) for tinzaparin and enoxaparin oligosaccharides originally 
bearing amino sugars in hemiacetalic form (Fig.4.13a). The RE amino sugars may be also 
oxidized (Fig.4.13a,b), as reported in IV.4.2. 
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TSD – trisulfated disaccharide, ATBR – antithrombin binding region 
 
On the other hand, LC-MS showed that several NRE residues of gs-dalteparin are 
susceptible to glycol-splitting and to a further chain cleavage (as illustrated in Fig.4.12). In the 
case of the non-sulfated uronic acid at the NRE, simultaneous oxidation of the three vicinal 
OH-groups at C-2, C-3 and C-4 is likely to occur. Further loss of the formed remnants at the 
NRE (R(Unr), Fig.4.13c) seems to easily occur. In fact, a relatively large number of gs-
dalteparin odd-numbered oligosaccharides start with a glucosamine (Fig.4.12c,d). Hydrolytic 
loss of the remnants formed at the NRE were also observed to lower extents in enoxaparin, due 
to the low amount of oligosaccharides starting with glucuronic acid at the NRE. For example, 
R(Unr)-A3,5,0-ol and R(Unr)-A3,5,0-1,6aA (Fig.4.11, Annex 8) were observed in gs-
enoxaparin and the last trisaccharide could be structurally correlated with a tetrasaccharide     
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G-ANS3S6S-U2S-1,6aANS, isolated from the enoxaparin dp 4 fraction (unpublished data of our 
group). A further remnant loss at the NRE is reflected, especially in gs-enoxaparin, by the 
presence of the trisaccharides A3,5,0-ol and A3,6,0-ol, this latter bearing an ANS3S6S residue.  
For species starting with glucosamine at the NRE, splitting between C(3) and C(4) is also 
possible. On the other hand, it seems that A5,8,0-1,6aA in enoxaparin (Fig.4.11) and A5,8,0-
aM.ol in dalteparin (Fig.4.12) are resistant to the oxidation because the corresponding analytes 
were found unchanged in the corresponding gs-derivative chromatograms. The experiment, 
performed also on the synthetic pentasaccharide ANS6S-G-ANS3S6S-I2S-A-OMeNS6S (Arixtra®), 
showed that an excess of periodate should be used for completing the splitting of both internal 
glucuronic acid and glucosamine at the NRE (Ferro M., Master degree thesis, 2009). The 
C(3)-C(4) bond of the NRE saturated I2S was also found to be resistant to periodate oxidation, 
at least under the applied conditions. It is likely that the prevalent a-/a-trans-position of the 
corresponding OH groups in 1C4 conformation of I2S (Fig.1.8), shown by Ferro et al., 1990, 
does not permit the formation of cyclic intermediate with periodate ion. 
The possibility to obtain more structural information by differentiating isomers through 
gs-modification is also worth noting. For example, after glycol-splitting the enoxaparin 
tetrasaccharide ΔU4,5,0 gives rise to at least two tetrasaccharides with a terminal alditol 
residue, one containing internal 2-O-sulfated uronic acid ΔU4,5,0-ol and another one 
containing a gs uronic acid (ΔU4,5,0,1gs-ol) (Fig.4.11). As particular cases, several gs-ATBR 
containing oligosaccharides were found (Table 4.4). The corresponding unmodified 
oligosaccharides were further found in the HA fraction of enoxaparin, independently 
confirming the presence of ATBR within their sequences (unpublished data of our group).  
 
 
 
 
 
 113
Table 4.4. LC-MS data (m/z value of the prevalent ion form and retention times) of gs-
oligosaccharides likely containing gs-ATBR 
Compound 
Prevalent  
ion form 
Monoisotopic  
m/z value  
Retention time, min 
ΔU8,10,1,2gs-ol 
(may contain gs-ATBR) 
[M‐3H+2DBA]3‐  817.104  80.3 
ΔU8,9,1,2gs-1,6aA 
(may contain gs-ATBR) 
[M‐3H+2DBA]3‐  783.776  75.9 
ΔU10,13,1,2gs-ol 
(may contain gs-ATBR) 
[M‐3H+5DBA]3‐  1138.579  89.6 
ΔU12,15,1,2gs-1.6aA 
(may contain gs-ATBR) 
[M‐3H+8DBA]3‐  1426.727  94.0 
ΔU12,16,1,2gs-ol 
(may contain gs-ATBR) 
[M‐3H+9DBA]3‐  1503.105  95.7 
ΔU14,19,1,2gs-ol 
(may contain gs-ATBR) 
[M‐3H+12DBA]3‐  1824.581  102.2 
 
The formation of R(Unr)-fragments also permitted to distinguish isomers that was not 
possible to individually identify in unmodified LMWHs. For example, the broad U8,11,0-
aM.ol peak in the dalteparin LC-MS chromatogram can be explained by the presence of 
several isomers. Various sequences may correspond for this number of sulfate groups: either a 
regular sequence constituted by repeating TSD units (I2S-ANS6S-I2S-ANS6S-I2S-ANS6S-I2S-
aM.ol6S) or another one with a G-A* unit. The formation of R(Unr)-A7,11,0-aM.ol in gs-
dalteparin (Fig.4.12d) indicates the presence of the structure with the G-A* disaccharide unit 
at the NRE, which is well-separated from the regular octasaccharide U8,11,0-aM.ol 
(unaffected by glycol-splitting). This observation correlates with the NMR data indicating a 
relatively high contents of A*, G-(A*) and Gnr residues in the parent dalteparin (Table 4.2) 
and its octasaccharide fraction (A* and G-(A*): ~10% of total glucosamine uronic acid 
content, respectively; Gnr: about 50% of total glucuronic acid amount). 
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IV.4. Glycol-splitting-induced modifications of peculiar end-groups (linkage region, 
1,6-anhydro-D-mannosamine-N-sulfate, D-glucosamine-N-sulfate and D-mannosamine 
N-sulfate) 
IV.4.1. Glycol-splitting induced modifications of linkage region sequence 
The LC-MS chromatogram of tinzaparin reveals the presence of highly sulfated species 
(ΔU4,3,1-LR, ΔU4,4,1-LR, ΔU8,6,2-LR, ΔU8,9,1-LR, ΔU10,11,1-LR, ΔU10,11,2-LR 
(Fig.4.10)), containing the intact linkage region GLR-Gal-Gal-Xyl-Ser. As expected and 
confirmed by NMR (Chapter III), the GLR and Xyl units of the LR are susceptible to glycol-
splitting. Analysis of gs-LMWHs after enzymatic digestion (Fig.4.5a) showed that, depending 
on the reaction conditions, the LR can generate two forms, such as the one shown in Fig.1.19d 
(gsLR) or further hydrolyzed at the level of gsXyl, to give the serine lacking fragment gsG-
Gal-Gal-CH(CH2OH)2  (gsLR(2)).  
The LC-MS analysis of the oligosaccharides containing the gsLR/gsLR(2) in the gs-
tinzaparin digest allowed the characterization of the environment near the LR. Non-N-
acetylated gsLR-oligosaccharides were not found, in accord with the knowledge that the first 
glucosamine is always N-acetylated (Iacomini et al., 1999). Of note, ΔU2,1,1-gsLR(2) is 
formed in trace amount, which indicates that the first uronic acid preceding GLR is almost 
always non-sulfated. Otherwise, it would have been split and then not recognized by the 
enzymes. A similar concept, that each product of the enzymatic digestion should contain a     
2-O-sulfated uronic acid at its NRE, was applied for further oligosaccharide identification. 
Different mono-N-acetylated tetrasaccharides containing one gs residue linked to the gsLR(2) 
ΔU2S-ANS(6S)-gsU-ANAc(6S)-gsLR(2) were detected (Table 4.5).  
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Table 4.5. First-level structures and hypothesis of the sulfation pattern identified in tinzaparin 
and gs-tinzaparin, and the corresponding LC-MS data (monoisotopic m/z for the prevalent ion 
form and retention time (RT)) for several linkage region containing oligosaccharides 
Compound  Structure hypothesis *  Prevalent  
ion form 
Monoisotopic
m/z value  RT, min 
TINZAPARIN 
ΔU4,3,1‐LR  ΔU2S‐ANS6S‐G/I‐ANAc‐LR  [M‐2H]2‐  836.640  17.4 
ΔU4,4,1‐LR  ΔU2S‐ANS6S‐G/I‐ANAc6S‐LR  [M‐2H]2‐  876.619  26.5 
ΔU8,6,2‐LR  ΔU2S‐ANS(6S)‐I2S‐ANS(6S)‐G/I‐ANAc(6S)‐G/I‐ANAc‐LR  [M‐3H]3‐  876.119  46.3 
ΔU8,9,1‐LR  ΔU2S‐ANS6S‐I2S‐ANS6S‐I2S‐ANS6S‐G/I‐ANAc‐LR  [M‐3H+    2DBA]3‐  1028.173  57.5 
ΔU10,11,1‐LR  ΔU2S‐ ANS(6S)‐I2S‐ANS(6S)‐I2S‐ANS(6S)‐I2S‐ANS(6S)‐G/I‐ANAc‐LR  [M‐3H+    4DBA]3‐  1279.946  66.3 
ΔU10,11,2‐LR  ΔU2S‐ANS6S‐I2S‐ANS6S‐I2S‐ANS6S‐G/I‐ANAc6S‐G/I‐ANAc6S‐LR  [M‐3H+    4DBA]3‐  1293.949  66.4 
GLYCOL‐SPLIT TINZAPARIN 
ΔU2,1,1‐gsLR(2) 
(trace)  ΔU2S‐ANAc‐gsLR(2)  [M‐2H]
2‐  516.622  8.5 
ΔU4,2,1,1gs‐gsLR(2)  ΔU2S‐ANS‐gsU‐ANAc‐gsLR(2)  [M‐2H]2‐  726.159  31.6 
ΔU4,3,1,1gs‐gsLR(2)  [M‐2H]2‐  766.137  37.6 
ΔU4,3,1,1gs‐gsLR 
ΔU2S‐ANS(6S)‐gsU‐ANAc(6S)‐gsLR(2)/gsLR 
[M‐2H]2‐  825.150  39.8 
ΔU4,4,1,1gs‐gsLR(2)  ΔU2S‐ANS6S‐gsU‐ANAc6S‐gsLR(2)  [M‐2H]2‐  806.115  40.9 
ΔU4,1,2,1gs‐gsLR(2) 
(trace)  ΔU2S‐ANAc‐gsU‐ANAc‐gsLR(2)  [M‐2H]
2‐  707.186  20.3 
ΔU6,3,1,2gs‐gsLR(2) 
(trace)  ΔU2S‐ANS‐gsU‐ANS‐gsU‐ANAc‐gsLR(2)  [M‐2H]
2‐  935.695  38.5 
ΔU6,2,2,2gs‐gsLR(2)  ΔU2S‐ANS‐gsU‐ANAc‐gsU‐ANAc‐gsLR(2)  [M‐2H]2‐  916.722  35.2 
ΔU6,3,2,2gs‐gsLR(2)  [M‐2H]2‐  956.700  39.7 
ΔU6,3,2,2gs‐gsLR 
ΔU2S‐ANS(6S)‐gsU‐ANAc(6S)‐gsU‐ANAc(6S)‐gsLR(2)/gsLR  [M‐2H+ 
  1DBA]2‐  1080.290  46.2 
ΔU6,4,2,2gs‐gsLR 
(trace)  ΔU2S‐ANS6S‐gsU‐ANAc6S‐gsU‐ANAc‐gsLR 
[M‐2H+ 
  1DBA]2‐  1120.268  49.5 
ΔU8,2,3,3gs‐gsLR(2) 
(trace)  ΔU2S‐ANS(6S)‐gsU‐ANAc(6S)‐gsU‐ANAc(6S)‐gsU‐ANAc‐gsLR(2)  [M‐2H]
2‐   1107.286  37.3 
ΔU8,3,3,3gs‐gsLR(2) 
(trace)  ΔU2S‐ANS(6S)‐gsU‐ANAc(6S)‐gsU‐ANAc(6S)‐gsU‐ANAc‐gsLR(2)  [M‐2H]
2‐   1147.264  41.3 
The hypothesis of the structures are based on the fact that gs-residues are resistant to the heparinases, while 2-O-
sulfated iduronic acid residues are susceptible to these enzymes, so that the first residue within the heparinase-
generated oligosaccharides is always ΔU2S. Since glucosamines with unsubstituted NH2-group were not found in 
the tinzaparin sample by NMR, all the glucosamines should be N-substituted in the proposed structure. Moreover, 
the first glucosamine in the closest proximity to the LR is almost always N-acetylated and rarely 6-O-sulfated, as 
shown in the present study and by Iacomini (1999).  
Symbol (6S) indicates possible 6-O-sulfation. 
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The first level structure of ΔU4,3,1,1gs-gsLR(2) corresponds to the previously observed 
heparin oligosaccharides ΔU2S-ANS6S-G/I-ANAc-LR (Iacomini et al., 1999). Only one species 
containing two acetyl groups (ΔU4,1,2,1gs-gsLR(2)) was observed, but in very low amounts, 
indicating that, when the second uronic acid after GLR is 2-O-sulfated, the second glucosamine 
residue is almost always N-sulfated and not N-acetylated. Moreover, the presence of 
ΔU4,4,1,1gs-gsLR(2) indicates that the first N-acetyl-glucosamine can also be 6-O-sulfated, as 
previously found in unmodified heparin (Iacomini et al., 1999). 
Among gsLR-bearing hexasaccharides, those incorporating two N-acetyl-glucosamines 
and two gs-residues (ΔU6,3,2,2gs-gsLR(2) and ΔU6,2,2,2gs-gsLR(2)) were the most evident, 
while a mono-N-acetylated analog (ΔU6,3,1,2gs-gsLR(2)) was observed in traces, indicating 
that when the second uronic acid after GLR is non-sulfated, the following glucosamine is N-
acetylated. Notably, no species with three N-acetyl-glucosamines was found. Octasaccharide 
chains with three gs units linked to the gsLR(2) were also found, even if in traces (Table 4.5, 
see Discussion). Several gsLR-bearing gs-oligosaccharides with the sulfation/acetylation 
pattern similar to that observed in tinzaparin were also found in enoxaparin after SEC-
fractionation of its digested gs-derivative (Fig.4.6). No oligosaccharides bearing 2-O-
phosphorylated xylose (Tone et al., 2008) were observed.  
 
IV.4.2. Susceptibility to periodate of the enoxaparin reducing end amino sugars  
Enoxaparin oligosaccharides bear various amino sugars at their reducing end (RE): 
glucosamine N-sulfate (ANS(6S), ~9% of total amino sugar content; Guerrini et al., 2007) and 
unnatural residues formed during depolymerisation of heparin under alkaline conditions 
(Mourier, and Viskov. US Pat. 2005/0119477 A1, 2005), namely mannosamine N-sulfate 
(MNS(6S)), 1,6-anhydro-glucosamine N-sulfate (1,6aANS) and 1,6-anhydro-mannosamine N-
sulfate (1,6aMNS), respectively estimated ~3, 2 and 2.5% of the total amino sugar content; 
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Guerrini et al., 2007). These residues were expected to be resistant to periodate because of N-
substitution. The oxidation by periodate of amino sugars having vicinal OH- and NH2-groups 
is a well-known process leading to splitting of the corresponding C-C bond (Dryhurst, 1970). 
However, the presence of different N-substituents induces a variety of oxidative behaviors. For 
example, N-alkyl-amino alcohols are also susceptible to periodate oxidation but the reaction 
rate largely varies for secondary and tertiary amines (Dryhurst, 1970; Perlin, 2006). However, 
when the amino-group is N-sulfated the nucleophilic properties of nitrogen are expected to be 
diminished. Unlike RE ANS/MNS groups, whose disappearance from the NMR spectra could be 
explained by their susceptibility to borohydride reduction, the disappearance of 1,6aMNS (see 
Fig.4.1b) was unexpected. 
Interestingly, LC-MS analysis of both intact gs-enoxaparin and its heparinase-digest 
indicated the generation of unknown structures by glycol-splitting. To better understand 
whether these structures are associated with the modification of 1,6aMNS residues, the less 
complex enzymatically depolymerized sample was studied with particular attention. The LC-
MS data show that the analytes with the unknown structures likely have the same backbone 
but they differ in the number of sulfate groups, and gs residues (Table 4.6). Odd-numbered 
mass values indicate the presence of only one nitrogen atom within these molecules. 
The fact that all the three species absorb at 232 nm indicates the presence of a ΔU2S at 
the NRE. Useful information was obtained also by a subsequent SEC-fractionation (Fig. 
4.14a). LC-MS analysis showed that the SEC-fraction “F” eluted between the pools of lowly 
(fraction G in Fig.4.14) and highly sulfated (fraction E in Fig.4.14) tetrasaccharides is enriched 
in compounds of the unknown structures (m/z 448.5, 449.5 and 488.5, Fig.4.14), that is in 
agreement with the hypothesized neutral formula (tetrasaccharides with 3-4 sulfate groups, 
Table 4.6).  
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Table 4.6. Experimental data obtained by LC-UV-MS analysis and proposed neutral formula 
of some unknown compounds found in gs-enoxaparin after its enzymatic digestion 
EXPERIMENTAL DATA  
m/z experimental  [M‐2H]2‐  448.524  449.532  488.504 
Experimental isotope pattern 
(M)/(M+1)/(M+2) 
Overlapped with 449.532 
(due to similar RT)  100/31/23  100/30/30 
Absorbance at 232 nm  +  +  + 
m/z experimental [M‐2H]2‐ after 
additional reduction with NaBH4  448.524  449.533  488.504 
HYPOTHESIS of STRUCTURE  
Neutral molecular formula  
(tolerance <5 ppm)  C24H37N1O29S3  C24H39N1O29S3  C24H37N1O32S4 
Structural connections between species  M  M  + 2H (1gs)  M + 1SO3 
Monoisotopic neutral mass (theoretical)  899.0613   901.0770  979.0182 
m/z theoretical  [M‐2H]2‐  448.523  449.531  488.502 
Theoretical isotope pattern     
(M)/(M+1)/(M+2)  100/30/24  100/30/24  100/31/29 
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Fig.4.14. SEC profile (a) of gs-enoxaparin digested with heparinases and LC-MS 
chromatogram of the fraction enriched in unknown species with m/z 448.5, 449.5 and 488.5 (b) 
Components of all the fractions were determined by LC-MS. Major components were: fraction I – ΔU2,2,0, 
fraction H – ΔU2,3,0, fraction G - ΔU2,3,0-R and ΔU4,2,1,1gs, fraction F – unknown species (see panel b), 
fraction E - ΔU4,5,0,1gs and ΔU4,6,0-ol, fraction D – ΔU6,6,1,2gs, fraction C – octasaccharides (see Fig.4.6)  
LC-MS conditions and abbreviations used: see Fig.4.6.  
 
These species were also found to be resistant to borohydride reduction, suggesting that 
they do not have a hemiacetalic monosaccharide at the RE. Their presence in the enzymatic 
digest and, therefore, their resistance to the heparinases suggests the presence of unnatural 
terminal residue(s) in their molecules. 
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Two different structures with the same neutral formula were found to correspond to the 
observed unusual m/z values: the first one an unsaturated N-acetylated trisaccharide containing 
the remnant of amino sugar (Ram) and the second structure bearing a split 1,6-anhydro-amino 
sugar at the RE (Table 4.7). A subsequent MS/MS experiment indicated that the main 
fragments could be formed from both the backbone types (Fig.4.15). A minor signal m/z 
247,494 may be more informative: it corresponds to a disaccharide unit with two sulfate 
groups, suggesting that the unique glucosamine, present in the molecule, is N-sulfated, ruling 
out the structure with a remnant and a N-acetyl substituent.  
 
Table 4.7. Possible structures of analytes with m/z 448.5, 449.5, 488.5 found in the 
heparinase-digest of gs-enoxaparin 
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Fig.4.15. MS/MS fragmentation of m/z 488.5 with two different interpretations  
(a) trisaccharide bearing a remnant of the oxidized mannosamine (Ram), (b) tetrasaccharide 
with the split 1,6-anhydro-aminosugar residue (gs1,6a) 
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NMR data also suggest that the structure with split 1,6-anhydro-ring is more probable. 
The HSQC spectrum of the SEC fraction enriched in the structurally unknown compounds did 
not show cross-peaks corresponding to the ANAc6S linked to I2S (H1/C1 5.15/96.6 ppm, H2/C2 
4,03/56.2 ppm, Yates et al, 1996). This cross-peak should have been observed if the unknown 
compound with m/z 488.5 had the N-acetylated structure ΔU2S-ANAc6S-I2S-Ram. Moreover, the 
ANAc6S-(I2S) sequence is rarely present within heparin chains according to its biosynthesis 
pathway.  
All the experimental data, i.e.: i) absorbance at 232 nm; ii) resistance under the reductive 
conditions; iii) m/z value; iv) correspondence of the experimental isotopic pattern with the 
theoretic one; v) resistance to the reduction and to the enzymatic cleavage; and vi) NMR data, 
indicate that the split 1,6-anhydro-ring sugar is the most probable structure. However, it was 
still difficult to prove that its formation is caused by oxidation of the 1,6aMNS.  
To verify whether periodate can split terminal 1,6aMNS residues of some enoxaparin 
oligosaccharides, model compounds were needed. Since no oligosaccharide standards 
containing 1,6-anhydro-sugars are available, we performed a multi-step fractionation of 
enoxaparin components to isolate a fraction containing two isomeric pentasulfated 
tetrasaccharides ∆U2S-ANS6S-I2S-1,6aANS and ∆U2S-ANS6S-I2S-1,6aMNS (Fig.4.16).  
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Fig.4.16. Multi-step isolation scheme of two epimeric tetrasaccharide pairs: pentasulfated 
tetrasaccharides ∆U2S-ANS6S-I2S-1,6aANS and ∆U2S-ANS6S-I2S-1,6aMNS and hexasulfated 
tetrasaccharides ∆U2S-ANS6S-I2S-ANS6S and ∆U2S-ANS6S-I2S-MNS6S 
(adapted from Alekseeva et al., Carb. Res. 2014) 
 
The tetrasaccharide fraction was chosen because its structural characterization by NMR 
and LC-MS is easier with respect to longer-chain oligosaccharides. To verify the role of the 
1,6-anhydro-bridge in the susceptibility towards oxidation a fraction containing the 
hexasulfated tetrasaccharides ∆U2S-ANS6S-I2S-ANS6S and ∆U2S-ANS6S-I2S-MNS6S have been also 
studied in the presence of periodate. As first step, SEC-fractionation of the enoxaparin sample 
was carried out to obtain a fraction enriched in tetrasaccharides, which was, then, sub-
fractionated by IPRP-HPLC to isolate the target tetrasaccharides (Fig.4.16). The obtained 
fractions were fully characterized by 2D NMR and LC-MS analysis. The corresponding 
spectral data are reported in Fig.4.17.  
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Fig.4.17. HSQC NMR spectra (anomeric region) and LC-MS data of (a) enoxaparin 
fraction containing pentasulfated isomers ∆U2S-ANS6S-I2S-1,6aANS and ∆U2S-ANS6S-I2S-
1,6aMNS, (b) fraction containing hexasulfated tetrasaccharides ∆U2S-ANS6S-I2S-ANS6S 
and ∆U2S-ANS6S-I2S-MNS6S (reported from Alekseeva et al., Carb. Res. 2014) 
 
 
Behavior of reducing end 1,6-anhydro-amino sugars in the presence of periodate 
The periodate treatment of the isolated mixture of ∆U2S-ANS6S-I2S-1,6aANS and          
∆U2S-ANS6S-I2S-1,6aMNS was performed directly in the NMR tube in order to monitor the 
anomeric signals in real time. The absence of ANS-G disaccharide unit within the isolated 
tetrasaccharides permitted to monitor the anomeric signal of 1,6aMNS by monodimensional 1H 
NMR spectroscopy. In the case of more complex fractions or unfractionated enoxaparin, the 
1,6aMNS 1H NMR signal (at 5.57-5.59 ppm; Guerrini et al., 2007; Mascellani et al., 2007) 
overlaps with the anomeric signal of ANS followed by G (at 5.58 ppm; Guerrini et al., 2005). 
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Even if their differentiation is possible by 2D HSQC NMR spectroscopy, it could not permit 
monitoring reaction because of much longer acquisition times. In Fig.4.18 the 1H NMR spectra 
of the pentasulfated tetrasaccharide mixture in the presence of periodate after different time 
periods are shown.  
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Fig.4.18. 1H NMR real-time monitoring of anomeric H1 signals and H4 signals of unsaturated 
uronic acids of ∆U2S-ANS6S-I2S-1,6aANS and ∆U2S-ANS6S-I2S-1,6aMNS mixture before and after 
addition of periodate (reported from Alekseeva et al., Carb. Res. 2014) 
Symbol * indicates the anomeric signal of I2S adjacent the modified 1,6aMNS 
 
It can be noted that the chemical shifts of the 1,6-anhydro-residues (1,6aMNS 5.56 ppm 
and 1,6aANS 5.60 ppm) are slightly shifted with respect to the published values for enoxaparin 
(1,6aMNS 5.59 ppm and 1,6aANS 5.63 ppm; Guerrini et al., 2007), probably due to the shorter 
length of these oligosaccharides. In fact, the observed values are similar to those of some 
disaccharides with 1,6-anhydro-terminal units (1,6aMNS 5.57 ppm and 1,6aANS 5.61 ppm; 
Mascellani et al., 2007). The anomeric 1,6aMNS signal showed a notable intensity decrease 
after 5 h of reaction with periodate, and after 20 h it was present only in trace amount 
(Fig.4.18). Together with the disappearance of 1,6aMNS peak, a new signal (indicated as * in 
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the Fig.4.18), likely corresponding to the anomeric signal of I2S adjacent to the modified 
1,6aMNS, at 5.30 ppm (see below) appeared. 
LC-MS analysis of the reaction mixture after 40 h showed one of the unaffected isomeric 
pentasulfated tetrasaccharides (Fig.4.19), identified as 1,6aANS-containing isomer because all 
its signals were preserved in the NMR spectrum (Fig.4.18). On the contrary, the LC-MS peak 
of the second isomer, bearing the 1,6aMNS residue, disappeared, and a new peak with m/z 
486.4881 appeared in the LC-MS chromatogram (Fig.4.19).  
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Fig.4.19. LC-MS data of the mixture of ∆U2S-ANS6S-I2S-1,6aMNS and ∆U2S-ANS6S-I2S-
1,6aANS after periodate addition (40 h) (adapted from Alekseeva et al., Carb. Res. 2014) 
(a) – LC-MS chromatogram, (b) – mass spectra of the two peaks observed (errors between 
experimental and calculated m/z values are reported for each ion form of the new compound 
generated by periodate) 
Arrows indicate sodium adducts 
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The odd value of the nominal mass (975 Da) suggests the presence of a single nitrogen 
atom. Since the internal ANS6S residue was shown by NMR to be unaffected (Fig.4.18), it is the 
RE 1,6-anhydro-ring that does not have a nitrogen atom. The hypothesized structure 
containing split 1,6-anhydro-ring is shown in Fig.4.19. Interestingly, in the MS spectrum it 
appeared in free (theoretical m/z 486.4861(2-)) as well as hydrated and methyl acetal forms 
(formed by both methanol and water present in the eluent), proving the presence of two 
aldehyde groups in its molecule (Fig.4.19).  
The solution recovered from the NMR tube was treated with sodium borohydride to 
stabilize the formed aldehydes and, then, analyzed by NMR and LC-MS. HSQC NMR 
spectroscopy showed that all the cross-peaks in the anomeric region, except for 1,6aMNS and 
the adjacent I2S preceding it (I2S-(1,6aMNS)), maintained the same positions as in the original 
mixture of the two pentasulfated tetrasaccharides (Fig.4.20). The anomeric signal of I2S linked 
to the modified terminal residue shifted from 5.37 (blue spot of I2S-(1,6aMNS) in HSQC 
spectrum, Fig.4.20a) to 5.31 ppm (red spot of I2S-(gs1,6a) in HSQC spectrum) as shown by 
TOCSY spectroscopy (Fig.4.21). 
Notably, while the anomeric 1,6aMNS cross-peak disappeared, a new signal at 5.04/105.9 
ppm was observed in the region typical for anomeric signals of gs-units (4.8-5.0/105-107 
ppm). Its correlation with the cross-peak at 3.72/64.0 ppm, typical for CH2OH groups (their 
presence was confirmed by HSQC-DEPT experiment, not shown), supports the presence of a 
gs-residue. The other three signals that appeared in the “ring region” after the 
periodate/borohydride reaction (Fig.4.20b), namely, at 4.10/69.5 ppm, 3.94/82.1 ppm and 
3.75/64.7 ppm (gs1,6a H3/C3), correlate in the TOCSY spectrum (indicated as gs1,6a in Fig.s 
4.20, 4.21). The latter signal was assigned by HSQC-DEPT experiment (not shown) to the 
second CH2OH group of the gs-unit, arising from the C(3) of the starting 1,6aMNS residue. 
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Fig.4.20. HSQC spectra of ∆U2S-ANS6S-I2S-1,6aANS and ∆U2S-ANS6S-I2S-1,6aMNS mixture 
before (blue spots) and after (red spots) periodate/borohydride treatment (reported from 
Alekseeva et al., Carb. Res. 2014) 
(a) – anomeric region, (b) – “ring” region. In panel (c) the structures of the unaffected 
tetrasaccharide ∆U2S-ANS6S-I2S-1,6aANS and the gs one ∆U2S-ANS6S-I2S-gs1,6a are shown.  
The first two residues ∆U2S and ANS6S within their sequence (cross-peaks shown in black) show very 
similar chemical shifts in the anomeric region of the spectrum, whereas the I2S and terminal 
1,6aMNS/1,6aANS (shown in red) differ from each other. Chemical shifts of I2S residues differ from each 
other due to the so-called “sequence effect” 
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Fig.4.21. TOCSY 
spectrum of the mixture 
containing the unaffected 
tetrasaccharide ∆U2S-
ANS6S-I2S-1,6aANS and the 
gs-product ∆U2S-ANS6S-
I2S-gs1,6a 
(reported from Alekseeva 
et al., Carb. Res. 2014) 
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The LC-MS chromatograms of the pentasulfated tetrasaccharide mixture before and after 
periodate/borohydride treatment are shown in Fig.4.22.  
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Fig.4.22. LC-MS chromatogram of the ∆U2S-ANS6S-I2S-1,6aANS and ∆U2S-ANS6S-I2S-1,6aMNS 
mixture (a) and the same mixture after periodate/borohydride treatment (b). In panel (c) the 
corresponding mass spectra are shown (reported from Alekseeva et al., Carb. Res. 2014) 
Peak at 70 min in panel (b) is a system signal (due to the gradient) 
 
Combining NMR and LC-MS data several conclusions can be drawn. First of all, as in 
the case of the solution treated only with periodate, the 1,6aANS-containing epimer remains 
unaffected (m/z 526.983(2-)). Our knowledge about the elution order of heparin 
oligosaccharides in IPRP mode is in agreement with this result. It has been noted that 
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1,6aMNS-containing oligosaccharides were eluted before their 1,6aANS isomers (unpublished 
data from our group). In fact, the peak with a shorter retention time (RT 55.0 min) disappeared 
from the chromatogram, while the second one (RT 58.2 min) remained unaffected (Fig.4.22). 
The new peak (RT 32.9 min) observed in the chromatogram after periodate/borohydride 
treatment corresponds to the reduced form (m/z 488.506(2-)) of the compound generated by 
periodate oxidation (m/z 486.488(2-), Fig.4.19). The increase of the nominal mass value by       
4 Da after reduction is in agreement with the proposed structure with two aldehyde groups. 
The analyte formed after reduction is the same observed in the heparinase-digest of the gs-
enoxaparin. 
Based on the well-known mechanism of periodate oxidation that includes the formation 
of a cyclic intermediate (Dryhurst, 1970; Perlin, 2006) and the predicted conformations of the 
tetrasaccharides under study (Alekseeva et al., Carb. Res. 2014, Fig.4.22), the observed 
oxidation of the 1,6-anhydro-D-mannosamine-N-sulfate may be explained by the e-/a-cis-
position of NHSO3- and OH groups at the C(2) and C(3), respectively (Fig. 4.23b). It is likely 
that the coordination of nitrogen atom by periodate ion could lead to N-desulfation, formation 
of a cyclic intermediate and further splitting of the C(2)-C(3) bond. In the case of 1,6aANS the 
a-/a-trans-position of NHSO3- and OH groups (Fig.4.23a) should not allow the formation of a 
periodate cyclic intermediate, and, as a consequence, the 1,6aANS should not be oxidized. 
1,6aANS
1,6aMNS
ANS6S
U2S
U2S
ANS6S
I2S
I2S
a‐a‐
a‐ e‐
(a)
(b)
 
 
Fig.4.23. Conformation predicted for the 
tetrasaccharides ∆U2S-ANS6S-I2S-1,6aANS (a), 
U2S-ANS6S-I2S-1,6aMNS (b) 
(from Alekseeva et al., Carb. Res. 2014) 
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Behavior of terminal N-sulfated mannosamine and glucosamine residues in the presence 
of periodate  
Unlike for 1,6-anhydro-tetrasaccharides, monodimensional 1H NMR could not be used 
for monitoring the anomeric signals of RE amino sugars of  ∆U2S-ANS6S-I2S-ANS6S and                
∆U2S-ANS6S-I2S-MNS6S because of the overlapping of the H1/C1 of MNS6S (α-anomer) with that 
of the internal ANS6S (Fig.4.1b). 2D HSQC spectra were acquired after 5, 10 and 20 h. 
However, even after 40 h and additional portion of periodate, the cross-peak volumes of 
H1/C1 signals of ANS6Sα and MNS6Sα did not significantly change, as, at first glance, also the 
LC-MS profile of the hexasulfated tetrasaccharide mixture (Fig.4.24). Both the isomeric peaks 
were still present in the chromatogram after 40 h (after borohydride treatment appeared in their 
alditol forms, not shown), along with a new peak with m/z 506.47(2-) observed only in trace 
amount (Fig.4.24). The observed m/z value 506.47(2-) corresponds to ∆U2S-ANS6S-I2S-Ram, 
where Ram is a remnant formed by simultaneous splitting of C(1)-C(2) and C(2)-C(3) bonds of 
the RE amino sugar (Fig.4.24c). Borohydride treatment gave rise to its reduced form with     
m/z 507.47(2-). A mass increase of 2 Da, together with the presence of only a mono-methyl 
acetal form of ∆U2S-ANS6S-I2S-Ram (m/z 522.48(2-)) (Fig.4.24c), confirms the presence of one 
aldehyde group in its structure.  
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Fig. 4.24. LC-MS chromatograms of isomeric hexasulfated tetrasaccharides ∆U2S-ANS6S-I2S-
ANS6S and ∆U2S-ANS6S-I2S-MNS6S before (a) and after (b) periodate treatment (40 h). In panel (c) 
the mass spectrum of the peak generated by periodate oxidation is shown after 5 days but not 
after 40 h because for the latter case the peak intensity was too low for exact mass 
determination (reported from Alekseeva et al., Carb. Res. 2014) 
Peak broadening may be explained by the presence of numerous forms of the oxidized tetrasaccharide because 
aldehyde groups reversibly react with water and methanol present in the mobile phase. Signals in the mass 
spectrum without attribution correspond to sodium and potassium adducts of the ion form shown. 
 
∆U2S-ANS6S-I2S-Ram could be generated by both epimers. However, a change in the peak 
intensity ratio of the two hexasulfated tetrasaccharides after addition of periodate suggested a 
prevalent oxidation of the isomer with a longer RT (73.8 min) (Fig.4.24). Based on our 
knowledge about the elution order of enoxaparin oligosaccharides (unpublished data of our 
group), this component is the MNS6S-bearing isomer. Because of a slow reaction rate and 
insufficient chromatographic resolution it was difficult to establish whether also the terminal 
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ANS6S residue was affected by periodate. The possibility of its oxidation was independently 
verified using a disaccharide ∆U2S-ANS6S, isolated during SEC fractionation of the heparinase-
digest of gs-enoxaparin (fraction H in Fig. 4.14a). The natural ANS6S residue of this 
disaccharide (formed by enzymatic hydrolysis) was found to be partially oxidized by 0.1 M 
sodium periodate: a new minor peak, corresponding to the ∆U2S-Ram (m/z 436,9701), appeared 
in the LC-MS chromatogram after 20 h of oxidation (not shown). We also carried out the 
oxidation of hexasulfated tetrasaccharides for longer time (5 days). Even if the intensity of 
∆U2S-ANS6S-I2S-Ram was slightly increased with respect to the results shown in Fig.4.24, about 
90 % of tetrasaccharides were still unaffected (not shown).  
Altogether, these data indicate that both terminal residues, MNS6S and ANS6S, may be 
partially affected by periodate under drastic conditions (long reaction time and high periodate 
concentration). The oxidation of the MNS6S-isomer appeared relatively faster probably due to 
the cis-a-/e-position of NHSO3- and OH groups (Fig.4.25), but much slower than that of 
1,6aMNS, suggesting an essential role of the 1,6-anhydro-“bridge” (see Discussion).  
ANS6S
MNS6S
ANS6S
U2S
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ANS6S
I2S
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a‐e‐
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Fig.4.25. Conformation predicted for the 
tetrasaccharides ∆U2S-ANS6S-I2S-ANS6S (a),  
U2S-ANS6S-I2S-MNS6S (b) 
(from Alekseeva et al., Carb. Res. 2014) 
 
It is worth noting that C(2) NHSO3- and C(3) OH groups of the internal ANS6S residue of 
all the target tetrasaccharides as well as RE residue of ∆U2S-ANS6S-I2S-ANS6S are in e-/e-trans-
position that could allow the formation of a cyclic periodate intermediate (Fig.4.25). However, 
the internal ones were found resistant to the oxidation, probably due to the effect of bulky and 
electrostatic repulsive groups of the adjacent 1,4-linked residues. 
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IV.5. Discussion 
Modifications generated in LMWHs by the glycol-splitting periodate oxidation followed 
by a “stabilizing” borohydride reaction involve not only internal non-sulfated uronic acids but 
also several end-residues, that was not observed for gs derivatives of the unfractionated 
heparins (Chapter III). Combination of NMR spectra and LC-MS data revealed all these 
structural modifications in the LMWHs, providing complementary and characteristic 
fingerprints of both LMWHs and their gs-derivatives. It is worth noting that under the mild 
experimental conditions used for gs-LMWHs preparation (i.e. acetic acid used for pH 
neutralization after borohydride reduction), the conversion yields of the parent LMWHs to the 
corresponding gs-derivatives were quite high (>85%). However, a slight Mw decrease (9-15% 
lower than for the parent LMWHs, Table 4.1) was still observed, indicating some chain 
shortening.  
As for gs-heparins, a note of caution is necessary when dealing with gs-derivatives of 
LMWHs, since the local flexibility of gs residues may affect their relaxation times T2 (Casu et 
al., 2002). Quantification of the internal residues of gs-heparin chains was possible, as shown 
in Chapter III. However, it should be considered with caution especially for terminal residues, 
such as gsXyl, because of longer T2 values of the more mobile gs residues. In fact, the highest 
discordance was observed for gs-LR residues: the gsXyl content was almost always 
overestimated with respect to the other residues of gsLR (gsGLR, Gal1 and Gal2, Table 4.2). 
The reported quantitative data for gs-LMWHs (Table 4.2), though compatible with our overall 
conclusions, should accordingly be taken as provisional, until a deeper study is made using 
well-defined model compounds.  
Both HSQC NMR spectra and LC-MS profiles of gs-LMWHs (as well as their digests) 
also retain some features characteristic of the LMWH production method: partial 
depolymerisation with heparinase I (tinzaparin), base-catalyzed β-elimination (enoxaparin), and 
nitrous acid depolymerisation (dalteparin) in terms of typical end groups. All of these 
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depolymerisation methods cleave only glycosidic bonds between an amino sugar and the 
adjacent uronic acid, leading to formation of even-numbered oligosaccharides (Fig1.15). 
Accordingly, all the parent LMWHs as well as gs-tinzaparin and gs-enoxaparin mainly 
consisted of even-numbered oligosaccharides. Surprisingly, gs-dalteparin contained numerous 
odd-numbered oligosaccharides in its LC-MS chromatogram (Fig.4.12). Their formation is 
likely associated with glycol-splitting of the dalteparin terminal uronic acid residues at the 
NRE bearing 3,4-diol groups and the further hydrolysis of the generated remnants (Fig.4.13c). 
Together with the observed high content of odd-numbered oligosaccharides, also the 
occurrence of occasional ring contracted residues Rc diversifies gs-dalteparin from the other 
gs-LMWHs (Fig. 4.12). In the case of tinzaparin and enoxaparin, 4,5-unsaturated 2-O-sulfated 
uronic acids at the NRE “protect” the chains from shortening during periodate oxidation. Given 
their susceptibility to periodate, minor ΔU and saturated uronic acid residues of enoxaparin 
may contribute to some chain shortening from the NRE.  
As for RE, tinzaparin and enoxaparin amino sugars are susceptible to borohydride 
reduction, while dalteparin aM.ol rings are resistant. The apparently anomalous behavior of 
terminal enoxaparin 1,6-anhydro-D-mannosamine-N-sulfate residues has been studied and 
confirmed by NMR spectroscopy and LC-MS using model tetrasaccharides isolated from the 
LMWH enoxaparin. Moreover, also RE D-mannosamine-N-sulfate and D-glucosamine N-
sulfate, lacking the 1,6-anhydro-bridge, can be oxidized by periodate but with significantly 
lower rate. It is likely that the cis-position of OH and NHSO3- groups of terminal residues 
(1,6aMNS or MNS6S) is not a sufficient requirement for the oxidation. The 1,6-anhydro-bridge 
present at the RE of ∆U2S-ANS6S-I2S-1,6aMNS induces a rigid ring conformation more favorable 
for oxidation to occur. Also the differences in residue electrostatic charge between 1,6aMNS 
(charge = -1) and MNS6S (charge = -2) may explain the preference for the negatively charged 
periodate to react with the former substrate.  
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The partial or minimal slow oxidation of RE ANS6S and MNS6S is likely to be associated 
with their hemiacetalic or acyclic hydrated aldehyde forms, whose C(1) hydroxyl groups can 
partially contribute to the formation of cyclic periodate intermediates, involving the adjacent 
C(2) N-sulfated groups. Notably, the generated oligosaccharide ∆U2S-ANS6S-I2S-Ram             
(∆U3,5,0-Ram) was observed in relatively high quantity in the digest of gs-enoxaparin (Fig.4.5) 
and in trace in the heparinase-digests of gs-heparins (Chapter III). Initially, its formation in the 
gs-heparins digests was hypothesized to be the result of oxidation of non-N-substituted amino 
sugars that could be present in heparins. The present study suggests that also partial oxidation 
of RE hexosamines of heparin and enoxaparin chains may lead to the formation of                  
∆U2S-ANS6S-I2S-Ram. Its relatively higher quantity in the gs-enoxaparin digest is likely to be 
explained by its lower molecular weight and, consequently, higher amount of RE terminal N-
sulfated amino sugars (~16% of total glucosamine content; Guerrini et al., 2007) with respect 
to unfractionated heparins (<3%; Desai and Linhardt, 1995). 
In order to compare the behavior of 1,6aMNS residues with that of non-sulfated uronic 
acids and to evaluate its possible contribution to the gs-product heterogeneity, we also 
performed the oxidation of enoxaparin for different time periods (Fig.4.26). 2D HSQC NMR 
analysis has shown that the complete oxidation of non-sulfated iduronic acids occurred in 2 h, 
while glucuronic acids appeared more resistant under the applied conditions, and both 
glucuronic acids and 1,6aMNS residues were totally oxidized only after 12 h of reaction 
(Fig.4.26). The obtained data indicate that N-substitution and conformational flexibility may 
drive periodate oxidation. Despite N-substitution, 1,6aMNS is oxidized with almost the same 
rate than non-sulfated glucuronic acid, probably because it is “blocked” in a conformation     
(cis-a-/e-position of OH and NHSO3- groups) favorable for formation of a cyclic intermediate 
with periodate. Glucuronic acid is mainly present in 4C1 conformation with trans-e-/e-position 
of OH and NHSO3- groups (Fig.1.8), which is probably less favorable for periodate-cycle 
formation. 1C4 conformation of iduronic acid with trans-a-/a-position of OH and NHSO3- 
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(Fig.1.8) could not form a cyclic intermediate with periodate ion. Consequently, its higher 
susceptibility to periodate with respect to glucuronic acid may be explained by its higher 
conformational flexibility (Ferro et al., 1990).  
The difference in the oxidation kinetics of different units could permit to control the 
glycol-splitting reaction. 
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1,6aANS – 1,6-anhydro-D-glucosamine-
N-sulfate,    1,6aMNS – 1,6-anhydro-D-
mannosamine-N-sulfate, I – L-iduronic 
acid, I2S – L-iduronic acid 2-O-sulfate, 
G-(ANS) – D-glucuronic acid followed by   
D-glucosamine-N-sulfate, G-(ANS3S6S) – 
D-glucuronic acid followed by D-
glucosamine-N,3-O,6-O-trisulfate,        
G-(ANAc) – D-glucuronic acid followed 
by N-acetyl-D-glucosamine 
 
LC-MS analysis of heparinase digests provide additional structural information on 
oligosaccharide components of gs-LMWHs, and, indirectly, on the parent compounds. Their 
LC-MS profiles are more complex, and probably more informative, than those of gs-heparins 
(Chapter III) because of interference on the enzyme by several unnatural end-groups. RE 
terminals, such as alditols (in gs-tinzaparin and gs-enoxaparin), 1,6-anhydro-mannosamine (in 
gs-enoxaparin), 2,5-anhydro-mannitol (in gs-dalteparin), were not recognized by heparinases, 
leading to the preferential cleavage of glycosidic bond one disaccharide unit further towards the 
NRE. In fact, LC-MS peaks of the disaccharides with such unnatural residues at the NRE were 
never observed in the enzymatic digests. These results are in agreement with previous reports 
on enoxaparin and dalteparin (Linhardt et al., 1990; Ozug et al., 2012; Viskov and Mourier, 
2004), showing that tetrasaccharide fragments were generated instead of disaccharides as it 
would be the case if the end residues were unmodified glucosamines. It may be useful to 
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characterize the sequences at the RE of the LMWH chains. For example, the presence of 
ΔU3,4,0-ol in the gs-enoxaparin digest suggests that I2S-ANS6S-I2S sequence, probably generated 
during the bleaching manufacture process, was at the RE of several enoxaparin chains. 
An additional inhibition exerted by gs-residues, first observed on gs-heparins (Chapter 
III), permitted to characterize the heparin sequences near the LR by the first time, and to 
identify the ATBR-containing sequences with different sulfation/N-acetylation patterns.  
The results obtained for the gs-tinzaprin digest suggest that the sequences in the closest 
proximity to the LR are shorter (i.e., dp 2-6) than previously assumed. Traditional 
representation of heparin structure (Fig.1.2) shows a well-defined low sulfated N-acetylated 
domain constituted by repeating ANAc-G disaccharide units, however, the present results (see 
IV.4.1) show that its sulfation degree is not so low. Oligosaccharides ΔU4,3,1-LR, ΔU4,4,1-
LR, ΔU8,6,2-LR, ΔU8,9,1-LR, ΔU10,11,1-LR and ΔU10,11,2-LR were the prevalent LR-
containing species of tinzaparin, while ΔU4,3,1,1gs-gsLR, ΔU4,3,1,1gs-gsLR, ΔU6,2,2,2gs-
gsLR and ΔU6,3,2,2gs-gsLR (Table 4.5) were prevalent in the gs-tinzaparin digest. 
Octasaccharides bearing gs-LR were observed only in trace, and longer sequences were not 
detected even after accurate fractionation of gs-enoxaparin digest. Similar conclusions were 
made for the internal sequences: the found gs-octasaccharides with three gs residues are mono-
N-acetylated (∆U8,8,1,3gs, ∆U8,9,1,3gs, etc), suggesting that the sequences with three 
contiguous non-sulfated uronic acids within the original heparin chains are highly sulfated. 
Concerning ATBR-containing oligosaccharides, the hexasaccharide ΔU6,7,1,2gs (in the 
case of dalteparin it could be also incorporated in the minor octasaccharide ΔU8,9,1,2gs-aM.ol) 
was observed in the LC-MS profiles of all the gs-LMWH digests. As for gs-heparins, 
tetrasaccharide ΔU4,6,0,1gs (generated from a highly sulfated ATBR variant) was found in 
trace amount also in all gs-LMWHs digests.  
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It is important to note that the glycol-splitting-induced local mobility is likely to exert an 
influence on retention times in LC-MS profiles of components of gs-LMWHs, allowing 
separation of some isomeric oligosaccharides otherwise difficult to achieve. Several trends in 
the elution order in ion-pair reversed phase HPLC, which are in agreement with the separation 
mechanism (Fig.1.24), were observed. For oligosaccharides with the same dp, the higher the 
sulfation degree, the higher the retention time RT (for example, RT (ΔU6,7,0) < RT (ΔU6,8,0) 
< RT (ΔU6,9,0) in enoxaparin Fig.4.11): the greater number of negatively charged sulfate 
groups induces stronger interaction with the stationary phase, dynamically modified by the 
positively charged dibutylamine cation. The presence of a N-acetyl group causes a slight 
increase of the retention time (RT (ΔU6,7,0) < RT (ΔU6,7,1)) that indicates that not only 
electrostatic but also hydrophobic interactions between analytes and stationary phase can take 
place. Probably for the same reason, enoxaparin oligosaccharides with 1,6aA-residues are 
eluted after their analogs bearing hemiacetalic aminosugars (RT ΔU6,8,0 < RT ΔU6,8,0-
1.6aA). Unexpectedly, the retention time of ΔU16,21,0 is somewhat lower than that of 
ΔU14,21,0 in tinzaparin (Annex 5) and enoxaparin (Annex 6). This finding may be explained 
by the fact that the longer the oligosaccharide chains, the less the influence of additional 
disaccharide units and the more crucial the influence of the number of anionic groups per 
chain. Unsaturation in the NRE uronic acid increases the RT (RT (U6,9,0) < RT (ΔU6,9,0)), 
probably due to the higher acidity of the uronic acid carboxy-group when conjugated with a 
double bond, leading to a stronger interaction with the dibutylammonium cation. The same 
effect may take place in the case of the odd enoxaparin oligosaccharides starting with ΔU(2S), 
which show higher RT than oligosaccharides starting with a glucosamine residue (RT (A3,4,0) 
< RT (ΔU3,4,0)); moreover, ΔU3,4,0, bearing two carboxyl groups, have more anion centres 
able to interact with dibutylammonium cation. Oligosaccharides in alditol form are eluted after 
their unmodified analogs (RT (ΔU6,8,0) < RT (ΔU6,8,0-ol)), and this is probably caused by the 
higher flexibility of the reduced open form with respect to that of the hemiacetalic one, that 
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facilitates the interactions between sulfate groups and dibutylamine on the stationary phase. 
The presence of an uronic acid remnant increases the retention time (e.g., in gs-tinzaparin (RT 
(ΔU8,12,0-ol) < RT (ΔU8,12,0-R)), probably due to the additional charge of the remnant 
carboxyl group (R) present at the RE (Fig.1.19e). 
Not only the total charge but its distribution within the analyte molecules plays a role in 
the IPRP-HPLC separation. For the tetrasaccharides epimeric pairs, ∆U2S-ANS6S-I2S-1,6aANS/          
∆U2S-ANS6S-I2S-1,6aMNS and ∆U2S-ANS6S-I2S-ANS6S/∆U2S-ANS6S-I2S-MNS6S, the value of the 
electric dipole appeared to influence the epimer capacity to interact with the stationary phase, 
driving their separation. In this case the higher dipole moment magnitude of the molecule 
correlates with the stronger interaction with the stationary phase. The 1,6aANS-bearing 
tetrasaccharide with a dipole moment length (11.9 eÅ, reported in Alekseeva et al., 2014), 
greater than that of 1,6aMNS-bearing isomer (9.0 eÅ, reported in Alekseeva et al., 2014), is 
characterized by a longer RT (Fig.4.22a). The same observation can be done for the isomeric 
hexasulfated tetrasaccharides: ∆U2S-ANS6S-I2S-ANS6S, characterized by a lower dipole moment 
(8.5 eÅ, reported in Alekseeva et al., 2014), is eluted with a shorter RT (73.5 min,) than its 
isomer ∆U2S-ANS6S-I2S-MNS6S (dipole moment 9.3 eÅ, reported in Alekseeva et al., 2014; RT 
73.8 min, Fig.4.24a). These data underline a possible correlation between the molecule electric 
dipole moment, calculated using molecular mechanics techniques, and retention time in the 
ion-pair reversed phase mode of LC separation.  
 
IV.6. Conclusions 
The combined NMR/LC-MS method developed for gs-heparins was successfully applied 
for gs-LMWH characterization. The obtained data show that also the direct LC-MS analysis 
without cleavage with heparinases, even if does not give detailed structural information 
because of the high complexity of the sample, is sensitive to the structural differences and 
composition of gs-products and can be a useful tool for gs-LMWH development. When used 
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together, these techniques permit the detection of the major internal modifications introduced 
in LMWH chains, including those caused by side hydrolytic processes, as well as 
modifications of several end residues susceptible to periodate/borohydride. As for gs-heparins, 
the combination of glycol-splitting and enzymatic digestion provides more informative data 
also on the starting material (chain distribution of non-sulfated uronic acids, structure of 
terminal sequences in gs-LMWHs, gs-ATBR containing sequences). In particular, the N-
acetylated domain in the closest proximity to the LR was characterized using this approach. 
Additional heparinase-resistance of the oligosaccharides with unnatural residues, typical for 
each type of LMWHs/gs-LMWHs, may provide even more detailed structural information 
about the LMWH sequences. Ring contracted residues were observed in dalteparin and its 
heparinase-digest by LC-MS for the first time. Different oxidation rate of isomeric iduronic 
and glucuronic acid has been shown in the present study, which can be useful for further 
optimization of the reaction conditions in order to obtain more homogeneous gs-products. 
The data obtained by LC-MS analysis suggest that numerous interactions, such as 
electrostatic, hydrophobic etc., take place in the ion-pair reversed phase separation mechanism. 
Total charge and sulfate distribution were shown to drive the separation efficacy. Using model 
tetrasaccharides it has been shown that the higher the electric dipole moment magnitude value, 
the longer is the retention time. These data may give a possibility to predict the 
chromatographic behavior of heparin-related oligosaccharides and to distinguish epimers in the 
ion-pair reversed phase mode of separation. Glycol-splitting as well as end group 
modifications (such as alditol formation) definitely improve the separation of isomers. 
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CHAPTER V: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
General conclusions 
In the present study a method, combining advanced analytical techniques NMR, LC-MS 
and SEC-TDA, has been developed, providing previously unavailable criteria for structural 
analysis of gs-heparins and gs-LMWHs as well as a complement to current methods for 
characterization of parent unfractionated and low-molecular weight heparin preparations. It is 
worth noting that even if NMR, LC-MS and SEC-TDA give characteristic sample fingerprints, 
they provide much more structural information when used in combination, in particular for 
complex polysaccharides such as heparins/gs-heparins.  
It has been shown that numerous reactions may occur during glycol-splitting, 
contributing significantly to the composition of the final gs-product. Major internal 
modifications introduced by periodate oxidation/borohydride reduction in heparin/LMWH 
chains, as well as in the end residues, can be detected by the developed method, allowing both 
characterization of individual gs-heparins/gs-LMWHs and comparison of gs-samples from 
different preparations. Our results show that the present analytical approach can be used for 
monitoring the reaction completeness and hydrolytic side reactions. In view of a further 
optimization of reaction conditions that could limit the impact of side-reactions, this approach 
represents a useful and reproducible tool for fingerprinting gs-samples. 
2D HSQC NMR turned out to be a useful technique, not requiring previous 
depolymerisation, to determine the average monosaccharide composition of gs-samples. As for 
unmodified heparins and LMWHs, the anomeric region is the most informative. All the HSQC 
NMR anomeric signals characteristic for gs-heparins and gs-LMWHs, including those of the 
linkage region and signals markers of hydrolytic chain cleavage, have been assigned in the 
present work. The performed study permits to distinguish gs-iduronic and gs-glucuronic acids 
(as well as associated glucosamine residues) in various sequences with different 
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sulfation/acetylation pattern, a differentiation that is impossible to achieve by LC-MS analysis. 
Since the coupling constants measured for gs-uronic acids were negligibly different from those 
of unmodified uronic acids, the HSQC NMR spectra permit quantitative analysis of gs-
heparins. However, these analytical results should be considered with caution until more 
detailed investigation will be performed, because the longer relaxation time T2 values 
characteristic for gs residues may lead to overestimation of their quantities.  
SEC-TDA data may turn out useful not only for characterizing molecular weight 
distribution, but also for determining hydrodynamic properties of heparins/gs-LMWHs and 
their gs-derivatives, which may be of interest for understanding interaction with proteins. The 
hydrodynamic parameters were sensitive to molecular weight, sulfation degree, and the 
introduced gs-residues. Interestingly, glycol-splitting favors the formation of random coil 
structures in solution, suggesting higher chain flexibility with respect to unmodified heparins. 
The developed ion-pair reversed phase HPLC separation, coupled with ESI-Q-TOF 
mass spectrometer, are reproducible and effective for profiling both digested gs-heparin/gs-
LMWH samples and for fingerprinting intact gs-LMWHs. Unlike heparins/gs-heparins, 
characterized by molecular weights too high to be directly analyzed by LC-MS, profiling of 
intact LMWHs/gs-LMWHs is possible due to their lower molecular weight. It should be noted 
that the mass spectrometer used in this work provided a mass accuracy and signal resolution 
sufficient to identify oligosaccharides up to dp 22 in complex mixtures. Direct LC-MS analysis 
permitted to determine prevalently the major components, however, it provided also 
information on the primary composition of the oligosaccharide mixture.  
LC-MS analysis of enzymatically digested gs-heparins/gs-LMWHs provides an 
informative profiling complementary to that currently obtained for the starting heparin. The 
additional information is mainly due to the resistance of gs-residues to heparinases leading to 
the generation of longer sequences with internal gs-units. Along with a better resolution of 
isomeric oligosaccharides, the LC-MS chromatograms of heparinase-digested gs-LMWHs 
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permitted the detection of minor components, such as end-residues in LMWHs. It should be 
highlighted that the method, initially developed for characterizing gs-samples only, appeared a 
potentially powerful technique for sequencing the original heparins. Combination of glycol-
splitting and enzymatic digestion permitted to characterize for the first time: i) heparin chains 
in the closest proximity to the linkage region, which appeared shorter and with higher sulfation 
degree than currently reported, ii) variants of the antithrombin binding region, including its 
closest environment, iii) sequences of contiguous disaccharides containing non-sulfated uronic 
acids. It has been also shown that the exhaustive glycol-splitting (as in the case of HI-3 
samples) followed by the enzymatic digestion may be used for characterizing N-acetylation 
pattern of heparin-related samples. 
For both intact LMWHs and digested gs-heparin/LMWHs samples, glycol-splitting has 
been shown to improve the resolution of isomeric oligosaccharides, for example, dalteparin 
oligosaccharides with or without non-sulfated glucuronic acid at the non-reducing end 
enoxaparin epimers containing reducing end 1,6-anhydro-D-glucosamine-N-sulfate and 1,6-
anhydro-D-mannosamine-N-sulfate. 
This study revealed also a possible correlation between the molecule electric dipole 
moment, calculated using molecular mechanics techniques, and retention time in the ion-pair 
reversed phase mode of LC separation. For each pair of isomeric tetrasaccharides, the higher 
the electric dipole moment magnitude value, the longer appears the retention time. These data 
provide additional insights about the ion-pair reversed phase separation mechanism and may 
give a possibility to predict the chromatographic behavior of heparin-related oligosaccharides 
and to distinguish epimers. 
 
Future directions 
The results obtained in the present study, namely a better understanding of modifications 
induced by glycol-splitting in internal and terminal residues of heparin/LMWH samples as 
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well as resistance of gs-residues to heparinases, were used for rationalizing the preparation of 
gs-oligosaccharides of different length that can also be used for studying interactions with 
heparanase or other target proteins. The initial idea to fractionate a LMWH and treat the 
fraction of interest with periodate/borohydride was discarded. The susceptibility of terminal 
groups to oxidation and/or reduction could generate fragments with unnatural terminals, both 
NRE and RE, residues that could influence their interaction with heparanase. For this reason, 
we prepared an extensively glycol-split heparin (HI-3), starting from a partially 2-O-desulfated 
porcine mucosal heparin, using mild conditions in order to avoid hydrolytic chain cleavage. 
The obtained gs-residue-enriched heparin was digested with heparinases I and II, and the 
obtained oligosaccharide mixture was fractionated by SEC. As shown by NMR and LC-MS 
analysis, the isolated fractions are characterized by high glycol-splitting extent (all the internal 
uronic acids are split) and different chain length (dp from 4 up to 10) and various sulfation 
degree, representing a good oligosaccharide library for structure – activity relationship studies 
by affinity chromatography, NMR and MS (Fig.5.1). The gs-tetrasaccharide fraction is 
planned to be used as a model for the signal assignment in the complex “ring” region of the 
HSQC NMR spectra. 
Another issue raised by the present study is concerning the dependence of periodate 
oxidation kinetics on various factors. We have observed that glucuronic acid is more resistant 
to periodate with respect to its isomer, iduronic acid, that may be associated with the 
conformational differences of these isomer residues. Based on preliminary results, the reaction 
rate may depend also on the pH value. The on depth investigation of these aspects by NMR, 
LC-MS and molecular modelling could be useful for further reaction optimization and control. 
The pH value may also drive hydrolytic side reactions at various steps of the gs-sample 
preparation, so that further study of the susceptibility of gs-residues to acidic and basic 
hydrolysis should be investigated in detail. 
 
 145
dp 2
dp 4
dp 6
dp 8
dp 10
dp 2dp 3
salts
30 35 40 45 50 55 60 Time [min]
0
1
2
3
4
6x10
Intens.
30 35 40 45 50 55 60 Time [min]
0.5
1.0
1.5
2.0
6x10
Intens.
∆U6,7,0,2gs + ∆U6,7,1,2gs ∆U6,6,0,2gs + ∆U6,6,1,2gs ∆U8,9,0,3gs + ∆U8,9,1,3gs ∆U8,8,1,3gs + ∆U8,8,0,3gs 
∆U8,7,1,3gs
gsI gsG
gsU‐(A*)
A*
∆U2S
∆U2S
ANS‐(gsU)
ANS α
ANAc‐(gsU)
gsGLR
Gal1
Gal2gsI
gsG
A*
∆U2S
∆U2S
ANS‐(gsU)
ANS α
ANAc‐(gsU)
gsGLR
Gal1
>dp 10
 
Fig.5.1. SEC profile of the heparinase-digest of a HI-3 sample (containing~50% of gs uronic 
acids) and LC-MS profiles and HSQC NMR spectra of the hexa- and octasaccharide fractions 
enriched in gs-containing compounds 
The work is in progress. Only major components are shown in these preliminary results. 
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CHAPTER VI: EXPERIMENTAL 
VI.1. Reagents and starting materials 
Heparins were commercial and experimental preparations from: porcine mucosal heparin, 
PMH, bovine mucosal heparin, BMH (both from Laboratori Derivati Organici, Italy), bovine 
lung heparin, BLH (Upjohn), ovine mucosal heparin, OMH (Sigma-Aldrich). Low-molecular 
weight heparins were samples of commercially formulated or bulk materials of: tinzaparin 
sodium (Innohep, LEO Pharma, Denmark), enoxaparin sodium (Clexane, Sanofi Aventis, Italy) 
and dalteparin sodium (Fragmin, Pfizer, Italy). N-acetyl-heparosan was a gift of K. Jann), and 
the synthetic pentasaccharide Arixtra® (fondaparinux) was from GSK (France). Uronate 
unsaturated disaccharides standards ΔU2S-ANS6S (> 95%), ΔU2S-ANS (> 95%) ΔU-ANS6S (> 
95%), ΔU-ANS (> 95%), ΔU-ANAc6S (> 95%) and ΔU2S-ANAc (> 95%) were from Iduron, UK. 
Heparin lyases I (EC4.2.2.7), II, III (EC4,2,2,8) were from Iduron or Grampian Enzymes, UK.  
Sodium chloride (>99.5%), formic acid (98-100%), hydrochloric acid standard solution 
0.1 N, Tris (tris(hydroxymethyl)aminomethane)), hydrochloric acid >37% (p.a.), sodium 
periodate (> 99%), dibutylamine (>99.5%), pentylamine (99%), hexylamine (99%), methanol 
(LC-MS grade), acetonitrile (LC-MS grade), acetic acid (glacial, 99.9%), formic acid (98-
100%), and ammonium chloride (> 99.5%) were purchased from Sigma-Aldrich. Volumetric 
solutions of sodium hydroxide 0.1 N and sodium borohydride (95%) were from Riedel-de 
Haën. Solid sodium hydroxide (>99%) and sodium acetate were from Merck, calcium acetate 
(>97%), from BDH, ethylenediaminetetraacetic acid (EDTA, >98%) from Fluka. Deionized 
water was prepared with an osmosis inverse system (conductivity less than 0.06 µS), filtered 
(Millipore filter 0.22 µm) and used for sample dilution and mobile phases. 
Preparation of an antithrombin high affinity fraction of PMH 
A column of AT-Sepharose gel (10 x 1.6 cm) prepared as previously reported (Bisio et 
al., 2009) was used for a semi-preparative affinity fractionation of a 12 mg PMH by a two steps 
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elution. The fraction with no AT affinity (NA) was eluted at lower ionic strength (Tris-HCl 
0.05 M pH 7.4, containing 0.05 M NaCl) while the high affinity fraction (HA) was eluted at 
higher salt concentration (Tris-HCl 0.05 M pH 7.4, containing 2.5 M NaCl). Fractions HA and 
NA were desalted first by dialysis with 3500 Da cut-off membranes (Spectrapor), then by size 
exclusion chromatography with Toyopearl HW-40 resin (TOSOH) column (58 x 2.6 cm). To 
remove the last traces of Tris buffer a cation-exchange chromatography was finally performed 
on an Amberlite IR-120 [H+] column (12.5 x 2 cm).  Eluents were neutralized with 0.1 N 
NaOH, and samples recovered after freeze drying. 
Preparation of partially 2-O-desulfated heparin  
Partially and selectively 2-O-desulfated heparins were prepared by alkaline treatment as 
described previously (Casu et al., 2002). PMH (~1g) was dissolved in 6.4 ml of water; after 
addition of 6.4 ml of 2M NaOH the solution was heated at 60°C for 30 min under stirring. The 
reaction was stopped by cooling, and the solution was neutralized to pH 7 with 0,1M HCl. The 
obtained intermediate heparin epoxide was freeze-dried, dissolved in 75 mL of water and 
heated for 48 h at 70°C. After cooling, desalting, dialysis, and freeze drying the partially 2-O-
desulfated heparin derivative was obtained in a 80% yield.  
VI.2. Preparation of glycol-split derivatives of heparins and LMWHs 
Glycol-split heparins were prepared by periodate oxidation followed by borohydride 
reduction of parent heparin/LMWH samples (40 – 50 mg). All the material was dissolved in 3 
ml of 0.1M NaIO4 and, then the reaction mixture was stirred at 4°C overnight in the dark. The 
excess of periodate was neutralized by adding 150 μl of ethylene glycol maintaining the stirring 
for further   2–3 h at 4°C. Solid sodium borohydride (~70 mg) was added in portions to the 
reaction mixture, which was then kept for 16 h at 4°C in the dark under stirring. After 3h the 
pH was adjusted to 4 with 0,1M HCl, and the solution was then neutralized with 1M NaOH. 
For gs-LMWH preparation the pH value at this step was adjusted under stirring at 4°C to 7 
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with 5% (v/v) acetic acid. Prepared gs-derivatives were desalted on a Sephadex G-10 column 
(80 x 2.5 cm) using water – ethanol 9:1 (v/v) as a mobile phase at 2.6 ml/min, monitoring the 
absorbance at 210 nm (Cary 50 UV-Vis spectrophotometer, Varian). After freeze drying, gs-
samples were obtained with yields in the range of 80-92 %. The gs-derivative of HA PMH was 
prepared starting from 4 mg of HA PMH prepared as described above. 
The Smith degradation of a gs-PMH sample was performed by adding 1M HCl to lower 
to 3 the pH value of the sample solution. After 3h of incubation at room temperature, the pH 
was increased to 7 by addition of 5% NaOH. The sample was desalted by dialysis using a 
membrane with 100-500 Da cut-off, freeze-dried, and then analyzed by SEC-TDA and NMR. 
VI.3. Molecular weight determination 
Molecular weight determinations were performed by HP-SEC-TDA on a Viscotek 
(Houston, Texas) instrument equipped with a VE1121 pump, Rheodyne valve (100 μl), and 
triple detector array 302 equipped with refraction index (RI), viscometer, and light-scattering 
(90° and 7°) systems. A separation system, including G2500 and G3000 (7.8 mm x 30 cm TSK 
GMPWxl) Tosoh columns, was used with 0.1M NaNO3 as eluent (flow, 0.6 ml/min). Samples 
were dissolved in the eluent to obtain 5-10 mg/ml solution. Peak integration and data 
processing were performed by using OMNISEC 4,1 software. All molecular weight parameters 
(number-average molecular mass (Mn), weight-average molecular mass (Mw), and 
polydispersity (Mw/Mn, D)) were determined for each sample. 
Hydrodynamic parameters were determined using the same HP-SEC-TDA system and 
0,01M NaNO3 as eluent in order to decrease the ionic strength and to better discriminate 
between different heparin samples. 
VI.4. NMR analysis of parent heparin/LMWH samples and their gs-derivatives 
The samples (5 – 8 mg of parent heparin/LMWHs and their gs-derivatives) were 
dissolved in 600 µl of D2O, containing 2 mM solution of EDTA, then freeze dried. 500 µl of 
  149
D2O were added to each lyophilized sample and lyophilization was repeated. Spectra were 
recorded at 25°C on a Bruker Avance 500 MHz or on a Bruker Avance 600 MHz spectrometer 
(Karlsruhe, Germany). Both instruments were equipped with 5-mm TCI cryoprobe. Integration 
of peak volumes in the HSQC spectra was made using standard Bruker TOPSPIN 3.0 software. 
The relative content of monosaccharide residues was calculated from the corresponding 
anomeric cross-peaks (Guerrini et al., 2005) and to LMWHs (Guerrini et al., 2007).  
HSQC spectra were obtained in phase-sensitive, sensitivity pure-absorption mode with 
decoupling in the acquisition period (Bruker pulse program hsqcetgpsisp.2). The JC-H coupling 
constant was set to 150 Hz. Spectra were recorded using a spectral width of 8 ppm and 80 ppm 
in the proton and carbon dimensions, respectively. The carrier frequencies for proton and 
carbon were 4.7 ppm and 80 ppm. Spectra were acquired into a time domain of 1024 complex 
points, using from 16 to 32 scans for each of 320 increments. The repetition time and the 
acquisition time were set at 2s and 0.178s, respectively. The matrix size of 1024 × 320 data 
points was zero filled to 4096 × 2048 and a squared cosine function was applied prior to 
Fourier transformation.  
One-bond heteronuclear coupling constants 1JC-H, measured for gsI and gsG residues 
present in a gs-PMH sample, were determined by removing the carbon decoupling during 
acquisition of the HSQC sequence. 
2D-TOCSY spectra was acquired using 32 scans per series of 2048 × 512 data points and 
a mixing time of 80ms. A zero filling in F1 (4096 × 2048) and a shifted (π/3) squared cosine 
function was applied prior to Fourier transformation. HMBC spectra were acquired in phase-
sensitivity enhanced pure-absorption mode (Bruker pulse program hmbcetgpl2nd).  Spectra 
were recorded using a long range JC-H coupling of 8 Hz. Spectral widths of 8 ppm and 190 ppm 
were set for the proton and carbon dimensions, respectively. The carrier frequencies for proton 
and carbon were 4.7 ppm and 95 ppm. Spectra were acquired into a time domain of 1024 
complex points, using 64 scans for each of 360 increments. The repetition time and the 
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acquisition time were set at 2.5 s and 0.107 s, respectively. The matrix size of 1024 × 360 data 
points was zero filled to 4096 × 2048 prior to Fourier transformation. 
VI.5. LC-MS analysis of the heparinase-digests of gs-heparins and gs-LMWHs 
Enzymatic cleavage of original heparins and their gs-derivatives 
The original heparin and gs-heparin samples (100 µg) were enzymatically depolymerised 
by heparin lyases I, II and III. The substrate (5-10 mg) was dissolved in water to obtain a 20 
mg/ml solution. Then 149 μl of solution containing 50 mM sodium acetate and 5 mM calcium 
acetate, and 3 μl of heparin lyases mixture (1 μl of each lyase, 2 mU/μl enzyme solution) were 
added to 5 l of the substrate 20 mg/ml solution. The reaction was stirred at 37°C (Termo 
shaker TS-100 Biosan) for 24 h, then, stopped by adding 3 μl of 3% formic acid. Each sample 
was diluted two times with water and analyzed by LC-MS. 
IPRP-HPLC/ESI-TOF-MS analysis 
LC-MS analysis was performed on a LC system (Dionex Ultimate 3000, Dionex) 
equipped with degasing system (model LPG-3400), pump (model LPG-3400A), autosampler 
(model WPS-3000TSL) and UV-detector (model VWD-3100) and coupled with an ESI-QTOS 
mass-spectrometer (microqTOF, Bruker Daltonics).  
The chromatographic separation was performed using a Kinetex C18 analytical column 
(100 × 2.1 mm I.D., 2.6 μm particle size, Phenomenex) with Security Guard Cartridges Gemini 
C18 (4 x 2.0 mm, Phenomenex). A binary solvent system was used for gradient elution. 
Solvent A (10 mM DBA, 10 mM CH3COOH in water:methanol (9:1)) and solvent B (10 mM 
DBA and 10 mM CH3COOH in methanol) were delivered at 0.1 ml/min. Oligosaccharides 
were separated using a multi-step gradient: the solvent composition was held at 17% B for the 
first ten minutes, then increased to 42% B over 20 min, and to 50 % B over another 20 min; 
afterwards, the content of the eluent B was increased to 90 % where it was held for 10 min; 
finally, it was returned to 17% B over 1 min, and held for the last 19 min for equilibrating the 
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chromatographic column before the injection of the next sample. The injection volume was 5 
μl. The MS spectrometric conditions were as follows: ESI in negative ion mode, drying gas 
temperature +180°C, drying gas flow-rate 7.0 l/min, nebulizer pressure 0.9 bar; and capillary 
voltage +3.2 kV. The mass spectra of the oligosaccharides were acquired in a scan mode (m/z 
scan range 200 – 2000). An external calibration method using sodium formate clusters as 
calibrants was used to achieve an accuracy of better than 5 ppm.  
The quantitative analysis of the unsaturated disaccharides has been performed using 
calibration curves obtained with the standard solutions that were prepared by diluting the 
disaccharides stock solutions (10 mg/ml in H2O). The regression equations, correlation 
coefficients, limit of detection (LOD), limit of quantification (LOQ) and area variability (RSD) 
are given in Table 3.7. LOD and LOQ values were calculated as the concentration of the 
injected sample (with constant injection volume, 5 µl) which gave signal-to-noise ratio equal 
to 3 and 10, respectively, using the calibration curves based on the linear regression between 
signal-to-noise ratio (S/N) value and analyte concentration. Despite of the lower LOQ values 
provided by MS, for quantitative analyses the calibration curves obtained with UV detection 
was used because the area variability is lower than for the MS detection mode (Table 3.7).  
For the digest of the parent PMH ΔU-ANS and ΔU-ANAc6S content were also evaluated. 
Since their extinction coefficients at 232 nm were shown to be equal under the applied 
analytical conditions, it was possible to quantify their total content, even if eluted together, 
using the same calibration curve. The content of ΔU-ANS6S, present in the PMH digest, was 
determined using the calibration curve of its positional isomer ΔU2S-ANS. 
VI.6. Direct LC-MS analysis of LMWHs and gs-LMWHs 
For profiling the intact unmodified LMWHs and gs-LMWHs, methanol in the mobile 
phases, used for the analysis of the enzymatic digests (see VI.5), was substituted by acetonitrile 
(IV.3.1). Thus, for profiling the non-digested original and gs-LMWHs, mobile phases A (10 
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mM dibutylamine, 10 mM acetic acid in water – acetonitrile (9:1)) and B (10 mM dibutylamine 
and 10 mM acetic acid in acetonitrile), delivered at 0.25 ml/min, were used. Since enoxaparin, 
tinzaparin and dalteparin are characterized by a different molecular weight distribution, slightly 
different multistep gradients were used for their profiling (Table 6.1). Under the applied 
conditions the retention times vary in a range 1.0 – 1.5 %. The MS conditions were the same as 
for LC-MS analysis of the heparinase-digests (see VI.5). 
Table 6.1. Gradient used and the LMWH quantity loaded for LC-MS profiling of the 
LMWHs and their gs-derivatives 
Tinzaparin and gs‐tinzaparin  Enoxaparin and gs‐enoxaparin  Dalteparin and gs‐dalteparin 
Multi‐step gradient 
Time (min)  % Eluent B  Time (min)  % Eluent B  Time (min)  % Eluent B 
0 
5 
125 
130 
135 
138 
160 
5 
5 
35 
70 
70 
5 
5 
0 
5 
130 
140 
145 
148 
170 
0 
0 
35 
70 
70 
0 
0 
0 
4 
15 
30 
115 
133 
138 
140 
160 
10 
10 
18 
18 
35 
70 
70 
10 
10 
Sample quantity loaded, µg 
15  15  30  30  30  30 
Corresponding Figure 
Fig. 4.10 and Annex 5  Fig. 4.11 and Annex 6  Fig. 4.12 and Annex 7 
Column C18 100 x 2.1 mm, 2.6 µm; eluents A and B – 10 mM DBA and 10 mM CH3COOH in H2O-CH3CN = 9:1 
(v/v) and CH3CN, respectively; flow rate – 0.25 ml/min 
 
VI.7. Study of susceptibility of enoxaparin RE groups to periodate oxidation 
Gs-enoxaparin was digested with heparinases I, II and III also on preparative scale for 
further fractionation and detailed studies by LC-MS and NMR: 175 µl of 2 mU/µl solutions of 
each enzyme were added to a gs-enoxaparin solution (37 mg in 50 ml of a buffer containing 50 
mM sodium acetate buffer and 5 mM calcium acetate). The digestion was carried out for 24 h 
at 37°C, and after the second addition of an equivalent aliquot the enzymes, the reaction was 
maintained for further 24 h at 37°C, then, stopped by adding 1 ml of 3% formic acid. The 
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reaction mixture was filtered using a Millipore filter 3 µm and concentrated up to 2 ml for SEC 
fractionation (see next section) and further detailed LC-MS and NMR analysis. 
Preparative size-exclusion chromatography 
HPLC system (Bioline Knauer S1050) was used for the size fractionation of the 
heparinase-digested gs-enoxaparin. Oligosaccharide mixture (2 ml of the concentrated solution, 
see the previous section) was separated using two subsequent columns (Superdex S30, 48×3 
and 83×2 cm) and 0.25M ammonium chloride as eluent, at a flow-rate 5.0 ml/min. Based on 
the detection at 210 nm, seven fractions were obtained and, then, desalted on the Biofox 40/100 
SEC Agarose column (89 x 3 cm) using water – ethanol 9:1 (v/v) as eluent delivered at a flow-
rate 15 ml/min. After concentration and freeze-drying each gs-oligosaccharide fraction was 
analyzed by NMR and LC-MS. 
NMR spectra were acquired on a Bruker Avance 600 MHz spectrometer (Karlsruhe, 
Germany) using 3 mm NMR tubes (each fraction was prepared in 220 μl D2O). 
LC-MS analysis was performed as described in VI.5 for total enzymatic digests. The 
fragmentation of the ion with m/z 488.5 (Fig.4.15), present in the tetrasaccharide fraction of 
digested gs-enoxaparin, was performed by applying the LC-ESI-MS2 method. Collision-
induced dissociation (CID) was used, the isolation window was set at 5 Da and the collision 
energy was -20 eV. 
Sodium borohydride reduction of the digested gs-enoxaparin fractions 
The reduction of the several fractions obtained by SEC-fractionation of the digested gs-
enoxaparin (as described above) were performed by adding of 5 µl of 30 mg/ml solution of 
sodium borohydride into an aliquot (50 µl) of 0.5 mg/ml solution of each fraction. The mixture 
was left at room temperature for 4 h and, then, analyzed by LC-MS. 
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Multi-step isolation of enoxaparin tetrasaccharide fractions: pentasulfated 1,6-anhydro- 
and hexasulfated regular tetrasaccharides  
The first-step fractionation was performed using size exclusion chromatography 
(Fig.4.16).      2 ml of 120 mg/ml solution were loaded onto the column packed with Biogel P6 
and eluted with 0.25 M ammonium chloride at a flow-rate 1.8 ml/min. Based on the detection 
at 210 nm, the tetrasaccharide fraction was isolated and then desalted on a TSK gel HW40S 
column (100 x 5 cm) using water – ethanol 9:1 (v/v) as a mobile phase delivered at a flow-rate 
4.8 ml/min. After desalting, the sample was concentrated under reduced pressure at 35°C and 
freeze-dried. The obtained fraction (~6 mg) was then sub-fractionated by IPRP-HPLC 
(Fig.4.16) in order to isolate the isomeric tetrasaccharides of interest. The separation was 
carried out on a preparative HPLC/UV system “Knauer Smartline 1000”, using conditions 
described in Table 6.2. Three runs were performed.  
Table 6.2. IPRP-HPLC/UV conditions for isolation of pentasulfated 1,6-anhydro- and 
hexasulfated tetrasaccharides from the total tetrasaccharide fraction of enoxaparin 
Column   C18 Knauer 250 x 8 mm,  5 µm 
Eluents   Eluent A: 10 mM DBA, 10 mM CH3COOH in H2O‐CH3OH = 43:57 (v/v) 
Eluent B: 10 mM DBA, 10 mM CH3COOH in H2O‐CH3OH = 50:50 (v/v) 
Eluent C: 10 mM DBA, 10 mM CH3COOH in H2O‐CH3OH = 80:20 (v/v) 
Gradient  0 – 45 min              isocratic step   100 % A  
45 – 45.2 min   linear gradient from 100%A to 100%B 
45.2 – 60 min    isocratic step  100 %B 
60 – 60.2 min   linear gradient  from 100%B to 100%C 
60.2 – 65 min   isocratic step  100 %C 
65 – 65.2 min   linear gradient from 100%C to 100%A 
65.2 – 90 min   isocratic step  100 % A (column equilibrating) 
Flow  2,5 ml/min 
UV detection  232, 210 nm 
Sample amount  1 mg 
 
A fraction eluted in the range of RT 50 – 56 min (Fig.4.16) was concentrated; then, the 
solution was dialyzed using a 100-500 Da cut-off membrane in order to eliminate the excess of 
the DBA acetate. The same purification procedure was performed for the fraction eluted in the 
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range 60 – 65 min (Fig.4.16). After desalting, the samples was freeze-dried and characterized 
by NMR and LC-MS (Fig.4.17) before further study. The sample from the first fraction 
contained pentasulfated 1,6-anhydro-tetrasaccharides ∆U2S-ANS6S-I2S-1,6aANS and ∆U2S-ANS6S-
I2S-1,6aMNS (~1 mg), while from the second one a mixture of the hexasulfated tetrasaccharides 
∆U2S-ANS6S-I2S-ANS6S and ∆U2S-ANS6S-I2S-MNS6S (~4 mg) was obtained. 
Periodate oxidation/borohydride reduction of the enoxaparin tetrasaccharide mixtures 
All the content (~1 mg) of the first fraction containing 1,6-anhydro-tetrasaccharides was 
dissolved in 230 μl of D2O, and 5 mg of sodium periodate were added directly into the NMR 
tube. The final concentration of periodate ion corresponded to 0.1 M. The reaction was 
monitored by monodimensional NMR as described below. After 40 h, 2 μl of the solution 
containing the tetrasaccharide mixture and periodate was diluted with 50 μl of water and 
directly analyzed by  LC-MS (see below). 12 mg of sodium borohydride were added to the rest 
of the solution to reduce the formed aldehyde groups. The reaction was carried out for 20 h in 
the dark, at 4°C. The sample was then desalted using a 100-500 Da cut-off membrane and 
freeze-dried for further structural characterization by NMR and LC-MS. 
The oxidation of the hexasulfated tetrasaccharide-containing mixture was also performed 
directly in the NMR tube (3 mm). About 1 mg of the material was dissolved in 230 μl of D2O 
and 5 mg of sodium periodate (0,1 M final concentration) were added. Since no oxidation was 
observed after 20 h, an additional portion of periodate (5 mg of sodium periodate) was added 
(the final concentration of periodate ion was 0.2 M). The final 1H and 2D HSQC spectra as well 
as LC-MS chromatograms were acquired after 40 h. LC-MS analysis was repeated after 5 days. 
The further reduction was carried out as described above for 1,6-anhydro-tetrasaccharides. 
The periodate oxidation of ∆U2S-ANS6S (isolated from the gs-enoxaparin digest, fraction H 
in Fig.4.14; see VI.7) was performed by adding different volumes (230 and 460 μl) of 0.1 M 
sodium periodate to 1 mg of the disaccharide. 230 μl of 0.1 M correspond to 5 mg of periodate, 
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used for the oxidation of tetrasaccharides. After 20 h the LC-MS analysis was performed as 
described below. 
The oxidation of the total enoxaparin sample was performed in batch by adding 325 μl of 
0.1 NaIO4 to a portion of the solid material (~5.2 mg) and left at 4°C in the dark for different 
time periods (1, 2, 3, 4, 6, 8, 10 and 12 h). The oxidation was stopped by adding 25 μl of 
ethylene glycol, and after further 3 h the solution was treated by sodium borohydride. Each 
sample was desalted using a 100-500 Da cut-off membrane and freeze-dried for further HSQC 
NMR analysis. 
NMR study 
1H monodimensional NMR spectra of tetrasaccharide mixture were recorded at 30°C on a 
Bruker Avance 600 MHz spectrometer equipped with 5 mm TCI cryoprobe (Karlsruhe, 
Germany), the 1H spectra were acquired with 128 scans. Water presaturation was applied 
during each 12 s of relaxation delay. To follow the kinetic of the reaction, 1H spectra were 
performed as pseudo-2D NMR experiments, with 36 increments and 33 min of interval 
between experiments. Two-dimensional NMR was performed as described in VI.4. 
LC-MS analysis 
LC-MS operating conditions used for the analysis of the isolated tetrasaccharides before 
and after oxidation/reduction (Fig.4.17, 4.22, 4.24) are reported in Table 6.3.  
Analysis of the undesalted tetrasaccharide solution after the periodate oxidation, carried 
out directly in the NMR tube (Fig. 4.19), was performed using a modified gradient in order to 
selectively elute salt clusters (mainly periodate salt) and avoid the suppression of the signals. 
Initially, 0 % of eluent B was held for the first 15 min to eliminate the excess of the salt, then, 
a linear gradient from 0 to 40 %B was applied to elute the oligosaccharides. LC/MS conditions 
optimized for the heparinase-digested gs-heparins (VI.5) were used for the analysis of the 
disaccharide before and after its oxidation. 
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Table 6.3. LC-MS operating conditions for analysis of pentasulfated 1,6-anhydro- and 
hexasulfated tetrasaccharides of enoxaparin 
Column   C18 (Eurospher II 100‐5 C18 (250 x 4,6 mm,  5 µm, Knauer) 
Eluents   Eluent A 10 mM DBA, 10 mM CH3COOH in H2O‐CH3OH = 9:1 (v/v) 
Eluent B  10 mM DBA, 10 mM CH3COOH in CH3OH  
Gradient  0 – 18 min  isocratic step   33 % B  
18 – 19 min   linear gradient  from 33 to 35%B 
19 – 65 min    isocratic step  33 %B 
65 – 66 min   linear gradient  from 35 to 45%B 
66 – 80 min   isocratic step  45 %B 
80 – 82 min   linear gradient  80%B 
82 – 84 min   isocratic step  80%B 
84 – 85 min   linear gradient  from 80 to 33 %B 
85 – 105 min  isocratic step  33%B 
Flow  1 ml/min, splitted 1:2 before ESI‐source 
UV detection  232 nm 
ESI‐MS conditions  negative ion mode 
capillary voltage +3.2 kV 
drying gas 180°C, 7.0 l/min 
nebulizer pressure 0.9 bar 
m/z scan range 200 – 2000 
 
 
VI.8. Preparation of oligosaccharides enriched in internal glycol-split residues 
The starting HI-3 sample was prepared by glycol-splitting of a partially 2-O-desulfated 
PMH as described in VI.1 and VI.2. Its enzymatic depolymerisation was performed using ~60 
mg of substrate maintaining the same proportions substrate–heparinases as used for gs-
enoxaparin digestion (VI.7). The digestion mixture was further fractionated by SEC as 
described in VI.7 for gs-enoxaparin digest. The isolated fractions, analyzed by NMR and LC-
MS, contained oligosaccharides of dp 4, 6, 8, 10 with internal gs-residues (Fig.5.1). 
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Annex 1. Some structural features of heparinases I, II and III and their substrate specificity 
 Heparin lyase I Heparin lyase II Heparin lyase III Ref 
Basic sites 
(resembling heparin-
binding sequences) 
1 3 2 (Capila et 
al., 2002) 
2 – 2 Calcium-coordinating 
motifs 
Calcium enhances the enzymatic activity of heparin lyases I and III, but 
can inhibit the enzymatic activity of heparin lyase II 
(Capila et 
al., 2002) 
Catalytic domain The active site 
contains a cystein and 
a histidine residues 
It is thought to contain 
two active sites, the 
first acts on heparin, 
the other on HS.  
One cysteine and three 
histidine residues are 
essentical for its 
enzymatic activity 
Unlike the other two 
enzymes, its active 
site contains two 
histidine residues, and 
no cysteine residue 
(Capila et 
al., 2002) 
Specificity Strong specificity for 
the sulfated domains 
of both heparin and 
HS 
Very broad Strong specificity for 
HS 
(Capila et 
al., 2002) 
Major products of 
heparin partial 
digestion by each 
enzyme * 
(shown in the order of 
decreasing cleavage) 
ΔU2S-ANS6S (79-81%) 
ΔU2S-ANS 
ΔU-ANS6S 
 
ΔU2S-ANS6S (60-66%) 
ΔU-ANS6S 
ΔU2S-ANS 
ΔU-ANS 
ΔU-ANAc6S 
ΔU2S-ANac 
ΔU2S-ANS6S 
ΔU-ANAc  (39-52%) 
ΔU-ANS 
ΔU-ANAc6S 
ΔU-ANS6S 
 
 
(Zhang et 
al., 2011) 
* Symbol Δ is used to indicate the formation of double bond at the uronic acid as result of β-eliminative enzymatic 
cleavage 
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Annex 2. Heparanase sensitive and resistant oligosaccharides (Okada et al., 2002) 
Model oligosaccharide  Percentage cleavage by heparanase, % 
 ∆U2S – ANS6S – G – ANS6S – G – ANS6S  >95 
∆U2S – ANS6S – I – ANAc6S – G – ANS6S  85 
∆U2S – ANS6S – I – ANAc6S – G – ANS  59 
∆U2S –ANS – G – ANS6S  44 
∆U2S – ANS6S – I – ANAc – G – ANS6S  30 
∆U –ANS – G – ANAc  0 
∆U –ANS6S – G – ANAc  0 
∆U – ANS – I2S – ANAc – G – ANS  0 
∆U –ANAc – G – ANAc  0 
The substrate specificity of heparanase was studied using structurally defined oligosaccharides isolated form 
a heparin digested with heparinases (Okada et al., 2002) 
ΔU(2S) – 4,5-unsaturated uronic acid with or without 2-O-sulfation, ANS/NAc(6S) – N-sulfated/N-acetylated 
glucosamine with or without 6-O-sulfation, G – glucuronic acid, I – iduronic acid 
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Annex 3. Hydrodynamic radius (Rh) and Mark-Houwink parameters a and logK measured by SEC-TDA for heparins/LMWHs and their gs-derivatives 
 
Sample  Rh, nm 
Range,  
kDa  %  a  logK 
Range, 
kDa  %  a  logK 
Range,  
kDa  %  a  logK 
Range, 
 kDa  %  a  logK 
PMH  4.2  9 – 13   28  1.37  ‐6.3  13 – 16   21  0.94  ‐4.5  16 – 21  17  0.66  ‐3.3  21 – 36   17  0.57  ‐3.0 
BLH  3.6  8 – 10   24  1.32  ‐6.1  10 – 12   15  0.99  ‐4.7  12 – 23   28  0.74  ‐3.7  23 – 37   10  0.63  ‐3.2 
OMH  3.5  6 – 7   12  1.41  ‐6.4  7 – 14   50  0.99  ‐4.7  14 – 32   31  0.66  ‐3.4  > 32  nd  nd  nd 
H
e
p
a
r
i
n
s
 
BMH  4.0 
 
< 8  nd  nd  nd 
 
8 – 17   60  1.08  ‐5.1 
 
17 – 22   13  0.74  ‐3.7 
 
22 – 35   14  0.63  ‐3.2 
                                             
Gs‐PMH  2.7  3.5 – 4.5  15  1.44  ‐6.3  4.5‐8.5  38  0.90  ‐4.4  8.5 – 22  36  0.53  ‐2.9  > 22  nd  nd  nd 
Gs‐BLH  2.8  < 4.5  nd  nd  nd  4.5 – 8   43  1.20  ‐5.4  8 – 23   44  0.55  ‐3.0  > 23  nd  nd  nd 
Gs‐OMH  2.1  2.5 – 3   20  1.33  ‐5.8  3 – 6.5  42  0.71  ‐3.7  6.5 ‐ 17  29  0.55  ‐3.0  > 17  nd  nd  nd 
G
s
‐
h
e
p
a
r
i
n
s
 
Gs‐BMH  2.5 
 
< 3  nd  nd  nd 
 
3 – 7.5  51  0.97  ‐4.6 
 
7.5 – 21   38  0.56  ‐3.0 
 
> 21  nd  nd  nd 
                                             
 
Sample  Rh, nm 
Range, 
kDa  %  a  logK 
Range,  
kDa  %  a  logK 
Range, 
kDa  %  a  logK 
Range,  
kDa  %  a  logK 
Dalte  2.2  2.5 – 3.5   30  nd  nd  3.5 – 3.8  7  1.07  ‐4.8  3.8 – 4.5   12  0.61  ‐3.2  4.5 – 14   44  0.37  ‐2.3 
Tinza  2.3  2.5 – 3.2  18  nd  nd  3.2 – 4.5   25  0.98  ‐4.5  4.5 – 6.0  18  0.66  ‐3.4  6.0 – 17   35  0.50  ‐2.8 
L
M
W
H
s
 
Enoxa  1.8 
 
1.7 – 2.0  10  nd  nd 
 
–  –  –  – 
 
2.0 – 4.5  46  0.67  ‐3.5 
 
4.5 – 13   30  0.37  ‐2.4 
                                             
Gs‐Dalteparin  2.0  2.5 – 3.5  19  nd  nd  3.5 – 5   25  0.53  ‐2.9  5 – 11   33  0.26  ‐2.0  > 11  nd  nd  nd 
Gs‐Tinzaparin  2.2  < 2.5  nd  nd  nd  2.5 – 5  45  1.13  ‐5.2  5 – 11  40  0.48  ‐2.7  > 11  nd  nd  nd 
G
s
‐
L
M
W
H
s
 
Gs‐Enoxaparin  1.8 
 
1.5 – 2   20  nd  nd 
 
2 – 4   44  0.58  ‐3.2 
 
4 – 12   31  0.36  ‐2.4 
 
> 12  nd  nd  nd 
0.01M NaNO3 was used as eluent 
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Annex 4. Chemical shifts of some residues typical for LMWHs (tinzaparin, enoxaparin, dalteparin) 
Chemical shift  
1H/13C (ppm) LMWH  Residue  Signal 
Present work  Previously published data 
ΔU2S   H1/C1  5.53/100.1  5.53/100.1  (Guerrini 2007) 
ΔU2S‐(ANS6S)  H4/C4  5.98/108.8  6.01/108.7  (Guerrini 2007) Tinzaparin Enoxaparin 
ANSredα  H1/C1  5.47/93.9  5.47/93.9  (Guerrini 2007) 
ΔU  H1/C1  5.16/103.9  5.18/103.9  (Guerrini 2007) 
ΔU  H4/C4  5.81/110.5  5.83/110.4  (Guerrini 2007) 
MNSred  H1/C1  5.40/95.8  5.41/95.6  (Guerrini 2007) 
1.6aANS  H1/C1  5.61/104.3  5.63/104.3  (Guerrini 2007) 
1.6aMNS  H1/C1  5.57/103.9  5.59/103.9  (Guerrini 2007) 
G2S  H1/C1  4.75/102.9  4.75/102.8  (Guerrini 2007) 
Enoxaparin 
I2Sβ  H1/C1  4.97/94.8  4.99/94.8  (Guerrini 2007) 
I2S‐(aM.ol6S)  H1/C1 
5.18/102.4 
 (overlapped with I2S of 
the repeat sequences 
and I2S at the NRE) 
5.19/102.6 
(decamer)   (Huckerby 1986) 
Dalteparin 
I2S(nr)  H1/C1 
5.18/101.9 ppm 
(overlapped with I2S of 
the repeat sequences 
and I2S‐(aM.ol)) 
5.19/101.8  
(decamer)  (Huckerby 1986) 
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Annex 5. Total LC-MS profile of tinzaparin (a) and gs-tinzaparin (b) 
(a)
(b)
G5577_RB1_01_5497.d: BPC 199-3001 -All MS
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*8 – ∆U20,30,0
*9 – ∆U22,32,0
 
LC conditions: column C18 100 x 2.1 mm, 2.6 µm; eluents A and B – 10 mM DBA and 10 mM CH3COOH in 
H2O-CH3CN = 9:1 (v/v) and CH3CN, respectively; gradient: 0 min – 5%B, 5 min – 5%B, 125 min – 35%B, 130 
min – 70%B, 135 min – 70%B, 138 min – 5%B, 160 min – 5%B; flow rate – 0.25 ml/min 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates the 
terminal sugars in alditol (reduced) form, while R indicates remnant of uronic acids (hydrolysis marker) 
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Annex 6. Total LC-MS profile of enoxaparin (a) and gs-enoxaparin (b) 
*1 ∆U8,10,0,1gs-ol + ∆U8,10,0-ol + ∆U8,10,1,1gs-ol + ∆U8,10,1,2gs-ol + ∆U8,10,0-1.6aA + ∆U8,10,0,1gs-1.6aA
*2 ∆U10,13,0,1gs-ol  + ∆U10,13,0-ol  + ∆U10,13,1,1gs-ol  + ∆U10,13,1,2gs-ol + ∆U10,13,0-1.6aA + ∆U10,13,0,1gs-1.6aA
*3 ∆U12,16,0,1gs-ol + ∆U12,16,1,1gs-ol + ∆U12,16,1,2gs-ol + ∆U12,16,0-1.6aA + ∆U12,16,0,1(gs1,6a)
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LC conditions: column C18 100 x 2.1 mm, 2.6 µm; eluents A and B – 10 mM DBA and 10 mM CH3COOH in 
H2O-CH3CN = 9:1 (v/v) and CH3CN, respectively; gradient: 0 min – 0%B, 5 min – 0%B, 130 min – 35%B, 140 
min – 70%B, 145 min – 70%B, 148 min – 0%B, 170 min – 0%B; flow rate – 0.25 ml/min 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates the 
terminal sugars in alditol (reduced) form. 1,6aA indicates both 1,6-anhydro-glucosamine and 1,6-anhydro-
mannosamine. 
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Annex 7. Total LC-MS profile of dalteparin (a) and gs-dalteparin (b) 
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LC conditions: column C18 100 x 2.1 mm,.2.6 µm; eluents A and B – 10 mM DBA and 10 mM CH3COOH 
in H2O-CH3CN = 9:1 (v/v) and CH3CN, respectively; gradient: 0 min – 10%B, 4 min – 10%B, 15 min – 
18%B, 30 min – 18%B, 115 min – 35%B, 133 min – 70%B, 138 min – 70%B, 140 min – 10%B, 160 min – 
10%B; flow rate – 0.25 ml/min 
Abbreviation system includes the number of monosaccharide residues, sulfate and N-acetyl groups, and the 
number of gs-residues. Symbol ΔU indicates 4,5-unsaturated uronic acid at the NRE. Symbol “ol” indicates the 
terminal sugars in alditol (reduced) form. Symbols aM.ol and Rc indicate 2,5-anhydro-mannitol and ring-
contracted units. 
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Annex 8. LC-MS data for several compounds discussed in Chapter IV 
Compound  Prevalent ion form 
Monoisotopic 
mass‐to‐charge 
value (m/z) 
Retention time, 
min  Sample 
ΔU22,32,0  [M‐4H+22DBA]4‐  2276.009  111.0 
ΔU9,10,1  [M‐3H+3DBA]3‐  916.816  65.5 
ΔU4,3,1‐LR  [M‐2H]2‐  836.640  17.4 
ΔU4,4,1‐LR  [M‐2H]2‐  876.619  26.5 
ΔU8,6,2‐LR  [M‐3H]3‐  876.119  46.3 
ΔU8,9,1‐LR  [M‐3H+2DBA]3‐  1028.173  57.5 
ΔU10,11,1‐LR  [M‐3H+4DBA]3‐  1279.946  66.3 
ΔU10,11,2‐LR  [M‐3H+4DBA]3‐  1293.949  66.4 
Tinzaparin 
 
ΔU9,10,1‐ol  [M‐3H+3DBA]3‐  917.488  66.0 
ΔU4,5,0‐R  [M‐2H]2‐  594.999  40.2 
ΔU4,5,0,1gs‐R  [M‐2H]2‐  596.007  41.0 
ΔU4,6,0‐R  [M‐2H+1DBA]2‐  699.553  46.6 
ΔU6,6,0,1gs‐R  [M‐2H+3DBA]2‐  998.263  53.8 
ΔU6,9,0‐R  [M‐2H+4DBA]2‐  1181.767  62.5 
ΔU8,12,0‐R  [M‐3H+4DBA]3‐  979.832  73.9 
ΔU10,15,0‐R  [M‐3H+7DBA]3‐  1301.308  82.9 
gs‐Tinzaparin 
 
ΔU20,28,0  [M‐4H+17DBA]4‐  1950.34  115.3 
∆U5,6,0  [M‐2H+1DBA]2‐  728.556  61.8 
∆U5,7,0  [M‐2H+2DBA]2‐  833.110  67.3 
ΔU2,3,0  [M‐H]1‐  575.964  24.1 
ΔU3,4,0  [M‐2H]2‐  415.473  45.0 
ΔU4,5,0  [M‐2H]2‐  535.986 
49.3 
49.9 
50.6 
51.0 
A5,8,0‐1,6aA  [M‐2H+2DBA]2‐  865.607  68.9 
Enoxaparin 
 
ΔU2,3,0‐ol  [M‐H]1‐   577.982  24.5 
ΔU3,4,0‐ol  [M‐2H]2‐  416.481  45.5 
ΔU4,5,0‐ol  [M‐2H]2‐  536.993  50.4 
51.2 
ΔU4,5,0,1gs‐ol  [M‐2H]2‐  538.001  51.4 
gs‐Enoxaparin 
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ΔU8,10,1,2gs‐ol 
(contains gs‐ATBR)  [M‐3H+2DBA]
3‐  817.104  80.3 
ΔU8,9,1,2gs‐1,6aA 
(contains gs‐ATBR)  [M‐3H+2DBA]
3‐  783.776  75.9 
ΔU10,13,1,2gs‐ol 
(may contain gs‐ATBR)  [M‐3H+5DBA]
3‐  1138.579  89.6 
ΔU12,15,1,2gs‐1.6aA 
(may contain gs‐ATBR)  [M‐3H+8DBA]
3‐  1426.727  94.0 
ΔU12,16,1,2gs‐ol 
(may contain gs‐ATBR)  [M‐3H+9DBA]
3‐  1503.105  95.7 
ΔU14,19,1,2gs‐ol 
(may contain gs‐ATBR)  [M‐3H+12DBA]
3‐  1824.581  102.2 
R(Unr)‐A3,5,0‐ol  [M‐2H]2‐  532.001  50.6 
R(Unr)‐A3,5,0‐1,6aA  [M‐2H]2‐  521.988  51.4 
A3,5,0‐ol  [M‐2H]2‐  457.983  44.0 
A3,6,0‐ol  [M‐2H]2‐  497.961  54.3 
 
U22,31,0‐aM.ol  [M‐4H+21DBA]4‐  2224.48  98.0 
U22,32,0‐aM.ol  [M‐4H+22DBA]4‐  2276.76  101.0 
U8,10,0,Rc‐aM.ol  [M‐3H+3DBA]3‐  840.131  27.2 
U10,13,0,Rc‐aM.ol  [M‐3H+6DBA]3‐  1161.607  45.4 
47.6 
U12,16,0,Rc‐aM.ol  [M‐3H+9DBA]3‐  1483.082  60.3  
61.9  
U14,19,0,Rc‐aM.ol  [M‐3H+12DBA]3‐  1804.558  70.8 
72.3  
U16,22,0,Rc‐aM.ol  [M‐4H+12DBA]4‐  1497.661  79.6 
80.5 
U5,6,0  [M‐2H+1DBA]2‐  737.561  17.3 
U5,7,0  [M‐2H+2DBA]2‐  842.136  19.6 
U8,11,0‐aM.ol  [M‐3H+3DBA]3‐  871.787  32.0 
A5,8,0‐aM.ol  [M‐2H+3DBA]2‐  931.683  21.0 
Dalteparin 
 
U8,11,0,1gs‐aM.ol  [M‐3H+3DBA]3‐  872.459  32.3 
A7,11,0‐aM.ol    [M‐2H+7DBA]2‐  1478.472  33.2 
R(Unr)‐A7,11,0‐aM.ol  [M‐3H+4DBA]3‐  905.506  33.2 
A7,10,0‐aM.ol    [M‐2H+5DBA]2‐  1309.342  24.9 
A7,10,0,1gs‐aM.ol  [M‐2H+5DBA]2‐  1310.350  25.7 
gs‐Dalteparin 
 
